# EDGAR Filing Document

**Accession Number:** 0001420720
**File Stem:** 0001104659-25-097166
**Filing Date:** 2025-10
**Character Count:** 249671
**Document Hash:** d63858e85f7f04e139472d98b19b571b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-097166.hdr.sgml**: 20251006

**ACCESSION NUMBER**: 0001104659-25-097166

**CONFORMED SUBMISSION TYPE**: DEF 14A

**PUBLIC DOCUMENT COUNT**: 35

**CONFORMED PERIOD OF REPORT**: 20251120

**FILED AS OF DATE**: 20251006

**DATE AS OF CHANGE**: 20251006

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** iBio, Inc.
- **CENTRAL INDEX KEY:** 0001420720
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 262797813
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** DEF 14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35023
- **FILM NUMBER:** 251377628

**BUSINESS ADDRESS:**
- **STREET 1:** 600 MADISON AVENUE, SUITE 1601
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022-1737
- **BUSINESS PHONE:** 302 355-0650

**MAIL ADDRESS:**
- **STREET 1:** 600 MADISON AVENUE, SUITE 1601
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022-1737

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** iBioPharma, Inc.
- **DATE OF NAME CHANGE:** 20080806

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** InB:Biotechnologies, Inc.
- **DATE OF NAME CHANGE:** 20071210

?xml version='1.0' encoding='ASCII'? IBIO, INC.

[**Table of Contents**](#TOC)

------

**UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549**

**SCHEDULE 14A**

**Proxy Statement Pursuant to Section 14(a) ofthe Securities Exchange Act of 1934**

---

| | | |
|:---|:---|:---|
| Filed by the Registrant | Filed by the Registrant | ☒ |
| Filed by a party other than the Registrant | Filed by a party other than the Registrant | ☐ |
| Check the appropriate box: | Check the appropriate box: | Check the appropriate box: |
| ☐ | Preliminary Proxy Statement | Preliminary Proxy Statement |
| ☐ | **Confidential, for Use of the Commission Only (as permitted by Rule 14a**-**6(e)(2))** | **Confidential, for Use of the Commission Only (as permitted by Rule 14a**-**6(e)(2))** |
| ☒ | Definitive Proxy Statement | Definitive Proxy Statement |
| ☐ | Definitive Additional Materials | Definitive Additional Materials |
| ☐ | Soliciting Material Pursuant to Section 240.14a-12 | Soliciting Material Pursuant to Section 240.14a-12 |

---

**IBIO, INC.**

*(Name of Registrant as Specified in Its Charter)*

*(Name of Person(s) Filing Proxy Statement, if other than the Registrant)*

---

| | |
|:---|:---|
| Payment of Filing Fee (Check all boxes that apply): | Payment of Filing Fee (Check all boxes that apply): |
| ☒ | No fee required. |
| ☐ | Fee paid previously with preliminary materials. |
| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. |

---

------

[**Table of Contents**](#TOC)

Notice of Annual Meeting of Stockholders

![Graphic](ibio-20251120xdef14a_a004.jpg)

**11750 Sorrento Valley Road, Suite 200**

**San Diego, California 92121**

**October 6, 2025**

### NOTICE OF

## Annual Meeting of Stockholders

#### To the Stockholders of iBio, Inc.:
You are cordially invited to attend the 2025 Annual Meeting of Stockholders (the "2025 Annual Meeting") of iBio, Inc., a Delaware corporation (the "Company"). The meeting will be held on November 20, 2025 at 1:00 p.m. Pacific Time at 11750 Sorrento Valley Road, Suite 200, San Diego, California 92121. The purpose of the 2025 Annual Meeting and the matters to be acted on are stated below in this Notice of Annual Meeting of Stockholders. The Board of Directors knows of no other business that will come before the 2025 Annual Meeting.

At the 2025 Annual Meeting, stockholders will vote on the following matters:

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;**Proposals** | &nbsp;&nbsp;&nbsp;**Proposals** | **Board VoteRecommendation** | **For Further Details** |
| **(1)** | to elect the two (2) nominees for Class II director named in the accompanying proxy statement to our Board of Directors, each to serve a three-year term expiring at the 2028 Annual Meeting of Stockholders and until such director's successor is duly elected and qualified; | **"FOR"** each director nominee | Page **3** |
| **(2)** | to ratify the appointment of Grassi & Co., CPAs, P.C. as our independent registered public accounting firm for our fiscal year ending on June 30, 2026; | **"FOR"** | Page **19** |
| **(3)** | to approve, on an advisory, non-binding basis, the compensation of our named executive officers (Say-on-Pay); and | **"FOR"** | Page **22** |
| **(4)** | to approve, on an advisory, non-binding basis, the frequency of future executive compensation advisory votes. | **FOR EVERY "ONE YEAR" AS THE FREQUENCY** | Page **24** |

---

The matters listed in this notice of meeting are described in detail in the accompanying Proxy Statement. The Board of Directors has fixed the close of business on October 3, 2025 as the record date (the "Record Date") for determining those stockholders who are entitled to notice of and to vote at the 2025 Annual Meeting or any adjournment or postponement of the 2025 Annual Meeting. The list of the stockholders of record as of the Record Date will be made available for inspection at the 2025 Annual Meeting for the ten days preceding the meeting at the Company's offices located at 11750 Sorrento Valley Road, Suite 200, San Diego, California 92121 during ordinary business hours for any purpose germane to the 2025 Annual Meeting.

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;**IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE 2025 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON NOVEMBER 20, 2025.** |
| &nbsp;&nbsp;&nbsp;**The proxy materials together with our Annual Report on Form 10-K for the fiscal year ended June 30, 2025 (the "2025 Annual Report"), which is not a part of our proxy solicitation materials, are first being mailed to the stockholders of**  |

---

[**Table of Contents**](#TOC)

Notice of Annual Meeting of Stockholders

&nbsp;&nbsp;&nbsp;**record on or about October 17, 2025. This Notice of Annual Meeting of Stockholders, the proxy statement and our 2025 Annual Report are available at *https://ir.ibioinc.com*.**<br>

#### Your Vote Is Important.
WHETHER OR NOT YOU PLAN TO ATTEND THE 2025 ANNUAL MEETING, PLEASE SUBMIT A PROXY TO HAVE YOUR SHARES VOTED AS PROMPTLY AS POSSIBLE. RECORD HOLDERS CAN SUBMIT A PROXY VIA THE INTERNET OR TELEPHONE OR BY SIGNING, DATING AND RETURNING BY MAIL THE PROXY CARD ENCLOSED WITH THE PROXY MATERIALS. IF YOU DO NOT RECEIVE THE PROXY MATERIALS IN PRINTED FORM AND WOULD LIKE TO SUBMIT A PROXY BY MAIL, YOU MAY REQUEST A PRINTED COPY OF THE PROXY MATERIALS (INCLUDING THE PROXY) AND SUCH MATERIALS WILL BE SENT TO YOU BY CONTACTING THE CORPORATE SECRETARY, IBIO, INC., 11750 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO, CALIFORNIA 92121, OR BY PHONE AT (979) 446-0027.

---

| | | |
|:---|:---|:---|
| ![Graphic](ibio-20251120xdef14a_a005.jpg) | ![Graphic](ibio-20251120xdef14a_a006.jpg) | ![Graphic](ibio-20251120xdef14a_a007.jpg) |
| **INTERNET** | **TELEPHONE** | **MAIL** |
| To have your shares voted through the internet follow the instructions on the enclosed proxy card to complete an electronic proxy card. You will be asked to provide the Company number and control number from the enclosed proxy card. Your internet vote must be received by 11:59 p.m. Eastern Time on November 19, 2025 to be counted. | To have your shares voted through the telephone dial the toll-free number on the enclosed proxy card using a touch-tone phone and follow the recorded instructions. You will be asked to provide the Company number and control number from the enclosed proxy card. Your telephone vote must be received by 11:59 p.m. Eastern Time on November 19, 2025 to be counted. | To have your shares voted using the proxy card, simply complete, sign and date the enclosed proxy card and return it promptly in the envelope provided. |

---

Beneficial owners whose shares are held at a brokerage firm, or by a bank or other nominee, should follow the voting instructions that they received from the nominee. Please see "Additional Information About These Proxy Materials and Voting – How may I Vote?" in this proxy statement for more information on how to vote.

On behalf of the Board of Directors and the employees of iBio, Inc., we thank you for your continued support and look forward to speaking with you at the 2025 Annual Meeting.

/s/ William D. Clark

**William D. Clark**

Chairman of the Board

[**Table of Contents**](#TOC)

Proxy Statement for the 2025 Annual Meeting of Stockholders to be held on November 20, 2025

![Graphic](ibio-20251120xdef14a_a008.jpg)

11750 Sorrento Valley Road, Suite 200

San Diego, California 92121

### PROXY STATEMENT

## For the 2025 Annual Meeting of Stockholders to be held on November 20, 2025

#### GENERAL INFORMATION
We are providing these proxy materials to holders of shares of common stock, $0.001 par value per share (the "Common Stock"), of iBio, Inc., a Delaware corporation (referred to herein as "iBio," the "Company," "we," or "us"), in connection with the solicitation by the Board of Directors of iBio (the "Board of Directors" or the "Board") of proxies to be voted at our 2025 Annual Meeting of Stockholders (the "2025 Annual Meeting") to be held on November 20, 2025, beginning at 1:00 p.m., Pacific Time, at 11750 Sorrento Valley Road, Suite 200, San Diego, California 92121 and at any adjournment or postponement of our 2025 Annual Meeting. The purpose of the 2025 Annual Meeting and the matters to be acted on are stated in the accompanying Notice of Annual Meeting of Stockholders. The Board of Directors knows of no other business that will come before the 2025 Annual Meeting.

The Board of Directors is soliciting votes: (1) **FOR** each of the two (2) Class II directors named in this proxy statement for election to the Board of Directors ("Proposal 1" or the "Election of Directors Proposal"); (2) **FOR** the ratification of the appointment of Grassi & Co., CPAs, P.C. as our independent registered public accounting firm for the fiscal year ending on June 30, 2026 ("Proposal 2" or the "Auditor Ratification Proposal"); (3) **FOR** the approval, on an advisory, non-binding basis, of the compensation of our named executive officers (Say-on-Pay) ("Proposal 3" or the "Say-on-Pay Proposal"); and (4) **FOR**, the approval, on an advisory basis, of the frequency of future executive compensation advisory votes ("Proposal 4" or the ("Say-on-Frequency Proposal").

[**Table of Contents**](#TOC)

Proxy Statement for the 2025 Annual Meeting of Stockholders to be held on November 21, 2024

#### ANNUAL MEETING ADMISSION
Only stockholders as of the close of business on October 3, 2025 (the "Record Date") may attend the 2025 Annual Meeting. If you attend, please note that you will be asked to present government-issued identification (such as a driver's license or passport) and evidence of your share ownership of our Common Stock on the Record Date. Such evidence of ownership can be your proxy card if you are a stockholder of record. If your shares are held beneficially in the name of a bank, broker or other holder of record and you plan to attend the 2025 Annual Meeting, you will be required to present proof of your ownership of our Common Stock on the Record Date, such as a bank or brokerage account statement or voting instruction card, to be admitted to the 2025 Annual Meeting.

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;**IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE 2025 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON NOVEMBER 20, 2025.** |
| &nbsp;&nbsp;&nbsp;**On or about October 17, 2025, we will begin mailing the proxy materials, which includes the Notice of Annual Meeting of Stockholders, this Proxy Statement and proxy card, together with our Annual Report on Form 10-K for the year ended June 30, 2025 (the "2025 Annual Report"), which is not a part of our proxy solicitation materials. The proxy materials and our 2025 Annual Report are also available at *https://ir.ibioinc.com*.** |

---

#### Your Vote Is Important.
WHETHER OR NOT YOU PLAN TO ATTEND THE 2025 ANNUAL MEETING, PLEASE SUBMIT A PROXY TO HAVE YOUR SHARES VOTED AS PROMPTLY AS POSSIBLE. RECORD HOLDERS CAN SUBMIT A PROXY VIA THE INTERNET OR TELEPHONE OR BY SIGNING, DATING AND RETURNING BY MAIL THE PROXY CARD ENCLOSED WITH THE PROXY MATERIALS. IF YOU DO NOT RECEIVE THE PROXY MATERIALS IN PRINTED FORM AND WOULD LIKE TO SUBMIT A PROXY BY MAIL, YOU MAY REQUEST A PRINTED COPY OF THE PROXY MATERIALS (INCLUDING THE PROXY) AND SUCH MATERIALS WILL BE SENT TO YOU BY CONTACTING THE CORPORATE SECRETARY, IBIO, INC., 11750 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO, CALIFORNIA 92121, OR BY PHONE AT (979) 446-0027. Beneficial owners whose shares are held at a brokerage firm, or by a bank or other nominee, should follow the voting instructions that they received from the nominee.

**No cameras, recording equipment or electronic devices will be permitted in the 2025 Annual Meeting.**

[**Table of Contents**](#TOC)

**Table of Contents**

### TABLE OF

## Contents

---

| | |
|:---|:---|
| &nbsp;&nbsp;[**Proxy Statement**](#PROXYSTATEMENT_735973) |  |
| &nbsp;&nbsp;[**General Information**](#GENERALINFORMATION_872535) |  |
| &nbsp;&nbsp;[**Proxy Summary**](#PROXY_398335) | **2** |
| &nbsp;&nbsp;[**PROPOSAL 1: ELECTION OF DIRECTORS PROPOSAL**](#PROPOSAL1_576774) | **3** |
| &nbsp;&nbsp;[**Information Regarding the Board of Directors and Corporate Governance**](#INFORMATIONREGARDING_380163) | **9** |
| &nbsp;&nbsp;[**Information Regarding Committees of the Board of Directors**](#INFORMATION_599497) | **13** |
| &nbsp;&nbsp;[**Director Compensation for 2025 Fiscal Year**](#DIRECTORCOMPENSATION_248211) | **17** |
| &nbsp;&nbsp;[**PROPOSAL 2: AUDITOR RATIFICATION PROPOSAL**](#PROPOSAL2_22259) | **19** |
| &nbsp;&nbsp;[**Audit Committee Report**](#AUDIT_702902) | **21** |
| &nbsp;&nbsp;[**PROPOSAL 3: SAY-ON-PAY PROPOSAL**](#PROPOSAL3_382469) | **22** |
| &nbsp;&nbsp;[**PROPOSAL 4: SAY-ON-FREQUENCY PROPOSAL**](#PROPOSAL4_692300) | **24** |
| &nbsp;&nbsp;[**Executive Officers Who Are Not Directors**](#Executive_Officers) | **25** |
| &nbsp;&nbsp;[**Executive Compensation**](#EXECUTIVECompensation_947094) | **26** |
| &nbsp;&nbsp;[**Pay vs. Performance**](#PayvsPerformance) | **41** |
| &nbsp;&nbsp;[**Security Ownership of Certain Beneficial Owners and Management**](#SECURITYOWNERSHIPOF_667481) | **45** |
| &nbsp;&nbsp;[**Transactions With Related Persons, Promoters and Certain Control Persons**](#TRANSACTIONS_968102) | **48** |
| &nbsp;&nbsp;[**Additional Information About These Proxy Materials and Voting**](#ADDITIONALINFORMATION_588390) | **50** |
| &nbsp;&nbsp;[**Annual Report on Form 10-K**](#ANNUALREPORT_72334) | **56** |
| &nbsp;&nbsp;[**Notice Regarding Delivery of Stockholder Documents ("Householding" Information)**](#NOTICEREGARDINGDELIVERY_122423) | **57** |
| &nbsp;&nbsp;[**Stockholder Proposals for the 2026 Annual Meeting**](#STOCKHOLDERPROPOSALS_305012) | **58** |
| &nbsp;&nbsp;[**Other Matters**](#OTHER_429409) | **59** |

---

Proxy Statement **1**

[**Table of Contents**](#TOC)

Proxy Summary

**PROXY**

**Summary**

**Directors and Director Nominees**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;**Name and Position** | &nbsp;&nbsp;&nbsp;**Age** | &nbsp;&nbsp;&nbsp;**Director Since** | &nbsp;&nbsp;&nbsp;**Independent** | &nbsp;&nbsp;&nbsp;**Committee Memberships** | &nbsp;&nbsp;&nbsp;**Committee Memberships** | &nbsp;&nbsp;&nbsp;**Committee Memberships** |
| &nbsp;&nbsp;&nbsp;**Name and Position** | &nbsp;&nbsp;&nbsp;**Age** | &nbsp;&nbsp;&nbsp;**Director Since** | &nbsp;&nbsp;&nbsp;**Independent** | &nbsp;&nbsp;&nbsp;&nbsp;**Audit** | &nbsp;&nbsp;&nbsp;&nbsp;**Compensation** | &nbsp;&nbsp;&nbsp;&nbsp;**Nominating &CorporateGovernance** |
| &nbsp;&nbsp;&nbsp;**DR. MARTIN BRENNER**<br>Chief Executive Officer and Chief Scientific Officer of iBio | &nbsp;&nbsp;&nbsp;55 | &nbsp;&nbsp;&nbsp;June 2024 |  |  |  |  |
| &nbsp;&nbsp;&nbsp;**WILLIAM D. CLARK**<sup>♦</sup><br>Former President and Chief Executive Officer of Vibrant Biomedicines, Inc. | &nbsp;&nbsp;&nbsp;57 | &nbsp;&nbsp;&nbsp;August 2021 | &nbsp;&nbsp;&nbsp;![Graphic](ibio-20251120xdef14a_a009.jpg) | &nbsp;&nbsp;&nbsp; ![Graphic](ibio-20251120xdef14a_a010.gif) |  |  |
| &nbsp;&nbsp;&nbsp;**DR. ALEXANDRA KROPOTOVA**<br>Executive Vice President and Chief Medical Officer of SAb Biotherapeutics | &nbsp;&nbsp;&nbsp;53 | &nbsp;&nbsp;&nbsp;October 2020 | &nbsp;&nbsp;&nbsp;![Graphic](ibio-20251120xdef14a_a009.jpg) |  | &nbsp;&nbsp;&nbsp; ![Graphic](ibio-20251120xdef14a_a010.gif) | &nbsp;&nbsp;&nbsp; ![Graphic](ibio-20251120xdef14a_a013.jpg) |
| &nbsp;&nbsp;&nbsp;**EVERT SCHIMMELPENNINK**<br>Chief Executive Officer and President of LENZ Therapeutics, Inc. | &nbsp;&nbsp;&nbsp;53 | &nbsp;&nbsp;&nbsp;June 2021 | &nbsp;&nbsp;&nbsp;![Graphic](ibio-20251120xdef14a_a009.jpg) |  | &nbsp;&nbsp;&nbsp; ![Graphic](ibio-20251120xdef14a_a010.gif) |  |
| &nbsp;&nbsp;&nbsp;**GARY SENDER**<br>Former Chief Financial Officer of Nabriva Therapeutics plc | &nbsp;&nbsp;&nbsp;63 | &nbsp;&nbsp;&nbsp;October 2020 | &nbsp;&nbsp;&nbsp;![Graphic](ibio-20251120xdef14a_a016.jpg) | &nbsp;&nbsp;&nbsp; ![Graphic](ibio-20251120xdef14a_a013.jpg) | &nbsp;&nbsp;&nbsp; ![Graphic](ibio-20251120xdef14a_a013.jpg) |  |
| &nbsp;&nbsp;&nbsp;**DAVID ARKOWITZ**<br>Chief Financial Officer of Alkeus Pharmaceuticals, Inc. | &nbsp;&nbsp;&nbsp;64 | &nbsp;&nbsp;&nbsp;November 2024 | &nbsp;&nbsp;&nbsp;![Graphic](ibio-20251120xdef14a_a016.jpg) | &nbsp;&nbsp;&nbsp; ![Graphic](ibio-20251120xdef14a_a010.gif) |  | &nbsp;&nbsp;&nbsp; ![Graphic](ibio-20251120xdef14a_a010.gif) |
| &nbsp;&nbsp;&nbsp;**ANTóNIO PARADA**<br>Chief Executive Officer of FairJourney Biologics | &nbsp;&nbsp;&nbsp;57 | &nbsp;&nbsp;&nbsp;November 2024 | &nbsp;&nbsp;&nbsp;![Graphic](ibio-20251120xdef14a_a009.jpg) |  |  | &nbsp;&nbsp;&nbsp; ![Graphic](ibio-20251120xdef14a_a010.gif) |

---

![Graphic](ibio-20251120xdef14a_a024.jpg)Chair

![Graphic](ibio-20251120xdef14a_a025.jpg)Member

&nbsp;&nbsp;&nbsp;&nbsp;♦ Chair of the Board of Directors

**2** iBio, Inc.

[**Table of Contents**](#TOC)

Proposal 1 Election of Directors

### PROPOSAL 1

## Election of Directors
The Board of Directors currently consists of seven (7) directors and is divided into three classes. Each class serves for a term ending at the third annual meeting of stockholders following the election of such class, with the terms of office of the respective classes expiring in successive years. Directors in Class II will stand for election this year at the 2025 Annual Meeting, directors in Class III will stand for election at the 2026 Annual Meeting of Stockholders and directors in Class I will stand for election at the 2027 Annual Meeting of Stockholders.

At the 2025 Annual Meeting, our stockholders will consider and vote upon the election of two (2) Class II nominees: Dr. Martin Brenner and Dr. Alexandra Kropotova, to continue to serve as Class II directors. If re-elected, these nominees will serve for a term ending at our 2028 Annual Meeting of Stockholders. Our Board of Directors believes that all of our current directors, including the two (2) nominees for election, possess, among other attributes, personal and professional integrity, good judgment, a high level of ability, diversity of viewpoint and business acumen.

Each nominee has agreed to serve if elected and we have no reason to believe that either nominee will be unable to serve if elected. If either nominee becomes unavailable for election as a result of an unexpected occurrence, proxies will be voted FOR the election of a substitute nominee proposed by our Board of Directors or for election of only the remaining nominee.

Unless authority to do so is withheld, shares represented by executed proxies will be voted FOR the election of each of the director nominees. Proxies cannot be voted for a greater number of persons than the number of nominees standing for election. Since two (2) directors are to be elected at the 2025 Annual Meeting, the two (2) nominees for director who receive the highest number of votes for election will be elected as Class II directors. Cumulating votes is not permitted in connection with the election of directors.

#### Nominees to the Board of Directors
Each of the Class II director nominees and their age, position with our Company, length of service on the Board of Directors, the expiration of their respective term on the Board of Directors (assuming they are elected at the 2025 Annual Meeting), their principal occupation, business experience and certain other information are provided in the table below and in the additional biographical descriptions set forth in the text below the table.

---

| | | | | |
|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;**Name of Director Nominee** | **Age** | **Position** | **Director Since** | **Term Expires** |
| &nbsp;&nbsp;Dr. Martin Brenner | 55 | Class II Director,<br>Chief Executive Officer,<br>Chief Scientific Officer | June 2024 | 2028 |
| &nbsp;&nbsp;Dr. Alexandra Kropotova | 53 | Class II Director | October 2020 | 2028 |

---

#### CLASS II DIRECTORS

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;**DR. MARTIN BRENNER, 55** | &nbsp;&nbsp;&nbsp;**DR. MARTIN BRENNER, 55** |
| &nbsp;&nbsp;&nbsp;**DIRECTOR SINCE:**<br>June 2024 | &nbsp;&nbsp;&nbsp;**COMMITTEES:**<br>None |
| &nbsp;&nbsp;&nbsp;**BACKGROUND**<br>***Dr. Martin Brenner*** has served as the Company's Chief Executive Officer (CEO) since June 22, 2023, its interim CEO from January 20, 2023 until his appointment as CEO and as the Company's Chief Scientific Officer (CSO) since January 18, 2021. Dr. Brenner was appointed as a member of the Board of Directors on May 9, 2024 effective June 1, 2024. Dr. Brenner has a strong history of success heading drug discovery and development teams at several of the world's leading pharmaceutical companies, including AstraZeneca ("AstraZeneca"), Eli Lilly and Company ("Lilly"), Pfizer Inc. ("Pfizer"), and Merck Research Laboratories ("Merck Research Labs"). Most recently, Dr. Brenner served as Senior Vice President, CSO of Pemex Inc. from March 2019 until its acquisition by Ligand Pharmaceuticals Incorporated in October 2020. From 2017 to 2018, Dr. Brenner served as CSO at Recursion Pharmaceuticals, Inc., a publicly listed biotechnology company. From 2016 to 2017, Dr. Brenner served as Vice  | &nbsp;&nbsp;&nbsp;**BACKGROUND**<br>***Dr. Martin Brenner*** has served as the Company's Chief Executive Officer (CEO) since June 22, 2023, its interim CEO from January 20, 2023 until his appointment as CEO and as the Company's Chief Scientific Officer (CSO) since January 18, 2021. Dr. Brenner was appointed as a member of the Board of Directors on May 9, 2024 effective June 1, 2024. Dr. Brenner has a strong history of success heading drug discovery and development teams at several of the world's leading pharmaceutical companies, including AstraZeneca ("AstraZeneca"), Eli Lilly and Company ("Lilly"), Pfizer Inc. ("Pfizer"), and Merck Research Laboratories ("Merck Research Labs"). Most recently, Dr. Brenner served as Senior Vice President, CSO of Pemex Inc. from March 2019 until its acquisition by Ligand Pharmaceuticals Incorporated in October 2020. From 2017 to 2018, Dr. Brenner served as CSO at Recursion Pharmaceuticals, Inc., a publicly listed biotechnology company. From 2016 to 2017, Dr. Brenner served as Vice  |

---

Proxy Statement **3**

[**Table of Contents**](#TOC)

Proposal 1 Election of Directors

&nbsp;&nbsp;&nbsp;President and Head of Research and Early Development at Stoke Therapeutics, Inc., a biotechnology company. From 2013 to 2016, Dr. Brenner served as Executive Director, Diabetes & NASH, and Chair of Diabetes & NASH Early Discovery Unit at Merck Research Lab. From 2012 to 2013, Dr. Brenner served as Senior Director, Head of Bioscience, CVMD at AstraZeneca. From 2009 to 2012, Dr. Brenner served as an Associate Research Fellow for the Diabetes Prevention and Remission Group at Pfizer. From 2003 to 2009, Dr. Brenner served as Senior Research Scientist for the Diabetes Drug Hunting Team at Lilly. Dr. Brenner holds a Ph.D. in Pharmacology from the Veterinary School of Hannover in Hannover, Germany a DVM from Veterinary School of Ludwig-Maximilians-University in Munich, Germany.<br>We believe Dr. Brenner's experience and knowledge of drug discovery and his experience in various leadership roles in successful pharmaceutical companies and biologics is valuable to the Board of Directors and the Company. <br>

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;**DR. ALEXANDRA KROPOTOVA, 53** | &nbsp;&nbsp;&nbsp;**DR. ALEXANDRA KROPOTOVA, 53** |
| &nbsp;&nbsp;&nbsp;**DIRECTOR SINCE:**<br>October 2020 | &nbsp;&nbsp;&nbsp;**COMMITTEES:**<br>Chair of Nominating and Corporate Governance Committee<br>Member of Compensation Committee |
| &nbsp;&nbsp;&nbsp;**BACKGROUND**<br>***Dr. Alexandra Kropotova*** was appointed as a member of our Board of Directors in October 2020 and currently serves as Chair of the Nominating and Corporate Governance Committee of the Board of Directors and as a member of the Compensation Committee. Dr. Kropotova is a biopharmaceutical executive with expertise in all phases of global clinical development, translational medicine and medical affairs. Currently, Dr. Kropotova is Executive Vice President and Chief Medical Officer at SAb Biotherapeutics, a publicly traded biopharmaceutical company, leading the strategy, direction, and execution of the company's portfolio of innovative polyclonal antibody assets. Prior to SAb Biotherapeutics, she has served as Vice President, Global Specialty R&D, Respiratory & Inflammation Therapeutic Area at Teva Pharmaceuticals, where she led the design and execution of global clinical development programs, the majority of which are biologic candidates for pulmonary, chronic inflammatory or autoimmune indications. Prior to joining Teva, between 2007-2016, Dr. Kropotova served in various roles at Sanofi, including Vice President, Strategy & Strategic Planning Head, North American Medical Affairs; Associate Vice President and subsequently Vice President, Immuno-Inflammation, Global R&D; and Senior Medical Director, Respiratory, Allergy & Anti-Infectives. Prior to joining Sanofi, she served in various roles at Pfizer Inc. from 2002-2007, most recently as Director & Head of Global Clinical Respiratory and Analgesics. Dr. Kropotova received her Master of Business Administration Degree from Ohio University Graduate School of Business, Athens, Ohio, and her Medical Degree in Internal Medicine from the Vladivostok State Medical University, Vladivostok, Russia.<br>We believe Dr. Kropotova's experience and knowledge as a medical professional and biologics development experience across multiple therapeutic areas along with her experience in various leadership roles in successful pharmaceutical companies is valuable to the Board of Directors and the Company.  | &nbsp;&nbsp;&nbsp;**BACKGROUND**<br>***Dr. Alexandra Kropotova*** was appointed as a member of our Board of Directors in October 2020 and currently serves as Chair of the Nominating and Corporate Governance Committee of the Board of Directors and as a member of the Compensation Committee. Dr. Kropotova is a biopharmaceutical executive with expertise in all phases of global clinical development, translational medicine and medical affairs. Currently, Dr. Kropotova is Executive Vice President and Chief Medical Officer at SAb Biotherapeutics, a publicly traded biopharmaceutical company, leading the strategy, direction, and execution of the company's portfolio of innovative polyclonal antibody assets. Prior to SAb Biotherapeutics, she has served as Vice President, Global Specialty R&D, Respiratory & Inflammation Therapeutic Area at Teva Pharmaceuticals, where she led the design and execution of global clinical development programs, the majority of which are biologic candidates for pulmonary, chronic inflammatory or autoimmune indications. Prior to joining Teva, between 2007-2016, Dr. Kropotova served in various roles at Sanofi, including Vice President, Strategy & Strategic Planning Head, North American Medical Affairs; Associate Vice President and subsequently Vice President, Immuno-Inflammation, Global R&D; and Senior Medical Director, Respiratory, Allergy & Anti-Infectives. Prior to joining Sanofi, she served in various roles at Pfizer Inc. from 2002-2007, most recently as Director & Head of Global Clinical Respiratory and Analgesics. Dr. Kropotova received her Master of Business Administration Degree from Ohio University Graduate School of Business, Athens, Ohio, and her Medical Degree in Internal Medicine from the Vladivostok State Medical University, Vladivostok, Russia.<br>We believe Dr. Kropotova's experience and knowledge as a medical professional and biologics development experience across multiple therapeutic areas along with her experience in various leadership roles in successful pharmaceutical companies is valuable to the Board of Directors and the Company.  |

---

#### Vote Required
Provided that a quorum is present, the two nominees for director receiving a plurality of the votes cast by the stockholders entitled to vote on the election at the 2025 Annual Meeting will be elected. Accordingly, the two nominees receiving the highest number of votes will be elected.

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;![Graphic](ibio-20251120xdef14a_a026.jpg) | **THE BOARD OF DIRECTORS RECOMMENDS A VOTE "FOR" THE ELECTION OF EACH OF THE TWO NOMINEES LISTED ABOVE AS CLASS II DIRECTORS** |

---

**4** iBio, Inc.

[**Table of Contents**](#TOC)

Proposal 1 Election of Directors

#### Continuing Directors
The directors who will continue to serve as directors following the 2025 Annual Meeting and their ages, position, with our Company, length of service on the Board of Directors, the expiration of their respective terms, their principal occupation, business experience and certain other information are provided in the table below and in the additional biographical descriptions set forth in the text below the table.

---

| | | | | |
|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;**Name of Director**<br>&nbsp;&nbsp;**Class I Directors** | **Age**<br>| **Position**<br>| **Director Since**<br>| **Term Expires**<br>|
| &nbsp;&nbsp;Evert Schimmelpennink | 53 | Class I Director | June 2021 | 2027 |
| &nbsp;&nbsp;David Arkowitz | 64 | Class I Director | November 2024 | 2027 |
| &nbsp;&nbsp;António Parada | 57 | Class I Director | November 2024 | 2027 |
| &nbsp;&nbsp;**Class III Directors** |  |  |  |  |
| &nbsp;&nbsp;William D. Clark | 57 | Class III Director | August 2021 | 2026 |
| &nbsp;&nbsp;Gary Sender | 63 | Class III Director | October 2020 | 2026 |

---

#### CLASS I DIRECTORS

---

| | |
|:---|:---|
| 3<br>|  |
| &nbsp;&nbsp;&nbsp;**EVERT SCHIMMELPENNINK, 53** | &nbsp;&nbsp;&nbsp;**EVERT SCHIMMELPENNINK, 53** |
| &nbsp;&nbsp;&nbsp;**DIRECTOR SINCE:**<br>June 2021 | &nbsp;&nbsp;&nbsp;**COMMITTEES:**<br>Member of Compensation Committee |
| &nbsp;&nbsp;&nbsp;**BACKGROUND**<br>***Evert Schimmelpennink*** was appointed as a member of our Board of Directors in June 2021 and currently serves as a member of the Compensation Committee. Mr. Schimmelpennink has close to 25 years of biotech and pharmaceutical experience and brings a proven track record in successfully building and scaling public and private biopharmaceutical companies, securing funding around captivating strategies, and creating patient and shareholder value. Mr. Schimmelpennink currently serves as the Chief Executive Officer (CEO) and President of publicly listed LENZ Therapeutics, Inc. a position he has held since March 4, 2021. In addition to serving on the board of directors of LENZ Therapeutics, Mr. Schimmelpennink serves as chairman of the board of directors of Pipeline Therapeutics, Inc. Previously, from August 2017 to October 2020 he was the CEO of publicly listed Pfenex Inc., which he led through a turnaround and its first FDA approval resulting in an acquisition by Ligand Pharmaceuticals Inc. in late 2020. From November 13, 2019 until its sale, Mr. Schimmelpennink also served as the acting Principal Financial Officer and Principal Accounting Officer of Pfenex Inc. From October 2015 to July 2017, Mr. Schimmelpennink was CEO of then privately held Alvotech, where he led the company through a critical growth phase, and aligned R&D, manufacturing and commercial capabilities across a portfolio of monoclonal antibodies. Prior to that, he held senior positions at Pfizer Inc. and Hospira, Inc. within their global specialty injectables businesses, as well as Synthon BV. Mr. Schimmelpennink earned a M.Sc. in bioprocess engineering from the University of Wageningen in the Netherlands and a Business Degree from the Arnhem Business School.<br>Mr. Schimmelpennink brings extensive knowledge of the pharmaceutical and biotech industries as a result of his service in senior corporate positions in many medical companies that provide him with the qualifications to serve as a member of our Board of Directors. | &nbsp;&nbsp;&nbsp;**BACKGROUND**<br>***Evert Schimmelpennink*** was appointed as a member of our Board of Directors in June 2021 and currently serves as a member of the Compensation Committee. Mr. Schimmelpennink has close to 25 years of biotech and pharmaceutical experience and brings a proven track record in successfully building and scaling public and private biopharmaceutical companies, securing funding around captivating strategies, and creating patient and shareholder value. Mr. Schimmelpennink currently serves as the Chief Executive Officer (CEO) and President of publicly listed LENZ Therapeutics, Inc. a position he has held since March 4, 2021. In addition to serving on the board of directors of LENZ Therapeutics, Mr. Schimmelpennink serves as chairman of the board of directors of Pipeline Therapeutics, Inc. Previously, from August 2017 to October 2020 he was the CEO of publicly listed Pfenex Inc., which he led through a turnaround and its first FDA approval resulting in an acquisition by Ligand Pharmaceuticals Inc. in late 2020. From November 13, 2019 until its sale, Mr. Schimmelpennink also served as the acting Principal Financial Officer and Principal Accounting Officer of Pfenex Inc. From October 2015 to July 2017, Mr. Schimmelpennink was CEO of then privately held Alvotech, where he led the company through a critical growth phase, and aligned R&D, manufacturing and commercial capabilities across a portfolio of monoclonal antibodies. Prior to that, he held senior positions at Pfizer Inc. and Hospira, Inc. within their global specialty injectables businesses, as well as Synthon BV. Mr. Schimmelpennink earned a M.Sc. in bioprocess engineering from the University of Wageningen in the Netherlands and a Business Degree from the Arnhem Business School.<br>Mr. Schimmelpennink brings extensive knowledge of the pharmaceutical and biotech industries as a result of his service in senior corporate positions in many medical companies that provide him with the qualifications to serve as a member of our Board of Directors. |

---

Proxy Statement **5**

[**Table of Contents**](#TOC)

Proposal 1 Election of Directors

---

| | |
|:---|:---|
| &nbsp;&nbsp;**David Arkowitz, 64** | &nbsp;&nbsp;**David Arkowitz, 64** |
| &nbsp;&nbsp;&nbsp;**DIRECTOR SINCE:**<br>November 2024 | &nbsp;&nbsp;&nbsp;**COMMITTEES:**<br>Member of Audit Committee<br>Member of Nominating and Corporate Governance Committee |
| &nbsp;&nbsp;&nbsp;**BACKGROUND**<br>**David Arkowitz** was appointed as a member of our Board of Directors in November 2024 and serves as a member of the Nominating and Corporate Governance Committee and the Audit Committee. Currently, Mr. Arkowitz serves as the Chief Financial Officer (CFO) of Alkeus Pharmaceuticals, a private biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases. Previously he served as the CFO and Head of Business Development of publicly listed Seres Therapeutics, Inc., from June 2021 until March 2024. Previously, from May 2018 to May 2021, Mr. Arkowitz served as the CFO of Flexion Therapeutics, Inc. (acquired by Pacira BioSciences, Inc.) From September 2013 to May 2018, Mr. Arkowitz served as Chief Operating Officer and CFO at Visterra, Inc. (acquired by Otsuka Pharmaceuticals Co.) where he led the finance, business development, corporate planning and other functions. Mr. Arkowitz was CFO and General Manager at Mascoma LLC (acquired by Lallemand Inc.) from June 2011 to September 2013. Previously, Mr. Arkowitz served as CFO and Chief Business Officer at AMAG Pharmaceuticals, Inc., and CFO of Idenix Pharmaceuticals, Inc. (acquired by Merck & Co., Inc.). Prior to Idenix, Mr. Arkowitz spent more than 13 years at Merck & Co., Inc. where he held roles of increasing responsibility, including Vice President and Controller of the U.S. Human Health division and Controller of the Global Research and Development division, and CFO of the Canadian subsidiary. Mr. Arkowitz serves on the board of directors of Kineta, Inc., from December 2022 to June 2025, when it was acquired by TuHURA Biosciences and where he was a member of the audit and nominating and corporate governance committees. He has also served on the board of directors of F-Star Therapeutics, Inc. from November 2020 to March 2023, where he served as the chair of the audit committee and a member of the compensation committee and Yumanity Therapeutics from December 2020 to December 2022, where he served as a member of its audit and nominating and corporate governance committees. Mr. Arkowitz earned a B.A. in Mathematics from Brandeis University and an M.B.A. in Finance from Columbia University Business School. <br>Mr. Arkowitz is qualified as an "audit committee financial expert" as defined in Regulation S-K Item 407(d)(5)(ii). Mr. Arkowitz brings extensive financial and operational life sciences experience that provide him with the qualifications to serve as a member of our Board of Directors. | &nbsp;&nbsp;&nbsp;**BACKGROUND**<br>**David Arkowitz** was appointed as a member of our Board of Directors in November 2024 and serves as a member of the Nominating and Corporate Governance Committee and the Audit Committee. Currently, Mr. Arkowitz serves as the Chief Financial Officer (CFO) of Alkeus Pharmaceuticals, a private biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases. Previously he served as the CFO and Head of Business Development of publicly listed Seres Therapeutics, Inc., from June 2021 until March 2024. Previously, from May 2018 to May 2021, Mr. Arkowitz served as the CFO of Flexion Therapeutics, Inc. (acquired by Pacira BioSciences, Inc.) From September 2013 to May 2018, Mr. Arkowitz served as Chief Operating Officer and CFO at Visterra, Inc. (acquired by Otsuka Pharmaceuticals Co.) where he led the finance, business development, corporate planning and other functions. Mr. Arkowitz was CFO and General Manager at Mascoma LLC (acquired by Lallemand Inc.) from June 2011 to September 2013. Previously, Mr. Arkowitz served as CFO and Chief Business Officer at AMAG Pharmaceuticals, Inc., and CFO of Idenix Pharmaceuticals, Inc. (acquired by Merck & Co., Inc.). Prior to Idenix, Mr. Arkowitz spent more than 13 years at Merck & Co., Inc. where he held roles of increasing responsibility, including Vice President and Controller of the U.S. Human Health division and Controller of the Global Research and Development division, and CFO of the Canadian subsidiary. Mr. Arkowitz serves on the board of directors of Kineta, Inc., from December 2022 to June 2025, when it was acquired by TuHURA Biosciences and where he was a member of the audit and nominating and corporate governance committees. He has also served on the board of directors of F-Star Therapeutics, Inc. from November 2020 to March 2023, where he served as the chair of the audit committee and a member of the compensation committee and Yumanity Therapeutics from December 2020 to December 2022, where he served as a member of its audit and nominating and corporate governance committees. Mr. Arkowitz earned a B.A. in Mathematics from Brandeis University and an M.B.A. in Finance from Columbia University Business School. <br>Mr. Arkowitz is qualified as an "audit committee financial expert" as defined in Regulation S-K Item 407(d)(5)(ii). Mr. Arkowitz brings extensive financial and operational life sciences experience that provide him with the qualifications to serve as a member of our Board of Directors. |

---

**6** iBio, Inc.

[**Table of Contents**](#TOC)

Proposal 1 Election of Directors

---

| | |
|:---|:---|
| &nbsp;&nbsp;**António Parada, 57**  | &nbsp;&nbsp;**António Parada, 57**  |
| &nbsp;&nbsp;&nbsp;**DIRECTOR SINCE:**<br>November 2024 | &nbsp;&nbsp;&nbsp;**COMMITTEES:**<br>Member of Nominating and Corporate Governance Committee |
| &nbsp;&nbsp;&nbsp;**BACKGROUND**<br>***António Parada*** was appointed as a member of our Board of Directors in November 2024 and currently serves as a member of the Nominating and Corporate Governance Committee. He is currently the Founder and CEO of Fairjourney Biologics, a privately held company and a leading antibody discovery contract research organization supporting more than 250 clients across the globe, a role he has held since founding the company in May 2012. In June 2024, the Partners Group, one of the largest firms in the global private markets industry with approximately $150 billion in assets under management, acquired a majority ownership in FairJourney. Prior to Fairjourney, Mr. Parada was the General Manager of Instituto de Biologia Molecular e Celular (IBMC), in Porta, Portugal, from 2002 until 2013. From February 2011 until May 2012, Mr. Parada was the Manager of the Clinical Trial Unit of IPO Porto – Cancer Hospital in Porto, Portugal. From June 2008 to March 2012, Mr. Parada was the Site Manager of Ablynx' (a subsidiary of Sanofi S.A.) "Centre of Excellence in Phage Display" located in Portal, Portugal. In June 2002, Mr. Parada founded the BioCodex Group, a consulting firm, and was the CEO until December 2008, which firm had a turnover of approximately 10 million Euros. Mr. Parada was a Board Member of Centro de Diagnóstico y Estudios Metabólicos Avanzados de Cantabria (CDEMAC) from May 2014 until May 2017 and is currently the Chairman of the Supervisory Board of EMBLEM, a position he has held since January 2011. Mr. Parada has 15 publications in peer reviewed journals on pharmacology and several others in botany, management, marketing and security and holds the medal of Merit of the city of Porto, Portugal and career award of the city of Matosinhos, Portugal. Mr. Parada graduated from the University of Porto, Portugal and has a MBA from the Portuguese Catholic University. <br>Mr. Parada brings extensive antibody drug discovery, fundraising and management experience that provide him with the qualifications to serve as a member of our Board of Directors. | &nbsp;&nbsp;&nbsp;**BACKGROUND**<br>***António Parada*** was appointed as a member of our Board of Directors in November 2024 and currently serves as a member of the Nominating and Corporate Governance Committee. He is currently the Founder and CEO of Fairjourney Biologics, a privately held company and a leading antibody discovery contract research organization supporting more than 250 clients across the globe, a role he has held since founding the company in May 2012. In June 2024, the Partners Group, one of the largest firms in the global private markets industry with approximately $150 billion in assets under management, acquired a majority ownership in FairJourney. Prior to Fairjourney, Mr. Parada was the General Manager of Instituto de Biologia Molecular e Celular (IBMC), in Porta, Portugal, from 2002 until 2013. From February 2011 until May 2012, Mr. Parada was the Manager of the Clinical Trial Unit of IPO Porto – Cancer Hospital in Porto, Portugal. From June 2008 to March 2012, Mr. Parada was the Site Manager of Ablynx' (a subsidiary of Sanofi S.A.) "Centre of Excellence in Phage Display" located in Portal, Portugal. In June 2002, Mr. Parada founded the BioCodex Group, a consulting firm, and was the CEO until December 2008, which firm had a turnover of approximately 10 million Euros. Mr. Parada was a Board Member of Centro de Diagnóstico y Estudios Metabólicos Avanzados de Cantabria (CDEMAC) from May 2014 until May 2017 and is currently the Chairman of the Supervisory Board of EMBLEM, a position he has held since January 2011. Mr. Parada has 15 publications in peer reviewed journals on pharmacology and several others in botany, management, marketing and security and holds the medal of Merit of the city of Porto, Portugal and career award of the city of Matosinhos, Portugal. Mr. Parada graduated from the University of Porto, Portugal and has a MBA from the Portuguese Catholic University. <br>Mr. Parada brings extensive antibody drug discovery, fundraising and management experience that provide him with the qualifications to serve as a member of our Board of Directors. |

---

#### CLASS iII DIRECTORS

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;**WILLIAM D. CLARK, 57** | &nbsp;&nbsp;&nbsp;**WILLIAM D. CLARK, 57** |
| &nbsp;&nbsp;&nbsp;**DIRECTOR SINCE:**<br>August 2021 | &nbsp;&nbsp;&nbsp;**COMMITTEES:**<br>Member of Audit Committee |

---

Proxy Statement **7**

[**Table of Contents**](#TOC)

Proposal 1 Election of Directors

&nbsp;&nbsp;&nbsp;**BACKGROUND**<br>***William D. Clark*** was appointed as a member of our Board of Directors in August 2021 and has served as Chairperson of the Board since November 1, 2022. He also currently serves on the Audit Committee. Mr. Clark has more than 30 years of biotechnology and pharmaceutical experience, with a focus on business development, commercialization, strategic planning, and general management. Mr. Clark served as President and CEO of Vibrant Biomedicines, Inc. from June 2024 until June 2025. From 2011 until 2022, he served as the President and Chief Executive Officer of a publicly traded biopharmaceutical company, Genocea Biosciences, Inc. ("Genocea"). In that role, among other accomplishments, he executed Genocea's successful strategic pivot from infectious disease to immuno-oncology. Prior to joining Genocea, Mr. Clark was Chief Business Officer at Vanda Pharmaceuticals Inc. ("Vanda"), a company he co-founded in 2004. There, he played central roles in completing the company's 2006 initial public offering and its 2009 out-licensing deal with Novartis Pharma AG, from which Vanda received an upfront payment of $200 million, plus contingent additional future milestone payments totaling up to $265 million. Previously, he was a Principal at Care Capital, LLC, a venture capital firm investing in biopharmaceutical companies. Earlier in his career, he spent 10 years at SmithKline Beecham Corporation (now part of GlaxoSmithKline plc) in a variety of business development roles. Mr. Clark holds an MBA from The Wharton School at the University of Pennsylvania and a BA from Harvard University.<br>Mr. Clark is qualified as an "audit committee financial expert" as defined in Regulation S-K Item 407(d)(5)(ii). Mr. Clark's experience as a board member and executive of both public and private companies in the life sciences industry and his management experience is valuable to the Board of Directors and the Company.<br>

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;2020<br>|  |
| &nbsp;&nbsp;&nbsp;**GARY SENDER, 63** | &nbsp;&nbsp;&nbsp;**GARY SENDER, 63** |
| &nbsp;&nbsp;&nbsp;**DIRECTOR SINCE:**<br>October 2020 | &nbsp;&nbsp;&nbsp;**COMMITTEES:**<br>Chair of Audit Committee<br>Chair of Compensation Committee  |
| &nbsp;&nbsp;&nbsp;**BACKGROUND**<br>***Gary Sender*** was appointed as a member of our Board of Directors in October 2020 and served as the Lead Independent Director of the Board of Directors from December 2021 until November 10, 2022, when the Board of Directors approved removing the role of Lead Independent Director after the appointment of Mr. Clark as the Chairperson of the Board. Mr. Sender currently serves as the Chair of the Audit Committee and as Chair of the Compensation Committee. Mr. Sender currently serves on the board of directors of Schrodinger, Inc., a publicly traded company, and is the chair of their audit and compensation committees. Mr. Sender also serves on the board of directors of Harmony Biosciences Holdings, Inc., a publicly traded pharmaceutical company, and is the chair of their audit committee and is a member of their compensation committee. Mr. Sender serves on the board of Apnimed, a privately held biotechnology firm, and is the chair of their finance committee. Mr. Sender is a senior executive and board member with more than 25 years of financial leadership experience at both large, multi-national pharmaceutical and early-stage biotechnology companies. In March 2021, Mr. Sender retired as the Chief Financial Officer of Nabriva Therapeutics plc, a commercial-stage publicly traded biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. He held that position since May 2016. Prior to joining Nabriva, Mr. Sender was Executive Vice President and Chief Financial Officer of Synergy Pharmaceuticals Inc. from November 2015 to April 2016. Prior to joining Synergy, from August 2009 to June 2015, Mr. Sender served as Senior Vice President of Finance of Shire Plc's ("Shire"), a biopharmaceutical company since acquired by Takeda Pharmaceutical Company Limited supporting its Specialty Pharmaceuticals business and subsequently its Global Commercial businesses. Prior to joining Shire, Mr. Sender served as the Chief Financial Officer of Tengion, Inc., a regenerative medicine company, from August 2004 to July 2009. Mr. Sender also spent over 15 years in several leadership roles within Merck & Co. Inc., a publicly traded pharmaceutical company. Mr. Sender received a B.S. in Finance from Boston University and an M.B.A. from Carnegie-Mellon University. <br>Mr. Sender is qualified as an "audit committee financial expert" as defined in Regulation S-K Item 407(d)(5)(ii). Mr. Sender's experience as a board member and executive of both public and private companies in the life sciences industry and his management experience is valuable to the Board of Directors and the Company. | &nbsp;&nbsp;&nbsp;**BACKGROUND**<br>***Gary Sender*** was appointed as a member of our Board of Directors in October 2020 and served as the Lead Independent Director of the Board of Directors from December 2021 until November 10, 2022, when the Board of Directors approved removing the role of Lead Independent Director after the appointment of Mr. Clark as the Chairperson of the Board. Mr. Sender currently serves as the Chair of the Audit Committee and as Chair of the Compensation Committee. Mr. Sender currently serves on the board of directors of Schrodinger, Inc., a publicly traded company, and is the chair of their audit and compensation committees. Mr. Sender also serves on the board of directors of Harmony Biosciences Holdings, Inc., a publicly traded pharmaceutical company, and is the chair of their audit committee and is a member of their compensation committee. Mr. Sender serves on the board of Apnimed, a privately held biotechnology firm, and is the chair of their finance committee. Mr. Sender is a senior executive and board member with more than 25 years of financial leadership experience at both large, multi-national pharmaceutical and early-stage biotechnology companies. In March 2021, Mr. Sender retired as the Chief Financial Officer of Nabriva Therapeutics plc, a commercial-stage publicly traded biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. He held that position since May 2016. Prior to joining Nabriva, Mr. Sender was Executive Vice President and Chief Financial Officer of Synergy Pharmaceuticals Inc. from November 2015 to April 2016. Prior to joining Synergy, from August 2009 to June 2015, Mr. Sender served as Senior Vice President of Finance of Shire Plc's ("Shire"), a biopharmaceutical company since acquired by Takeda Pharmaceutical Company Limited supporting its Specialty Pharmaceuticals business and subsequently its Global Commercial businesses. Prior to joining Shire, Mr. Sender served as the Chief Financial Officer of Tengion, Inc., a regenerative medicine company, from August 2004 to July 2009. Mr. Sender also spent over 15 years in several leadership roles within Merck & Co. Inc., a publicly traded pharmaceutical company. Mr. Sender received a B.S. in Finance from Boston University and an M.B.A. from Carnegie-Mellon University. <br>Mr. Sender is qualified as an "audit committee financial expert" as defined in Regulation S-K Item 407(d)(5)(ii). Mr. Sender's experience as a board member and executive of both public and private companies in the life sciences industry and his management experience is valuable to the Board of Directors and the Company. |

---

**8** iBio, Inc.

[**Table of Contents**](#TOC)

### INFORMATION REGARDING

## The Board of Directors and Corporate Governance

#### Independence of the Board of Directors
Our Common Stock has traded on the Nasdaq Stock Market LLC, or Nasdaq, under the symbol "IBIO" since April 2025. Under the Nasdaq listing standards, independent directors must comprise a majority of a listed company's Board of Directors and all members of the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee must be independent. Audit Committee members must also satisfy the independence criteria set forth in Rule 10A-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act") and Compensation Committee members must also satisfy the independence criteria set forth in Rule 10C-1 under the Exchange Act. Under the Nasdaq listing standards, for a director to be deemed independent, the board must affirmatively determine that the director does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director.

In order to be considered to be independent for purposes of Rule 10A-3, a member of an Audit Committee of a listed company may not, other than in his or her capacity as a member of the Audit Committee, the Board of Directors, or any other board committee: (i) accept, directly or indirectly, any consulting, advisory or other compensatory fee from the listed company or any of its subsidiaries, or (ii) be an affiliated person of the listed company or any of its subsidiaries.

The Board of Directors undertook a review of the independence of each director and director nominee and considered whether any director or director nominee has a material relationship with us that could compromise his or her ability to exercise independent judgment in carrying out his or her responsibilities. Based upon information requested from and provided by each director and director nominee concerning their background, employment and affiliations, including family relationships, the Board of Directors has determined that all of our current directors and director nominees, other than Dr. Brenner, are independent. As a result, our Board of Directors has determined that each of David Arkowitz, William D. Clark, Dr. Alexandra Kropotova, António Parada, Evert Schimmelpennink and Gary Sender, are (or would be if elected) "independent directors" as that term is defined in Section 5605 of the Nasdaq Listing Manual. In addition, our Board of Directors determined that each director who served as a member of the Audit, Compensation, and Nominating and Corporate Governance Committees during the fiscal year 2025 was, and each current member of the Audit, Compensation, and Nominating and Corporate Governance Committees is, an independent director pursuant to all applicable listing standards of Nasdaq. General (Ret.) James T. Hill, a director during a portion of fiscal year 2025 whose term expired on November 21, 2024, was determined to be independent as defined in the applicable listing standards of the NYSE American LLC, or NYSE American (the Company's Common Stock was traded on the NYSE American at the time that General Hill served as a director of the Company).

In making these determinations, the Board of Directors considered the current and prior relationships that each director and director nominee has with our Company and all other facts and circumstances the Board of Directors deemed relevant in determining their independence, including the beneficial ownership of capital stock by each director and director nominee, and the transactions involving them described in the section of this Proxy Statement entitled "Transactions with Related Persons, Promoters and Certain Control Persons."

#### Board of Directors Composition and Refreshment Process
Our Board of Directors is divided into three classes with staggered three-year terms. Only one class of directors will be elected at each annual meeting of stockholders, with the other classes continuing for the remainder of their respective three-year terms.

At each annual meeting of stockholders, upon the expiration of the term of a class of directors, the successor to each such director in the class will be elected to serve from the time of election and qualification until the third annual meeting following his or her election and until his or her successor is duly elected and qualified, in accordance with our second amended and restated bylaws. Any additional directorships resulting from an increase in the number of

Proxy Statement **9**

[**Table of Contents**](#TOC)

directors will be distributed among the three classes so that, as nearly as possible, each class will consist of one-third of our directors.

In addition, under the terms of our second amended and restated bylaws, members of our Board of Directors may only be removed for cause. This requirement, as well as the classification of the Board described above, may have the effect of delaying or preventing changes in control of our Company. Our Board of Directors considers the enhancement of the skill sets, perspectives and experiences when selecting candidates for board service, among other criteria. To that end, our Board of Directors is committed to including individuals with a varied range of backgrounds, skills and perspectives on the board that align with our business strategy. The Board of Directors is focused on having a board comprised of highly qualified individuals with a broad spectrum of competencies and an appropriate mix of experience, expertise and perspectives. This commitment is key to enabling the Board of Directors to carry out its wide-ranging responsibilities and to enhancing stockholder value.

The Board of Directors recognizes the benefits of a variety of talents in its membership as a competitive advantage, For purposes of board composition, in selecting board candidates, our Nominating and Corporate Governance Committee considers individuals with a broad range of skills, perspectives, experience, personal qualities and attributes described under "Director Nomination Process - Nominating and Corporate Governance Committee – Director Qualifications", including integrity and commitment to the long-term interests of our stockholders. The Board of Directors will utilize these differences and distinctions among individuals to determine the optimum composition of the board in light of our business strategy, risks and opportunities. While education, knowledge and skills are important factors, the Board of Directors also considers how candidates will contribute to the overall balance of the board and enhance the oversight of our strategic plan, so that the Company benefits from directors with different perspectives, varying viewpoints, backgrounds and experiences.

#### Board Leadership Structure
William Clark was appointed our Chairman of the Board of Directors on November 1, 2022. The Board of Directors does not currently have a policy that requires the separation of the roles of Chief Executive Officer and Chairman of the Board of Directors, or that requires a separate lead independent director. The Board of Directors annually reviews its leadership structure to assess what best serves the interests of the Company and its stockholders at a given time. Currently, the positions of Chief Executive Officer and Chairman of the Board of Directors are held by different persons.

The principal responsibilities of our Chairman of the Board of Directors, William Clark, are to manage the operations of the Board and its committees and provide counsel to the Chief Executive Officer on behalf of the Board. As our Chief Executive Officer, Martin Brenner is responsible for our day-to-day operations and for executing our long-term strategies. The Board believes that an appropriate leadership structure depends on the opportunities and challenges facing a company at a given time. The Board believes that the current leadership structure is appropriate for us at this time. Each independent director has direct access to our Chairman and our Chief Executive Officer, as well as other members of the senior management team. The independent directors meet in executive session without management present at least quarterly.

**10** iBio, Inc.

[**Table of Contents**](#TOC)

#### The Board's Role in Risk Oversight

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;**OUR BOARD OF DIRECTORS OVERSEES OUR RISK MANAGEMENT.** | &nbsp;&nbsp;&nbsp;**OUR BOARD OF DIRECTORS OVERSEES OUR RISK MANAGEMENT.** | &nbsp;&nbsp;&nbsp;**OUR BOARD OF DIRECTORS OVERSEES OUR RISK MANAGEMENT.** | &nbsp;&nbsp;&nbsp;**OUR BOARD OF DIRECTORS OVERSEES OUR RISK MANAGEMENT.** |
| &nbsp;&nbsp;&nbsp;**The Board as a whole is responsible for consideration and oversight of risks facing the Company and is responsible for ensuring that material risks are identified and managed appropriately. Certain risks are overseen by committees of the Board and these committees make reports to the full Board.** | &nbsp;&nbsp;&nbsp;**The Board as a whole is responsible for consideration and oversight of risks facing the Company and is responsible for ensuring that material risks are identified and managed appropriately. Certain risks are overseen by committees of the Board and these committees make reports to the full Board.** | &nbsp;&nbsp;&nbsp;**The Board as a whole is responsible for consideration and oversight of risks facing the Company and is responsible for ensuring that material risks are identified and managed appropriately. Certain risks are overseen by committees of the Board and these committees make reports to the full Board.** | &nbsp;&nbsp;&nbsp;**The Board as a whole is responsible for consideration and oversight of risks facing the Company and is responsible for ensuring that material risks are identified and managed appropriately. Certain risks are overseen by committees of the Board and these committees make reports to the full Board.** |
| &nbsp;&nbsp;&nbsp;**Full Board of Directors**:<br>Business strategy, including projected opportunities and challenges facing the Company's business | &nbsp;&nbsp;&nbsp;**Audit Committee**:<br>&nbsp;&nbsp;&nbsp;&nbsp;●Financial statements and SEC reporting<br>&nbsp;&nbsp;&nbsp;&nbsp;●Internal controls over financial reporting<br>&nbsp;&nbsp;&nbsp;&nbsp;●Accounting and audit matters<br>&nbsp;&nbsp;&nbsp;&nbsp;●Company's financial risks and enterprise risk management, including cybersecurity<br>| &nbsp;&nbsp;&nbsp;**Compensation Committee**:<br>Compensation policies and practices and its relationship to our business objectives and goals | &nbsp;&nbsp;&nbsp;**Nominating and Corporate Governance Committee**: <br>● Board and Committee organization, membership, structure and performance<br>● Policies and strategies related to corporate social responsibility and environmental sustainability matters<br>● Corporate governance practices<br>|

---

#### Board and Committee Meetings and Attendance
During the fiscal year ended June 30, 2025, our Board of Directors held six meetings in person or by telephone. The Audit Committee, the Compensation Committee and the Nominating and Corporate Governance Committee held six, four and five meetings, respectively, in person or by telephone. In September 2024, the Board determined to disband the Science and Technology Committee, which had not yet held a meeting in fiscal year 2025. During fiscal year 2025, each current member of the Board of Directors attended at least 75% of the aggregate of all meetings of the Board of Directors and of all meetings of committees of the Board of Directors on which such member served that were held during the period in which such director served.

#### Board Attendance at Annual Stockholders' Meeting
Although we do not have a policy with regard to attendance of members of the Board of Directors at our annual meetings of stockholders, all of the directors are encouraged to attend such meetings. All of our directors at that time attended the 2024 Annual Meeting of Stockholders (the "2024 Annual Meeting") in person or via telephone conference.

#### Stockholder Communications with the Board of Directors
Interested parties may communicate with the Board of Directors or specific members of the Board of Directors, including the independent directors and the members of the Audit Committee or any other committee of the Board of Directors, by submitting correspondence addressed to the Board of Directors of iBio, Inc. c/o any specified individual director or directors at 11750 Sorrento Valley Road, Suite 200, San Diego, California 92121. Any such correspondence will be forwarded to the indicated directors. All communications received will be opened by the office of our Corporate Secretary and the Corporate Secretary's office will make sufficient copies of the contents to send to each director who is a member of the group or committee to which the envelope or e-mail is addressed. The Board of Directors has instructed the Corporate Secretary to forward stockholder correspondence only to the intended recipients and has also instructed the Corporate Secretary to review all stockholder correspondence and, in the Corporate Secretary's discretion, refrain from forwarding any items deemed to be of a commercial or frivolous nature or otherwise inappropriate for the Board of Directors' consideration. Any such items may be forwarded elsewhere in iBio for review and possible response.

Proxy Statement **11**

[**Table of Contents**](#TOC)

#### Code of Business Conduct and Ethics
We have adopted a written code of business conduct and ethics within the meaning of Item 406 of Regulation S-K, which applies to all of our employees, including our Chief Executive Officer, a copy of which can be found on our website at www.ibioinc.com. If we make any waivers or substantive amendments to the code of ethics that are applicable to our principal executive officer or our Chief Financial Officer, we will disclose the nature of such waiver or amendment on our internet website at www.iboinc.com.

#### Prohibitions on Hedging and Pledging
The Company's Insider Trading Policy, which is filed as an exhibit to the Company's annual report on Form 10-K, prohibits directors, officers and employees from trading in Company stock on the basis of material insider information, which is designed to ensure compliance with insider trading laws. The Company's Insider Trading Policy also prohibits such individuals from (1) pledging Company securities that involves pledging (or hypothecating) Company securities as collateral for a loan and (2) engaging in hedging or monetization transactions, including the use of financial instruments such as prepaid variable forwards, equity swaps, collars and exchange funds, that may permit a holder to continue to own Company securities but without the full risks and rewards of ownership.

The Company's Insider Trading Policy also provides that no director, officer or employee may engage in any of the following activities with respect to the Company's securities:

● trading in the Company's securities on a short-term basis - as a general rule, any Company securities purchased in the open market (i.e., not including stock purchased upon exercise of an employee stock option or pursuant to an employee stock purchase plan) should be held for a minimum of six months and ideally longer;

● purchases of Company securities on margin;

● short sales of the Company's securities; and

● buying or selling puts or calls on Company securities.

**12** iBio, Inc.

[**Table of Contents**](#TOC)

Information Regarding Committees of the Board of Directors

### INFORMATION REGARDING

## Committees of the Board of Directors
The Board of Directors has the authority to appoint committees to perform certain management and administration functions. At the beginning of the year ended June 30, 2025, the Board of Directors had four (4) standing committees: the Audit Committee, the Compensation Committee, the Nominating and Corporate Governance Committee and the Science and Technology Committee. In September 2024, the Board determined to disband the Science and Technology Committee, which held no meetings in fiscal year 2025 prior to its being disbanded. The Board of Directors may establish other committees to facilitate the management of our Company's business, including *ad hoc* committees to address particular matters. The composition and functions of each standing committee are described below. Members serve on these committees until their resignation or until otherwise determined by the Board of Directors.

The charters of each of our Board committees are available on our website at *www.ibioinc.com*. Information contained on or accessible through our website is not a part of this proxy statement and the inclusion of such website address in this Proxy Statement is an inactive textual reference only. All of the committees comply with all applicable requirements of the Sarbanes-Oxley Act of 2002, Nasdaq and the Securities and Exchange Commission (the "SEC"), rules and regulations as further described below.

The table set forth below shows the directors who are currently members or Chair of each of the Audit Committee, Compensation Committee, and the Nominating and Corporate Governance Committee. From time to time, the Board of Directors may also establish *ad hoc* committees to address particular matters.

Proxy Statement **13**

[**Table of Contents**](#TOC)

Information Regarding the Board of Directors and Corporate Governance

Below is a description of each committee of the Board of Directors.

---

| | | | | |
|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;**AUDIT COMMITTEE** | &nbsp;&nbsp;**AUDIT COMMITTEE** | &nbsp;&nbsp;**AUDIT COMMITTEE** | &nbsp;&nbsp;**AUDIT COMMITTEE** | &nbsp;&nbsp;**AUDIT COMMITTEE** |
| &nbsp;&nbsp;**CURRENT COMMITTEE MEMBERS:** | Gary Sender (Chair) | William D. Clark | David Arkowitz | **MEETINGS IN FISCAL YEAR 2025: 6** |
| &nbsp;&nbsp;The Audit Committee of the Board of Directors makes recommendations regarding the retention of the Company's independent public accounting firm, monitors the integrity of the Company's financial reporting process and risk management, including systems of internal controls regarding finance and cybersecurity, accounting and legal compliance, oversees the accounting and financial reporting processes of the Company and the audits of the Company's financial statements, oversees the Company's compliance with legal and regulatory requirements and provides an avenue for, and encourages open dialogue and communication among the independent registered public accounting firm, management and the Board of Directors. The Audit Committee monitors the qualifications and performance of the Company's independent registered public accounting firm and determines whether they are compatible with maintaining the registered public accounting firm's independence. The Audit Committee reviews and approves all related party transactions. The Audit Committee has a charter, which is reviewed annually and as may be required due to changes in industry accounting practices or the promulgation of new rules or guidance documents. <br>The responsibilities of the Audit Committee are further described in the Audit Committee Charter, which was adopted by the Board and a copy of which is available on the Company's website at *www.ibioinc.com*. <br>Messrs. Sender, Clark and Arkowitz are each qualified as an "audit committee financial expert" as defined in Regulation S-K Item 407(d)(5)(ii).<br>**Report**<br>The Report of Audit Committee is on page 21 of this proxy statement. | &nbsp;&nbsp;The Audit Committee of the Board of Directors makes recommendations regarding the retention of the Company's independent public accounting firm, monitors the integrity of the Company's financial reporting process and risk management, including systems of internal controls regarding finance and cybersecurity, accounting and legal compliance, oversees the accounting and financial reporting processes of the Company and the audits of the Company's financial statements, oversees the Company's compliance with legal and regulatory requirements and provides an avenue for, and encourages open dialogue and communication among the independent registered public accounting firm, management and the Board of Directors. The Audit Committee monitors the qualifications and performance of the Company's independent registered public accounting firm and determines whether they are compatible with maintaining the registered public accounting firm's independence. The Audit Committee reviews and approves all related party transactions. The Audit Committee has a charter, which is reviewed annually and as may be required due to changes in industry accounting practices or the promulgation of new rules or guidance documents. <br>The responsibilities of the Audit Committee are further described in the Audit Committee Charter, which was adopted by the Board and a copy of which is available on the Company's website at *www.ibioinc.com*. <br>Messrs. Sender, Clark and Arkowitz are each qualified as an "audit committee financial expert" as defined in Regulation S-K Item 407(d)(5)(ii).<br>**Report**<br>The Report of Audit Committee is on page 21 of this proxy statement. | &nbsp;&nbsp;The Audit Committee of the Board of Directors makes recommendations regarding the retention of the Company's independent public accounting firm, monitors the integrity of the Company's financial reporting process and risk management, including systems of internal controls regarding finance and cybersecurity, accounting and legal compliance, oversees the accounting and financial reporting processes of the Company and the audits of the Company's financial statements, oversees the Company's compliance with legal and regulatory requirements and provides an avenue for, and encourages open dialogue and communication among the independent registered public accounting firm, management and the Board of Directors. The Audit Committee monitors the qualifications and performance of the Company's independent registered public accounting firm and determines whether they are compatible with maintaining the registered public accounting firm's independence. The Audit Committee reviews and approves all related party transactions. The Audit Committee has a charter, which is reviewed annually and as may be required due to changes in industry accounting practices or the promulgation of new rules or guidance documents. <br>The responsibilities of the Audit Committee are further described in the Audit Committee Charter, which was adopted by the Board and a copy of which is available on the Company's website at *www.ibioinc.com*. <br>Messrs. Sender, Clark and Arkowitz are each qualified as an "audit committee financial expert" as defined in Regulation S-K Item 407(d)(5)(ii).<br>**Report**<br>The Report of Audit Committee is on page 21 of this proxy statement. | &nbsp;&nbsp;The Audit Committee of the Board of Directors makes recommendations regarding the retention of the Company's independent public accounting firm, monitors the integrity of the Company's financial reporting process and risk management, including systems of internal controls regarding finance and cybersecurity, accounting and legal compliance, oversees the accounting and financial reporting processes of the Company and the audits of the Company's financial statements, oversees the Company's compliance with legal and regulatory requirements and provides an avenue for, and encourages open dialogue and communication among the independent registered public accounting firm, management and the Board of Directors. The Audit Committee monitors the qualifications and performance of the Company's independent registered public accounting firm and determines whether they are compatible with maintaining the registered public accounting firm's independence. The Audit Committee reviews and approves all related party transactions. The Audit Committee has a charter, which is reviewed annually and as may be required due to changes in industry accounting practices or the promulgation of new rules or guidance documents. <br>The responsibilities of the Audit Committee are further described in the Audit Committee Charter, which was adopted by the Board and a copy of which is available on the Company's website at *www.ibioinc.com*. <br>Messrs. Sender, Clark and Arkowitz are each qualified as an "audit committee financial expert" as defined in Regulation S-K Item 407(d)(5)(ii).<br>**Report**<br>The Report of Audit Committee is on page 21 of this proxy statement. | &nbsp;&nbsp;The Audit Committee of the Board of Directors makes recommendations regarding the retention of the Company's independent public accounting firm, monitors the integrity of the Company's financial reporting process and risk management, including systems of internal controls regarding finance and cybersecurity, accounting and legal compliance, oversees the accounting and financial reporting processes of the Company and the audits of the Company's financial statements, oversees the Company's compliance with legal and regulatory requirements and provides an avenue for, and encourages open dialogue and communication among the independent registered public accounting firm, management and the Board of Directors. The Audit Committee monitors the qualifications and performance of the Company's independent registered public accounting firm and determines whether they are compatible with maintaining the registered public accounting firm's independence. The Audit Committee reviews and approves all related party transactions. The Audit Committee has a charter, which is reviewed annually and as may be required due to changes in industry accounting practices or the promulgation of new rules or guidance documents. <br>The responsibilities of the Audit Committee are further described in the Audit Committee Charter, which was adopted by the Board and a copy of which is available on the Company's website at *www.ibioinc.com*. <br>Messrs. Sender, Clark and Arkowitz are each qualified as an "audit committee financial expert" as defined in Regulation S-K Item 407(d)(5)(ii).<br>**Report**<br>The Report of Audit Committee is on page 21 of this proxy statement. |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;**COMPENSATION COMMITTEE** | &nbsp;&nbsp;**COMPENSATION COMMITTEE** | &nbsp;&nbsp;**COMPENSATION COMMITTEE** | &nbsp;&nbsp;**COMPENSATION COMMITTEE** | &nbsp;&nbsp;**COMPENSATION COMMITTEE** |
| &nbsp;&nbsp;**CURRENT COMMITTEE MEMBERS:** | Gary Sender (Chair) | Dr. Alexandra Kropotova | Evert Schimmelpennink | **MEETINGS IN FISCAL YEAR 2025: 4** |
| &nbsp;&nbsp;The Compensation Committee of the Board of Directors assists the Board in the discharge of the Board's responsibilities relating to compensation of the Company's executive officers and directors, reviews and approves compensation plans, policies and programs intended to attract, retain and appropriately reward executive officers and other employees and reviews and approves incentive compensation and equity-based plans, including grants and or awards under such plans. The Compensation Committee also considers other matters as may, from time to time, be referred to them by our Board of Directors. <br>The responsibilities of the Compensation Committee are further described in the Compensation Committee Charter, which was adopted by the Board and a copy of which is available on the Company's website at *www.ibioinc.com*.<br>In August 2024, the Compensation Committee retained Aon's Human Capital Solutions practice, a division of Aon, Inc. ("Aon") as its independent consultant to advise the Compensation Committee on compensation matters and to assist with the review of the Company's compensation programs and practices. Aon provided the Compensation Committee with advice regarding our executive and director compensation program for fiscal 2025, including competitive market analyses, a review and explanation of current and developing best practices in our market, and current and proposed regulatory changes which could impact the Company. See "Executive Compensation - Independent Consultant; Peer Group and Benchmarking."  | &nbsp;&nbsp;The Compensation Committee of the Board of Directors assists the Board in the discharge of the Board's responsibilities relating to compensation of the Company's executive officers and directors, reviews and approves compensation plans, policies and programs intended to attract, retain and appropriately reward executive officers and other employees and reviews and approves incentive compensation and equity-based plans, including grants and or awards under such plans. The Compensation Committee also considers other matters as may, from time to time, be referred to them by our Board of Directors. <br>The responsibilities of the Compensation Committee are further described in the Compensation Committee Charter, which was adopted by the Board and a copy of which is available on the Company's website at *www.ibioinc.com*.<br>In August 2024, the Compensation Committee retained Aon's Human Capital Solutions practice, a division of Aon, Inc. ("Aon") as its independent consultant to advise the Compensation Committee on compensation matters and to assist with the review of the Company's compensation programs and practices. Aon provided the Compensation Committee with advice regarding our executive and director compensation program for fiscal 2025, including competitive market analyses, a review and explanation of current and developing best practices in our market, and current and proposed regulatory changes which could impact the Company. See "Executive Compensation - Independent Consultant; Peer Group and Benchmarking."  | &nbsp;&nbsp;The Compensation Committee of the Board of Directors assists the Board in the discharge of the Board's responsibilities relating to compensation of the Company's executive officers and directors, reviews and approves compensation plans, policies and programs intended to attract, retain and appropriately reward executive officers and other employees and reviews and approves incentive compensation and equity-based plans, including grants and or awards under such plans. The Compensation Committee also considers other matters as may, from time to time, be referred to them by our Board of Directors. <br>The responsibilities of the Compensation Committee are further described in the Compensation Committee Charter, which was adopted by the Board and a copy of which is available on the Company's website at *www.ibioinc.com*.<br>In August 2024, the Compensation Committee retained Aon's Human Capital Solutions practice, a division of Aon, Inc. ("Aon") as its independent consultant to advise the Compensation Committee on compensation matters and to assist with the review of the Company's compensation programs and practices. Aon provided the Compensation Committee with advice regarding our executive and director compensation program for fiscal 2025, including competitive market analyses, a review and explanation of current and developing best practices in our market, and current and proposed regulatory changes which could impact the Company. See "Executive Compensation - Independent Consultant; Peer Group and Benchmarking."  | &nbsp;&nbsp;The Compensation Committee of the Board of Directors assists the Board in the discharge of the Board's responsibilities relating to compensation of the Company's executive officers and directors, reviews and approves compensation plans, policies and programs intended to attract, retain and appropriately reward executive officers and other employees and reviews and approves incentive compensation and equity-based plans, including grants and or awards under such plans. The Compensation Committee also considers other matters as may, from time to time, be referred to them by our Board of Directors. <br>The responsibilities of the Compensation Committee are further described in the Compensation Committee Charter, which was adopted by the Board and a copy of which is available on the Company's website at *www.ibioinc.com*.<br>In August 2024, the Compensation Committee retained Aon's Human Capital Solutions practice, a division of Aon, Inc. ("Aon") as its independent consultant to advise the Compensation Committee on compensation matters and to assist with the review of the Company's compensation programs and practices. Aon provided the Compensation Committee with advice regarding our executive and director compensation program for fiscal 2025, including competitive market analyses, a review and explanation of current and developing best practices in our market, and current and proposed regulatory changes which could impact the Company. See "Executive Compensation - Independent Consultant; Peer Group and Benchmarking."  | &nbsp;&nbsp;The Compensation Committee of the Board of Directors assists the Board in the discharge of the Board's responsibilities relating to compensation of the Company's executive officers and directors, reviews and approves compensation plans, policies and programs intended to attract, retain and appropriately reward executive officers and other employees and reviews and approves incentive compensation and equity-based plans, including grants and or awards under such plans. The Compensation Committee also considers other matters as may, from time to time, be referred to them by our Board of Directors. <br>The responsibilities of the Compensation Committee are further described in the Compensation Committee Charter, which was adopted by the Board and a copy of which is available on the Company's website at *www.ibioinc.com*.<br>In August 2024, the Compensation Committee retained Aon's Human Capital Solutions practice, a division of Aon, Inc. ("Aon") as its independent consultant to advise the Compensation Committee on compensation matters and to assist with the review of the Company's compensation programs and practices. Aon provided the Compensation Committee with advice regarding our executive and director compensation program for fiscal 2025, including competitive market analyses, a review and explanation of current and developing best practices in our market, and current and proposed regulatory changes which could impact the Company. See "Executive Compensation - Independent Consultant; Peer Group and Benchmarking."  |

---

**14** iBio, Inc.

[**Table of Contents**](#TOC)

Information Regarding Committees of the Board of Directors

---

| | | | | |
|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;**NOMINATING AND CORPORATE GOVERNANCE COMMITTEE** | &nbsp;&nbsp;**NOMINATING AND CORPORATE GOVERNANCE COMMITTEE** | &nbsp;&nbsp;**NOMINATING AND CORPORATE GOVERNANCE COMMITTEE** | &nbsp;&nbsp;**NOMINATING AND CORPORATE GOVERNANCE COMMITTEE** | &nbsp;&nbsp;**NOMINATING AND CORPORATE GOVERNANCE COMMITTEE** |
| &nbsp;&nbsp;**CURRENT COMMITTEE MEMBERS:** | Dr. Alexandra Kropotova (Chair) | David Arkowitz | António Parada | **MEETINGS IN FISCAL YEAR 2025: 5** |
| &nbsp;&nbsp;The Nominating and Corporate Governance Committee was formed to identify and recommend to the Board of Directors qualified candidates for election, nomination or appointment to the Board, to review and evaluate information available to it regarding candidates proposed by stockholders, to develop and recommend to the Board a set of corporate guidelines applicable to the Company and periodically review and update those guidelines as well as the charters for each of the committees of the Board and to oversee an annual evaluation of the Board and executive management to determine whether it and its committees are functioning effectively. <br>The responsibilities of the Nominating and Corporate Governance Committee are further described in the Nominating and Corporate Governance Committee Charter, which was adopted by the Board and a copy of which is available on the Company's website. at *www.ibioinc.com*. | &nbsp;&nbsp;The Nominating and Corporate Governance Committee was formed to identify and recommend to the Board of Directors qualified candidates for election, nomination or appointment to the Board, to review and evaluate information available to it regarding candidates proposed by stockholders, to develop and recommend to the Board a set of corporate guidelines applicable to the Company and periodically review and update those guidelines as well as the charters for each of the committees of the Board and to oversee an annual evaluation of the Board and executive management to determine whether it and its committees are functioning effectively. <br>The responsibilities of the Nominating and Corporate Governance Committee are further described in the Nominating and Corporate Governance Committee Charter, which was adopted by the Board and a copy of which is available on the Company's website. at *www.ibioinc.com*. | &nbsp;&nbsp;The Nominating and Corporate Governance Committee was formed to identify and recommend to the Board of Directors qualified candidates for election, nomination or appointment to the Board, to review and evaluate information available to it regarding candidates proposed by stockholders, to develop and recommend to the Board a set of corporate guidelines applicable to the Company and periodically review and update those guidelines as well as the charters for each of the committees of the Board and to oversee an annual evaluation of the Board and executive management to determine whether it and its committees are functioning effectively. <br>The responsibilities of the Nominating and Corporate Governance Committee are further described in the Nominating and Corporate Governance Committee Charter, which was adopted by the Board and a copy of which is available on the Company's website. at *www.ibioinc.com*. | &nbsp;&nbsp;The Nominating and Corporate Governance Committee was formed to identify and recommend to the Board of Directors qualified candidates for election, nomination or appointment to the Board, to review and evaluate information available to it regarding candidates proposed by stockholders, to develop and recommend to the Board a set of corporate guidelines applicable to the Company and periodically review and update those guidelines as well as the charters for each of the committees of the Board and to oversee an annual evaluation of the Board and executive management to determine whether it and its committees are functioning effectively. <br>The responsibilities of the Nominating and Corporate Governance Committee are further described in the Nominating and Corporate Governance Committee Charter, which was adopted by the Board and a copy of which is available on the Company's website. at *www.ibioinc.com*. | &nbsp;&nbsp;The Nominating and Corporate Governance Committee was formed to identify and recommend to the Board of Directors qualified candidates for election, nomination or appointment to the Board, to review and evaluate information available to it regarding candidates proposed by stockholders, to develop and recommend to the Board a set of corporate guidelines applicable to the Company and periodically review and update those guidelines as well as the charters for each of the committees of the Board and to oversee an annual evaluation of the Board and executive management to determine whether it and its committees are functioning effectively. <br>The responsibilities of the Nominating and Corporate Governance Committee are further described in the Nominating and Corporate Governance Committee Charter, which was adopted by the Board and a copy of which is available on the Company's website. at *www.ibioinc.com*. |

---

## Director Nomination Process
**Nominating and Corporate Governance Committee**

Except where the Company is legally required by contract, bylaw or otherwise to provide third parties with the right to nominate directors, the Nominating and Corporate Governance Committee is responsible for, among other matters, annually presenting to the Board a list of individuals recommended for nomination for election as directors at the annual meeting. At least annually and when Board vacancies arise, our Nominating and Corporate Governance Committee identifies and screens candidates for the Board and has the authority as it deems appropriate to retain a professional search firm to identify and evaluate director candidates.

The Nominating and Corporate Governance Committee continuously reviews the changing business conditions and macroeconomic environment that the Company operates in as well as the risks presented by changing business conditions for a company in our competitive industry and growth stage in order to align membership of the Board with our strategic plan, opportunities and challenges. The Nominating and Corporate Governance evaluates the current Board skills, experience, expertise and other attributes when making decisions regarding the nomination of new and incumbent directors.

Before recommending a director candidate, the Nominating and Corporate Governance Committee will review the candidate's qualifications to determine whether the director candidate meets the qualifications described below. In addition, given the time commitments required for effective board service in our rapidly changing industry, the Nominating and Corporate Governance Committee also considers the professional obligations and other commitments of board candidates, as well as service on other boards, in order to ensure that a director has sufficient time to devote to the duties and responsibilities of service on our Board of Directors. In the case of an incumbent director, the Nominating and Corporate Governance Committee will also review the director's service to the Company during the past term, including the number of meetings attended, level of participation, quality of performance, any transactions with the Company engaged in by such director during his term and whether the candidate continues to meet the qualifications for director as described below. In accordance with the Company's policy, Directors cannot be nominated for re-election if they will be 75 years of age or older on the date of the applicable annual meeting, absent a waiver by the Nominating and Corporate Governance Committee and the full Board of Directors. After completing this evaluation, the Nominating and Corporate Governance Committee will make a formal recommendation to the full Board as to election or re-election of the candidate.

Candidates may come to the attention of the committee through current and former Board members, management, professional search firms (to whom we would pay a fee), stockholders or other persons. The Nominating and Corporate Governance Committee does not distinguish between nominees recommended by our stockholders and those recommended by other parties. In considering any person recommended by one of our stockholders, the

Proxy Statement **15**

[**Table of Contents**](#TOC)

Information Regarding the Board of Directors and Corporate Governance

Nominating and Corporate Governance Committee will look for the same qualifications that it looks for in any other person that it is considering for a position on the Board of Directors. The Nominating and Corporate Governance Committee evaluates candidates for the Board on the basis of the needs of the Board and the standards and qualifications set forth below, regardless of the source of the candidate referral.

**Director Qualifications**

Our directors are considered based upon various criteria and principles which the Nominating and Corporate Governance Committee, in consultation with the Chairman develop. The set of criteria and principles are submitted to the Board of Directors for approval. Currently, the criteria and principles used by the Nominating and Corporate Governance Committee in the director selection process includes, but is not limited to, a candidate's broad-based business and professional skills and experiences, a global business and social perspective, concern for the long-term interests of our stockholders, other time commitments and personal integrity and judgment. Further, the Nominating and Corporate Governance Committee believes that the minimum qualifications for serving as our director are that a nominee demonstrate, by significant accomplishment in his or her field, an ability to make a meaningful contribution to the Board of Directors' oversight of our business and affairs and have an impeccable record and reputation for honest and ethical conduct in both his or her professional and personal activities.

**Board Representation**

The Board of Directors believes given the diverse skills and experience required to grow our Company that the input of all members of the Nominating and Corporate Governance Committee is important for considering the qualifications of individuals to serve as directors.

At least annually and when Board vacancies arise, our Nominating and Corporate Governance Committee and the Board will review the qualifications, judgment, attributes, background, experiences, perspectives and skills of each director and any director candidate and the interplay of these traits with the Board as a whole.

**Stockholder Recommendations for Director Nominees**

Any stockholder wishing to recommend a candidate for director should submit the recommendation in writing to our principal executive offices: iBio, Inc., 11750 Sorrento Valley Road, Suite 200, San Diego, California 92121, Attn: Corporate Secretary. The recommendation must include the same information that would be required for a candidate to be nominated by a stockholder at a meeting of stockholders as described under "Stockholder Proposals for the 2026 Annual Meeting" on page 58. Candidates who are recommended by stockholders, as opposed to nominated, will receive the same consideration as other proposed candidates.

**Director Candidates Nominated by Stockholders**

Other than a stockholder who has a contractual right to nominate a director, if a stockholder wishes to formally place a candidate's name in nomination, he or she must do so in accordance with the provisions of our second amended and restated bylaws. See "Stockholder Proposals for the 2026 Annual Meeting" on page 58.

**16** iBio, Inc.

[**Table of Contents**](#TOC)

Director Compensation

### DIRECTOR COMPENSATION

## For 2025 Fiscal Year

#### Director Compensation Table
The following table sets forth information regarding the compensation earned for service on our Board of Directors by our non-employee directors during the year ended June 30, 2025. Dr. Brenner, our Chief Executive Officer and Chief Scientific Officer, received no compensation for his service as a director, and is not included in the table below.

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  |  |  |  |  | **(f)** |  |  |
|  |  |  |  |  | **Change in** |  |  |
|  |  |  |  |  | **Pension Value** |  |  |
|  |  |  |  | **(e)** | **and** |  |  |
|  | **(b)** |  |  | **Non-Equity** | **Nonqualified** |  |  |
|  | **Fees Earned** | **(c)** | **(d)** | **Incentive** | **Deferred** | **(g)** |  |
|  | **or Paid** | **Stock** | **Option** | **Plan** | **Compensation** | **All Other** | **(h)** |
|  | **in Cash** | **Awards** | **Awards**<sup>(1)(2)(3)</sup> | **Compensation** | **Earnings** | **Compensation** | **Total** |
| **(a) Name** | **($)** | **($)** | **($)** | **($)** | **($)** | **($)** | **($)** |
| David Arkowitz | $33428 | $— | $30803 | $— | $— | $— | $64231 |
| William Clark | $88067 | $— | $46205 | $— | $— | $— | $134272 |
| General (Ret.) James T. Hill<sup>(4)</sup> | $21522 | $— | $30721 | $— | $— | $— | $52243 |
| Dr. Alexandra Kropotova | $54141 | $— | $46205 | $— | $— | $— | $100346 |
| António Parada | $27351 | $— | $30803 | $— | $— | $— | $58154 |
| Evert Schimmelpennink | $48063 | $— | $46205 | $— | $— | $— | $94268 |
| Gary Sender | $71351 | $— | $46205 | $— | $— | $— | $117556 |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) This column reflects the aggregate fair value of the option awards granted during the year ended June 30, 2025 computed as of their respective grant dates in accordance with Financial Accounting Standard Board Accounting Standards Codification Topic 718 for stock-based compensation transactions. The value assumption used in determining such amounts are described in Note 18 to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended June 30, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;(2) The aggregate number of stock options awarded to each non-employee director during Fiscal Year 2025 was as follows: Mr. Arkowitz 12,600, Mr. Clark 18,900, Gen. Hill 12,600, Dr. Kropotova 18,900, Mr. Parada 12,600, Mr. Schimmelpennink 18,900, and Mr. Sender 18,900.

&nbsp;&nbsp;&nbsp;&nbsp;(3) The aggregate number of stock options outstanding for each non-employee director was as follows as of June 30, 2025: Mr. Arkowitz 12,600 (2,450 vested), Mr. Clark 19,318 (11,443 vested), Gen. Hill 6,000 (6000 vested and 318 forfeited), Dr. Kropotova 19,318 (11,443 vested), Mr. Parada 12,600 (2,450 vested), Mr. Schimmelpennink 19,318 (11,443 vested) and Mr. Sender 19,318 (11,443 vested).

&nbsp;&nbsp;&nbsp;&nbsp;(4) General Hill's term as a director expired at the conclusion of the 2024 Annual Meeting on November 21, 2024.

Proxy Statement **17**

[**Table of Contents**](#TOC)

Director Compensation

#### Non-Employee Director Compensation Policy
Our non-employee director compensation policy is designed to provide competitive compensation to attract and retain high-quality outside directors. Under our non-employee director compensation policy, we pay each of our non-employee directors a cash retainer for service on the Board of Directors and for service on each committee on which the director is a member. The chair of each committee receives an additional cash retainer for such service. These retainers are payable in arrears in four equal quarterly installments on the last day of each quarter, provided that the amount of such payment will be prorated for any portion of such quarter that the director is not serving on the Board of Directors.

The cash retainers to be paid to non-employee Directors under our non-employee director compensation policy for service on the Board of Directors and for service on each committee of the Board for fiscal year 2025 were as follows:

---

| | | |
|:---|:---|:---|
|  | **Member** | **Chair** |
|  | **Annual** | **Annual** |
|  | **Service** | **Service** |
|  | **Retainer** | **Retainer** |
| &nbsp;&nbsp;Board | $40000 | $35000 |
| &nbsp;&nbsp;Audit Committee | $10000 | $20000 |
| &nbsp;&nbsp;Compensation Committee | $7500 | $15000 |
| &nbsp;&nbsp;Nominating and Corporate Governance Committee | $5000 | $10000 |

---

Our non-employee director compensation policy provides that upon initial election to the Board, each new non-employee director receives a one-time grant of an option to purchase 12,600 shares of Common Stock vesting over 36 months. In addition, the policy provides that on the date of each annual meeting of stockholders, each non-employee director that continues to serve as a non-employee director receives options to purchase shares of Common Stock. Directors have been and will continue to be reimbursed for expenses directly related to their activities as directors, including attendance at Board and committee meetings.

**18** iBio, Inc.

[**Table of Contents**](#TOC)

Proposal 2 Ratification of Appointment of Independent Registered Public Accounting Firm

### PROPOSAL 2

## Ratification of Appointment of Independent Registered Public Accounting Firm
Our independent registered public accounting firm for the fiscal year ended June 30, 2025 was the firm of Grassi & Co., CPAs, P.C. ("Grassi"). The Audit Committee of the Board of Directors has appointed Grassi as our independent registered accounting firm for the year ending June 30, 2026. A representative of Grassi is expected to be present either virtually or via teleconference at the 2025 Annual Meeting and available to respond to appropriate questions and will have the opportunity to make a statement if he or she desires to do so.

iBio is asking its stockholders to ratify the appointment of Grassi as iBio's independent registered public accounting firm for the fiscal year ending June 30, 2026. Although ratification is not required by law, our second amended and restated bylaws or other governing documents, we are submitting the selection of Grassi to you for ratification as a matter of good corporate practice. If the selection is not ratified by a majority of the votes cast on this proposal at the 2025 Annual Meeting, our Audit Committee will consider whether it is appropriate to select another registered public accounting firm. Even if the selection is ratified, our Audit Committee in its discretion may select a different registered public accounting firm at any time during the year if it determines that such a change would be in the best interests of the Company and our stockholders.

**Change in Auditor**

On February 15, 2024, we were notified by CohnReznick LLP ("CohnReznick"), our then independent registered public accounting firm that it was resigning its engagement with us effective immediately. CohnReznick's reports on our consolidated financial statements as of and for the fiscal years ended June 30, 2023 and June 30, 2022 did not contain any adverse opinion or disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope, or accounting principles, other than the report for the fiscal year ended June 30, 2023 contained an explanatory paragraph related to the Company's ability to continue as a "going concern." The decision of CohnReznick to resign was not initiated or approved by the Audit Committee of the Board of Directors.

During the fiscal years ended June 30, 2023 and June 30, 2022, and the subsequent interim periods through February 20, 2024, there were: (i) no disagreements within the meaning of Item 304(a)(1)(iv) of Regulation S-K and the related instructions between the Company and CohnReznick on any matters of accounting principles or practices, financial statement disclosure, or auditing scope or procedure which, if not resolved to CohnReznick's satisfaction, would have caused CohnReznick to make reference thereto in its reports; and (ii) no reportable events within the meaning of Item 304(a)(1)(v) of Regulation S-K, except that during the quarter ended March 31, 2023, the Company identified a material weakness in its controls relating to accounting for stock-based compensation expense relating to the vesting of severed employees' awards, which the Company fully remediated for the year ended June 30, 2023, as previously disclosed in the Company's 2023 annual report filed on Form 10-K. The Company filed a Form 8-K with the SEC disclosing this change in its independent registered public accounting firm on February 21, 2024.

On February 15, 2024, upon recommendation from management, the Audit Committee approved the engagement of Grassi & Co., CPAs, P.C. as the Company's independent registered public accounting firm for the Company's fiscal year ending June 30, 2024. On February 20, 2024, the Company entered into an engagement letter with Grassi and engaged Grassi as the Company's independent registered public accounting firm effective immediately.

During the fiscal year ended June 30, 2025 and the interim period February 20, 2024 through June 30, 2024, neither the Company nor anyone on its behalf consulted with Grassi regarding: (i) the application of accounting principles to a specific transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company's financial statements, and neither a written report nor oral advice was provided to the Company that Grassi concluded was an important factor considered by the Company in reaching a decision as to any accounting, auditing, or financial reporting issue; (ii) any matter that was the subject of a disagreement within the meaning of

Proxy Statement **19**

[**Table of Contents**](#TOC)

Proposal 2 Ratification of Appointment of Independent Registered Public Accounting Firm

Item 304(a)(1)(iv) of Regulation S-K and the related instructions; or (iii) any reportable event within the meaning of Item 304(a)(1)(v) of Regulation S-K.

#### Fees Paid to the Independent Registered Public Accounting Firm
The following table represents the aggregate fees including expenses billed to us for the years ended June 30, 2025 and 2024 by our auditors:

---

| | | |
|:---|:---|:---|
|  | **Year ended**  | **Year ended**  |
|  | **June 30,**  | **June 30,**  |
|  | **2025** | **2024** |
| &nbsp;&nbsp;Audit fees and expenses<sup>(1)</sup> | $330341 | $594463 |
| &nbsp;&nbsp;Taxation preparation fees |  |  |
| &nbsp;&nbsp;Audit related fees |  |  |
| &nbsp;&nbsp;Other fees |  |  |
| &nbsp;&nbsp;Total fees | $330341 | $594463 |
| (1) In the above table, in accordance with the SEC's definitions and rules, "audit fees" are fees we paid Grassi & Co., CPAs P.C. and/or CohnReznick for professional services for the audit of our financial statements included in our Annual Reports on Form 10-K, review of our financial statements included in our Quarterly Reports on Form 10-Q and services normally provided in connection with statutory and regulatory filings or engagements, consents, comfort letters and assistance with and review of our documents filed with the SEC. | (1) In the above table, in accordance with the SEC's definitions and rules, "audit fees" are fees we paid Grassi & Co., CPAs P.C. and/or CohnReznick for professional services for the audit of our financial statements included in our Annual Reports on Form 10-K, review of our financial statements included in our Quarterly Reports on Form 10-Q and services normally provided in connection with statutory and regulatory filings or engagements, consents, comfort letters and assistance with and review of our documents filed with the SEC. | (1) In the above table, in accordance with the SEC's definitions and rules, "audit fees" are fees we paid Grassi & Co., CPAs P.C. and/or CohnReznick for professional services for the audit of our financial statements included in our Annual Reports on Form 10-K, review of our financial statements included in our Quarterly Reports on Form 10-Q and services normally provided in connection with statutory and regulatory filings or engagements, consents, comfort letters and assistance with and review of our documents filed with the SEC. |

---

#### Pre-Approval Policies and Procedures
The Audit Committee's policy is to pre-approve all audit and permissible non-audit services provided by the independent registered public accounting firm. These services may include audit services, audit-related services, tax services and other services. Pre-approval is generally detailed as to the particular service or category of services and is generally subject to a specific budget. The independent registered public accounting firm and management are required to periodically report to the Audit Committee regarding the extent of services provided by the independent registered public accounting firm in accordance with this pre-approval, and the fees for the services performed to date. The Audit Committee may also pre-approve particular services on a case-by-case basis. The Audit Committee pre-approved all of the audit services provided by Grassi & Co., CPAs P.C. and/or CohnReznick to us during the fiscal years ended June 30, 2025 and June 30, 2024.

#### Vote Required
The affirmative vote of the holders of shares having a majority of the votes cast by the holders of the shares present or represented and voting on this proposal will be required to approve the ratification of the appointment of Grassi & Co., CPAs P.C. as iBio's registered public accounting firm for the fiscal year ending June 30, 2026. Since abstentions are not considered votes cast on this proposal, they will have no effect on this proposal. Broker non-votes are not expected for this proposal.

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;![Graphic](ibio-20251120xdef14a_a026.jpg) | **THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT YOU VOTE "FOR" RATIFICATION OF THE SELECTION OF GRASSI & CO., CPAS, P.C. AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OUR FISCAL YEAR ENDING JUNE 30, 2026.** |

---

**20** iBio, Inc.

[**Table of Contents**](#TOC)

Proposal 2 Ratification of Appointment of Independent Registered Public Accounting Firm

### AUDIT

## Committee Report
The Audit Committee reviews the Company's financial reporting processes on behalf of the Board. Management is responsible for the financial statements and the reporting processes, including the internal control over financial reporting. The Company's independent registered public accounting firm, Grassi, is responsible for expressing an opinion on the conformity of the audited financial statements with U.S. generally accepted accounting principles. The Audit Committee monitors these processes. The members of the Audit Committee are not our employees and are not performing the functions of auditors or accountants. Accordingly, it is not the duty or responsibility of the Audit Committee or its members to conduct "field work" or other types of auditing or accounting reviews or procedures or to set auditor independence standards. Members of the Audit Committee necessarily rely on the information provided to them by management and the independent auditors. Accordingly, the Audit Committee's considerations and discussions referred to below do not constitute assurance that the audit of our consolidated financial statements has been carried out in accordance with the standards of the Public Company Accounting Oversight Board ("PCAOB") or that our auditors are in fact independent.

The Audit Committee reviewed and discussed iBio's audited consolidated financial statements as of and for the year ended June 30, 2025 with the management of iBio and Grassi. Further, the Audit Committee discussed with Grassi (i) the matters required to be discussed by the applicable requirements of the PCAOB and the SEC and (ii) the independence of Grassi from the Company and management. The Audit Committee also has received the written disclosures and the letter from Grassi required by applicable requirements of the PCAOB regarding Grassi's communications with the audit committee concerning independence.

Based upon the review and discussions referred to above, the Audit Committee recommended to the Board of Directors, and the Board of Directors has approved, the inclusion of the audited financial statements in the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2025 for filing with the SEC.

Submitted by the Audit Committee of the Board of Directors.

Gary Sender (Chair) William D. Clark David Arkowitz

The material in this report is not "soliciting material," is not deemed "filed" with the SEC and is not incorporated by reference in any filing of iBio, Inc. under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.

Proxy Statement **21**

[**Table of Contents**](#TOC)

Proposal 3 Advisory Vote on the Approval of Executive Compensation

### PROPOSAL 3

## Advisory Vote on the Approval of Executive Compensation
The Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (the "Dodd-Frank Act") and related SEC rules require that we provide our stockholders with the opportunity to cast a nonbinding, advisory vote on the compensation of our named executive officers. This vote, commonly known as a "Say-on-Pay" vote, gives stockholders the opportunity to vote for or against named executive officer compensation during a given fiscal year.

Our executive compensation program is designed to (1) align executive officers' interests with those of our stockholders; (2) attract, motivate and retain executive officers; and (3) reward the achievement of our annual, long-term and strategic goals. Our executive officers are rewarded for the achievement of specific operating goals established by the Compensation Committee and the realization of increased stockholder value.

Our Compensation Committee continually reviews the compensation programs for our executive officers to ensure they achieve the desired goals of aligning our executive compensation structure with our stockholders' interests and current market practices.

The Board of Directors is asking our stockholders to indicate their support for our named executive officers' compensation as disclosed in this proxy statement. This proposal gives our stockholders the opportunity to express their views on our executive compensation. This vote is not intended to address any specific item of compensation, but rather the overall compensation of our named executive officers and the philosophy, policies and practices described in this proxy statement.

Accordingly, the Board of Directors will ask our stockholders to vote "FOR" the following resolution at the 2025 Annual Meeting:

"**RESOLVED**, that the Company's stockholders approve, on an advisory basis, the compensation of the named executive officers as disclosed in the proxy statement for the 2025 Annual Meeting pursuant to the compensation disclosure rules of the Securities and Exchange Commission (which disclosure includes the Summary Compensation Table for fiscal year 2025, and the other related tables and disclosures)."

The Say-on-Pay vote is advisory, and therefore is not binding on us, the Compensation Committee or the Board of Directors. The Board of Directors and the Compensation Committee value the opinions of our stockholders and we will consider our stockholders' concerns and the Compensation Committee will evaluate whether any actions are necessary to address those concerns.

Assuming it is determined that the Company will continue to hold annual "say on pay" votes, the "next say-on-pay vote will occur at our 2026 Annual Meeting.

**22** iBio, Inc.

[**Table of Contents**](#TOC)

Proposal 3 Advisory Vote on the Approval of Executive Compensation

#### Required Vote
The affirmative vote of holders of shares having a majority of the votes cast by the holders of the shares present or represented and voting on this proposal is required to approve, on an advisory basis, the compensation of the Company's named executive officers. Since abstentions and broker non-votes are not considered votes cast on this proposal, they will have no effect on this proposal.

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;![Graphic](ibio-20251120xdef14a_a028.jpg) | **THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE "FOR" THE APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION OF THE NAMED EXECUTIVE OFFICERS AS DISCLOSED IN THIS PROXY STATEMENT.** |

---

Proxy Statement **23**

[**Table of Contents**](#TOC)

Executive Compensation

### PROPOSAL 4

## Advisory Approval of the Frequency of the Advisory Vote on Named Executive Officer Compensation
Section 14a of the Exchange Act enables our stockholders to indicate how frequently we should seek an advisory vote on the compensation of our named executive officers. Stockholders may vote on whether they would prefer an advisory vote on the compensation of our named executive officers once every one, two, or three years. Stockholders have the option to vote for any one of the three options, or to abstain on the matter.

We are required to hold an advisory vote regarding the frequency of "say-on-pay" votes every six years. Our stockholders were provided with the opportunity to vote on the frequency of "say-on-pay" votes in 2019. The stockholders voted in favor of holding "say-on-pay" votes every year, and the board adopted this standard.

While our compensation philosophy and our executive compensation program promote a performance-based culture that rewards performance over the long-term, we acknowledge current stockholder expectations regarding having the opportunity to express their views on the compensation of our named executive officers on an annual basis. We value the opinions of our stockholders and encourage communication regarding our executive compensation policies and practices. The board believes that an annual stockholder vote on the compensation paid to the company's named executive officers provides the board with current information on stockholder sentiment about our executive compensation program and enables the board to respond timely, when deemed appropriate, to stockholder concerns about that program. Accordingly, the board recommends that the advisory vote on executive compensation occur every year.

Although our board recommends that the frequency of an advisory vote on executive compensation occur annually, our stockholders will be given the opportunity to vote in favor of: (i) one year; (ii) two years; (iii) three years; or (iv) abstain. This advisory vote does not approve or disapprove our named executive officers' compensation but rather advises our board on how often our stockholders prefer to vote on executive compensation. While the result of the advisory vote on this proposal is not binding on our board, our board will consider the overall outcome of the vote in establishing the frequency that the advisory vote on executive compensation is submitted to our stockholders.

**Required Vote** 

The recommendation of one year, two years, or three years that receives the highest number of affirmative votes cast by stockholders will be the frequency for future advisory vote on executive compensation that is recommended by stockholders.

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;![Graphic](ibio-20251120xdef14a_a028.jpg) | **THE BOARD RECOMMENDS A VOTE OF EVERY "ONE YEAR" AS THE FREQUENCY WITH WHICH STOCKHOLDERS ARE PROVIDED AN ADVISORY VOTE ON THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.** |

---

**24** iBio, Inc.

[**Table of Contents**](#TOC)

Executive Compensation

### EXECUTIVE OFFICERS

## Who Are Not Directors
Set forth below is certain information regarding the executive officers of the Company who do not serve as directors, including their ages, their positions with our Company and a brief biographical description.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | **Served as an** |
| &nbsp;&nbsp;**Name** | **Age** | **Position** | **Officer Since** |
| &nbsp;&nbsp;Felipe Duran | 46 | Chief Financial Officer | June 2023 |
| &nbsp;&nbsp;Marc Banjak | 48 | Chief Legal Counsel | August 2024 |

---

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;**Felipe Duran, 46** |
| &nbsp;&nbsp;&nbsp;**BACKGROUND**<br>Felipe Duran has been iBio's Chief Financial Officer (CFO) since June 2023 and prior thereto from January 20, 2023 he served as iBio's interim CFO, and previously as iBio's Vice President of Financial Planning and Analysis (FP&A) from May 2021. Previously, Mr. Duran served as the Executive Director (CFO), of Lupin Latin America, a subsidiary of Lupin Pharmaceuticals, overseeing finance, IT and supply chain for the region and for the US R&D finance organization, from May 2016 to May 2021. Previously, Mr. Duran served as the Executive Director (CFO), of Lupin Latin America, a subsidiary of Lupin Pharmaceuticals, from May 2016 – May 2021. In this role, Mr. Duran was responsible for finance, IT and supply chain for Latin America. Additionally, Mr. Duran was responsible for the US R&D finance organization. Prior to joining Lupin Pharmaceuticals, Mr. Duran held various strategic positions at Teva Pharmaceuticals in both its growth markets and Latin America regions. Earlier in his career, Mr. Duran held FP&A and other financial related roles with British United Provident Association Limited (BUPA), a multi-national health insurance and healthcare company, Noven Pharmaceuticals, Inc., Bayview Asset Management, LLC., HIG Capital and IBM Corporation. Mr. Duran received a B.A. in Finance and an M.B.A from the University of Miami. |

---

---

| |
|:---|
| Arc <br>|
| &nbsp;&nbsp;&nbsp;**Marc Banjak, 48** |
| &nbsp;&nbsp;&nbsp;**BACKGROUND**<br>Marc Banjak has been iBio's Chief Legal Officer (CLO) since August 2024 and prior thereto from February 21, 2022 he served as iBio's General Counsel and Corporate Secretary. Mr. Banjak previously served as the first general counsel of both Istari Oncology, a privately-held company, from April to September 2021, and Dova Pharmaceuticals, then a publicly traded company, leading the legal and compliance functions within both organizations, from October 2017 to April 2021. While at Dova, Mr. Banjak advised the company through the acquisition of Dova by Swedish Orphan Biovitrum AB. Prior to that, Mr. Banjak worked as an attorney at PRA Health Sciences, B. Braun Medical, and PPD. Prior to entering the biotechnology and contract research industries, Mr. Banjak served as an active-duty officer in the U.S. Air Force in a variety of legal roles. Mr. Banjak is admitted to the Colorado state bar. Mr. Banjak earned his JD from the University of Denver School of Law and a BA in Psychology from Franklin and Marshall College. |

---

Proxy Statement **25**

[**Table of Contents**](#TOC)

Executive Compensation

### Executive

## Compensation

#### Introduction
The Compensation Committee of our Board of Directors administers our compensation program for executive officers. This section discusses the principles underlying our policies and decisions with respect to the compensation of our executive officers named in the "Summary Compensation Table," who are referred to as our named executive officers (NEOs). For fiscal year 2025, our NEOs are:

---

| | | |
|:---|:---|:---|
| **DR. MARTIN B. BRENNER** | **FELIPE DURAN** | **MARC BANJAK** |
| **Chief Executive Officer and Chief Scientific Officer** | **Chief Financial Officer** | **Chief Legal Officer** |

---

#### Compensation Philosophy
At iBio, we want employees to share in the success of the Company while being challenged and motivated to perform to the best of their abilities. The Compensation Committee believes that compensation programs should include short-term and long-term components, including cash and equity-based compensation, and should encourage and reward performance as measured against pre-established goals. The Compensation Committee evaluates both performance and compensation to make sure that compensation provided to executives of the Company remains competitive relative to compensation paid by companies of similar size and stage of development operating in our industry, considering the Company's relative performance and strategic goals. The Compensation Committee considers the total current and potential long-term compensation of each executive officer in establishing each element of compensation but views each element as related but distinct.

*Overview of Our Compensation Program*

The Compensation Committee seeks to attract and retain superior executive talent by offering competitive base salaries, bonuses and long-term incentives. The Compensation Committee's philosophy is to deliver higher rewards for superior performance and consequences for underperformance. It is also the Compensation Committee's practice to provide a balanced mix of cash and equity-based compensation that aligns both the short and long-term interests of our executives with that of our stockholders. Our executive compensation program is based on the following philosophies and objectives:

● Compensation Should Align with Stockholders' Interests — The Compensation Committee believes that executives' interests should be aligned with those of the stockholders. Executives were granted stock options so that their compensation was tied directly to the value realized by our stockholders. Executive bonuses are tied directly to the achievement of performance goals that the Compensation Committee believes will ultimately drive stockholder value creation.

● Compensation is Competitive — The Compensation Committee seeks to provide a total compensation package that attracts, motivates and retains the executive talent that we need in order to maximize our return to stockholders. To accomplish this objective, executive compensation is reviewed annually to ensure that compensation levels are competitive and reasonable relative to our level of performance and to the compensation opportunities provided by comparable companies with which we compete for talent.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● Compensation Motivates and Rewards the Achievement of Goals — Our executive compensation program is designed to appropriately reward both individual and collective performance that meets and exceeds our annual, long-term and strategic goals. To accomplish this objective, a substantial percentage of total compensation is variable and "at risk," both through annual incentive compensation in the form of cash bonuses and the granting of long-term incentive awards.

**26** iBio, Inc.

[**Table of Contents**](#TOC)

Executive Compensation

#### Say-on-Pay
As part of the Compensation Committee's annual review of the executive compensation program, it considers the outcome of the annual advisory vote of stockholders. At the 2024 annual stockholder meeting, approximately 91% of the "say on pay" votes cast were in favor of the compensation of the Company's NEOs in fiscal year 2024. The Compensation Committee will continue to evaluate our compensation programs to ensure that the management team's interests are aligned with our stockholders' interests to support long-term value creation.

Proxy Statement **27**

[**Table of Contents**](#TOC)

Executive Compensation

#### Positive Pay Practices
In addition, the following features of our compensation program are designed to align the interests of our executive team with those of our stockholders and with market best practice:

---

| | | | |
|:---|:---|:---|:---|
| **What We Do** | **What We Do** | **What We Don't Do** | **What We Don't Do** |
| ![Graphic](ibio-20251120xdef14a_a030.jpg) | Grant compensation that is primarily at-risk and variable | ![Graphic](ibio-20251120xdef14a_a031.jpg) | Allow hedging or pledging of Company stock |
| ![Graphic](ibio-20251120xdef14a_a030.jpg) | Subject short-term incentive compensation to measurable and rigorous goals | ![Graphic](ibio-20251120xdef14a_a031.jpg) | Stock plan prohibits repricing of stock options without shareholder approval |
| ![Graphic](ibio-20251120xdef14a_a030.jpg) | Use an independent compensation consultant | ![Graphic](ibio-20251120xdef14a_a031.jpg) | Provide excessive perquisites |
| ![Graphic](ibio-20251120xdef14a_a030.jpg) | Cap annual cash incentive payments at 150% of target and stock options do not provide value unless there is a stock price increase | ![Graphic](ibio-20251120xdef14a_a031.jpg) | Provide supplemental executive retirement plans |
| ![Graphic](ibio-20251120xdef14a_a030.jpg) | Structure compensation to avoid excessive risk taking | ![Graphic](ibio-20251120xdef14a_a031.jpg) | Pay tax gross-ups on a change in control |
| ![Graphic](ibio-20251120xdef14a_a030.jpg) | Provide competitive compensation that is compared against an industry peer group | ![Graphic](ibio-20251120xdef14a_a031.jpg) | Provide "single trigger" change in control payments |
| ![Graphic](ibio-20251120xdef14a_a030.jpg) | Have a recoupment policy | ![Graphic](ibio-20251120xdef14a_a031.jpg) | Provide excessive severance benefits |

---

**28** iBio, Inc.

[**Table of Contents**](#TOC)

Executive Compensation

#### Compensation Evaluation Processes
The Compensation Committee considers a number of factors in setting compensation for its executive officers, including Company performance, the executive's functional performance, experience and responsibilities, and the compensation of executive officers in similar positions in our peer group of companies.

#### Independent Consultant; Peer Group and Benchmarking
The Compensation Committee has the authority to directly retain the services of independent consultants and other experts to assist in fulfilling its responsibilities. In August 2024, the Compensation Committee retained Aon to conduct a detailed assessment of the current executive compensation program to recommend any potential policy changes for fiscal year 2025. The Compensation Committee assessed the independence of Aon pursuant to SEC rules and in accordance with Nasdaq listing standards, noting that Aon (i) did not have any relationships with the Company, our executive officers or our Compensation Committee members that would impair its independence, and (ii) does not provide any services to the Company other than advice to the Compensation Committee regarding executive officer and director compensation, and concluded that Aon is free from conflicts of interest and is independent.

In October 2025, the Compensation Committee approved a peer group of 21 companies proposed by Aon (the "Peer Group"). The Peer Group was chosen using various parameters, bearing in mind that some of the companies in the Peer Group meet some but not all of the below criteria:

● Biotechnology with a focus on companies including artificial intelligence in drug discovery.

● Phase Preclinical, Phase I, and Phase I/II companies with preference towards AI enabled companies.

● Target companies with a market capitalization below $100 million.

● Target companies under 100 employees in anticipation of FYE 2024-25 headcount projections.

● Preference was given to US-based companies, with a focus on companies headquartered in San Diego, CA or other life science hubs.

At the time the peer group was approved, we had a market cap positioned at the 4th percentile of the peer group, as the peer group median equaled $75.3 million and our projected FYE 2024 headcount (18 employees) was positioned at the 24th percentile of the peer group; as the peer group median equaled 43, even though many companies are larger, they were chosen primarily for their business model, headcount, and stage of development rather than market cap alone. The approved peer group consisted of the following companies:

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;Agenus | Checkpoint Therapeutics | MediciNova |
| &nbsp;&nbsp;&nbsp;Alaunos Therapeutics | Chimerix | Precision Biosciences |
| &nbsp;&nbsp;&nbsp;Assembly Biosciences | Compugen | Rallybio |
| &nbsp;&nbsp;&nbsp;BioAtla | CytomX Therapeutics | Relmada Therapeutics |
| &nbsp;&nbsp;&nbsp;BullFrog AI | Dyadic | Spectral AI |
| &nbsp;&nbsp;&nbsp;CEL-SCI Corporation | Lantern Pharma |  |

---

Proxy Statement **29**

[**Table of Contents**](#TOC)

Executive Compensation

**Aon provided an analysis of data derived from members of our Peer Group. The Compensation Committee used Aon's analysis to help structure a competitive executive compensation program, position executive compensation by considering market data, and make individual compensation adjustments and decisions based on comparable positions at companies with which we compete for talent. While the Compensation Committee does not establish compensation levels solely based on a review of competitive data or benchmark to any particular level, it believes such data is a useful tool in its deliberations as our compensation policies and practices must be competitive in the marketplace for us to be able to attract, motivate and retain qualified executive officers. The Compensation Committee uses the peer group compensation data as one of several factors in determining appropriate compensation parameters for base salary, variable cash compensation and equity-based, long-term incentives. The Compensation Committee's executive compensation decisions are made on a case-by-case basis, and specific benchmark results do not, in and of themselves, determine individual target compensation decisions.**

#### Elements of Executive Compensation
Direct compensation for executives consists of three principal components: base salary, potential annual cash incentive bonus, and long-term equity incentives.

The Compensation Committee does not have any formal policies for allocating compensation among salary, annual cash incentive awards and long-term incentive equity grants, short- and long-term compensation or among cash and non-cash compensation. Instead, the Compensation Committee exercises judgment to establish a total compensation program for each named executive officer that is a mix of current, short- and long-term incentive compensation, and cash and non-cash compensation, that the Compensation Committee believes is appropriate to achieve the goals of our executive compensation program and our corporate goals and objectives. In setting the elements of compensation, the Compensation Committee considers prior compensation paid and amounts realizable from prior stock-based awards, as well as other benefits provided by the Company. The allocation of compensation across each of the elements of our executive compensation program is based on the following considerations:

#### BASE SALARY
Base salary represents the fixed portion of an executive officer's compensation and is intended to provide compensation for day-to-day performance. The Compensation Committee believes that a competitive base salary is a necessary element of any compensation program that is designed to attract and retain talented and experienced executives. Each executive officer's base salary is initially determined upon hire or promotion based on the executive officer's responsibilities, prior experience, individual compensation history and salary levels of other executives within the Company and similarly situated executives within our peer group. Base salary is typically reviewed annually.

**30** iBio, Inc.

[**Table of Contents**](#TOC)

Executive Compensation

The table below reflects annual base salaries for our NEOs as of the end of fiscal year 2025 compared to their annual base salaries for fiscal year 2024 (although Mr. Banjak's base salary for fiscal year 2024 was earned in his role as our General Counsel, prior to his appointment as an executive officer of the Company in August 2024).

---

| | | | | |
|:---|:---|:---|:---|:---|
|  |  | **FY2025 Base** | **FY2024 Base** | **Increase** |
|  |  | **Salary** | **Salary** | **YoY** |
|  |  | **($)** | **($)** | **(%)** |
| Dr. Martin Brenner | Dr. Martin Brenner | $538036 | $522365 | 3% |
| Felipe Duran | Felipe Duran | $371315 | $360500 | 3% |
| Marc Banjak | Marc Banjak | $369386<br><sup>(1)</sup> | $348477 | 6% |
| (1) | Mr. Banjak served as General Counsel for the first seven weeks of fiscal year 2025 at a base salary of $348, 477. Mr. Banjak's base salary was increased to $369,386 upon his appointment as Chief Legal Officer in August 2024.  | Mr. Banjak served as General Counsel for the first seven weeks of fiscal year 2025 at a base salary of $348, 477. Mr. Banjak's base salary was increased to $369,386 upon his appointment as Chief Legal Officer in August 2024.  | Mr. Banjak served as General Counsel for the first seven weeks of fiscal year 2025 at a base salary of $348, 477. Mr. Banjak's base salary was increased to $369,386 upon his appointment as Chief Legal Officer in August 2024.  | Mr. Banjak served as General Counsel for the first seven weeks of fiscal year 2025 at a base salary of $348, 477. Mr. Banjak's base salary was increased to $369,386 upon his appointment as Chief Legal Officer in August 2024.  |

---

#### ANNUAL CASH INCENTIVE BONUSES
The Compensation Committee believes that performance-based cash incentive bonuses play an important role in providing incentives to executives to achieve annual corporate goals. Fiscal year 2025 reflected the continuation of a formulaic plan.

The performance goals for our named executive officers were established by our Compensation Committee. Bonuses for fiscal year 2025 for all of our named executive officers were subject to a formulaic framework with performance goals within the following three categories: (i) business development, (ii) execute development plan, and (iii) financial stability. We have not disclosed the specific performance goals/strategic measures because we believe this disclosure would reveal confidential strategic objectives and information that is not otherwise publicly disclosed by us and would result in competitive harm to us. The strategic measures were designed to be "stretch" goals that were achievable with what we believe represented an elevated level of effort and performance.

Each category was assigned a weighting—40% for business development, 40% for execute development plan and 20% for financial stability. There would be no annual performance-based cash bonus payout with respect to any category for which the Compensation Committee and the Board determined that the Company had not performed and/or did not successfully achieve the performance goal.

Each named executive officer's target annual incentive opportunity is based on a number of factors, including the individual's role and responsibilities within the Company, the individual's experience and expertise, pay levels in the marketplace for similar positions, and performance of the individual and the Company as a whole. For fiscal year 2025, the Compensation Committee and Board set the bonus target, as a percentage of base salary, for each of our NEOs were as follows:

---

| | |
|:---|:---|
|  | **FY25** |
|  | **Bonus Target** |
|  | **(as % of**  |
|  | **Base Salary)** |
| &nbsp;&nbsp;Dr. Martin Brenner | 50% |
| &nbsp;&nbsp;Felipe Duran | 40% |
| &nbsp;&nbsp;Marc Banjak | 40% |

---

**Payouts could be earned at up to 150% of target, based on actual performance. The compensation committee and the board certified that performance bonuses should be paid out at 60% of target based on the Company's performance. Accordingly, for fiscal year 2025, based on the formula described above, the compensation committee and the board issued incentive cash bonuses of $161,411, $89,116 and $88,130 to each of Dr. Brenner and Messrs. Duran and Banjak, respectively.**

#### LONG-TERM EQUITY INCENTIVES
Our primary long-term incentive compensation vehicle is stock options. The number of equity awards granted is based on the executive's position, the executive's performance in the prior year (if applicable), the Company's

Proxy Statement **31**

[**Table of Contents**](#TOC)

Executive Compensation

overall performance, the executive's potential for continued sustained contributions to our success, and competitive market information. Based on market data provided by Aon, the Compensation Committee considers the equity grant levels of the Peer Group, including awards granted as a percent of outstanding shares when recommending equity awards for executive officers.

We grant options based on our belief that they naturally align executives with the creation of stockholder value and are the best long-term incentive vehicle to retain and promote our Company culture. The Compensation Committee believes that stock options are inherently performance-based, incentivize employees to make decisions that support long-term success, and are appropriate and advantageous for the following additional reasons:

● Value is only realized if the stock price increases, thereby aligning the interests of executives with those of stockholders.

● Stock options have greater downside risk than full-value awards, as they do not provide any value to the holder if the stock price declines below the exercise price (determined as of the date of grant).

● The ten-year term of options gives executives the opportunity to realize value over a long period of time, which promotes long-term thinking and value creation.

● Stock options are well understood and help attract and retain employees who contribute to the Company.

On February 21, 2025, Dr. Brenner, Mr. Duran, and Mr. Banjak were granted stock options to purchase 230,700 shares, 84,700 shares, and 71,000 shares, respectively, of the Company's Common Stock at an exercise price of $3.48 per share. The awards vest 25% of the initial award on the one year anniversary of the grant date and then the remainder in equal quarterly installments over a 36-month period.

All of the annual cycle equity grants in fiscal year 2025 were made in the form of time-based stock options.

#### Additional Policies and Benefits
**Equity Grant Policies.** The Compensation Committee typically grants equity-based awards, in the form of stock options , to our executive officers and other employees on an annual grant cycle in the first quarter of each calendar year and may also make off cycle awards from time to time on an as-needed basis. Awards to our directors are made following the annual meeting of stockholders. Executives' stock options are granted with an exercise price based on the fair market value on the date of grant. Equity grants to executives currently are made pursuant to our 2023 Omnibus Incentive Plan (the "2023 Plan"). The Company does not time the disclosure of material non-public information for the purpose of affecting the value of executive compensation, and it is the Compensation Committee's practice to generally avoid granting equity awards during periods in which there is undisclosed material non-public information about the Company.

**Restrictions on Hedging or Pledging.** The Company's Insider Trading Policy prohibits directors, officers and employees from (1) pledging Company securities that involves pledging (or hypothecating) Company securities as collateral for a loan and (2) engaging in hedging or monetization transactions, including the use of financial instruments such as prepaid variable forwards, equity swaps, collars and exchange funds, and may permit a holder to continue to own Company securities but without the full risks and rewards of ownership.

The Company's Insider Trading Policy also provides that no director, officer or employee (or any other person, such as a consultant or contractor, designated by the Company as subject to the Inside Trading Policy) may engage in any of the following activities with respect to the Company's securities: trading in the Company's securities on a short-term basis (i.e., shares of the Company's Common Stock purchased in the open market must be held for a minimum of six months and ideally longer; however, this rule does not apply to sales made following the exercise of options that were granted by the Company or to sales of shares purchased through the Company's equity incentive plans); purchases of Company securities on margin; short sales of the Company's securities; and buying or selling puts or calls on Company securities.

**Clawback/Recoupment Policy.** The Board has adopted a clawback policy which requires the clawback of erroneously awarded incentive-based compensation of past or current executive officers awarded during the three full fiscal years preceding the date on which the issuer is required to prepare an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the federal securities laws. There is no fault or misconduct required to trigger a clawback.

The Compensation Committee shall determine, in its sole discretion, the timing and method for promptly recouping such erroneously awarded compensation, which may include without limitation: (a) seeking reimbursement of all or

**32** iBio, Inc.

[**Table of Contents**](#TOC)

Executive Compensation

part of any cash or equity-based award, (b) cancelling prior cash or equity-based awards, whether vested or unvested or paid or unpaid, (c) cancelling or offsetting against any planned future cash or equity-based awards, (d) forfeiture of deferred compensation, subject to compliance with Section 409A of the Internal Revenue Code (the "Code") and the regulations promulgated thereunder, and (e) any other method authorized by applicable law or contract. Subject to compliance with any applicable law, the Compensation Committee may affect recovery under this policy from any amount otherwise payable to the executive officer, including amounts payable to such individual under any otherwise applicable Company plan or program, including base salary, bonuses or commissions and compensation previously deferred by the executive officer.

**Post-employment Compensation.** Our NEOs are entitled to certain severance and change in control benefits, the terms of which are described below under "Employment Agreements." These severance and change in control benefits are an essential element of the overall executive compensation package and assist the Company in recruiting and retaining talented individuals and aligning the executive's interests with the best interests of the stockholders.

**Other Benefits.** The Company provides certain additional benefits to executive officers that are also generally available to employees, including medical, dental, vision and life insurance coverage, 401(k) matching contributions; however, the Compensation Committee in its discretion may revise, amend or add to these benefits.

**Tax and Accounting Considerations.** The Compensation Committee reviews and considers the various tax and accounting implications of the compensation programs we utilize.

***Deductibility of Executive Compensation*.** Section 162(m) of the Code denies a publicly traded corporation a federal income tax deduction for remuneration in excess of $1 million per year per person paid to executives designated in Section 162(m) of the Code, including, but not limited to, its chief executive officer, chief financial officer, and the next three highly compensated executive officers. However, we believe that maintaining the discretion to provide compensation that is non-deductible allows us to provide compensation tailored to the needs of our Company and our named executive officers and is an important part of our responsibilities and benefits our stockholders.

***Accounting for Stock-Based Compensation*.** We follow Financial Accounting Standard Board Accounting Standards Codification Topic 718, Compensation — Stock Compensation ("ASC Topic 718") for our stock-based compensation awards. ASC Topic 718 requires companies to measure the compensation expense for all share-based awards made to employees and directors, including stock options and restricted stock units, based on the grant-date fair value of these awards. This calculation is performed for accounting purposes and reported in the compensation tables below, even though our executive officers may never realize any value from their awards.

Proxy Statement **33**

[**Table of Contents**](#TOC)

Executive Compensation

#### Summary Compensation Table for Fiscal Year 2025
The table below summarizes all compensation awarded to, earned by, or paid to our named executive officers for all services rendered in all capacities to us and our subsidiaries during the fiscal years noted below:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  |  |  |  |  |  | **Non-Equity** | **All** |  |
|  | **Fiscal** |  |  | **Stock** | **Option** | **Incentive** | **Other** |  |
| &nbsp;&nbsp;&nbsp;**Name and Principal Position** | **Year** | **Salary** | **Bonus** | **Awards**<sup>(1)</sup> | **Award(s)**<sup>(1)</sup> | **Compensation** <sup>(2)</sup> | **Compensation** <sup>(3)</sup> | **Total** |
| &nbsp;&nbsp;&nbsp;Dr. Martin B. Brenner | 2025 | $539366 | $— | $— | $799272 | $161411 | $9858 | $1509907 |
| &nbsp;&nbsp;&nbsp;*Chief Executive Officer and Chief Scientific Officer* | 2024 | $522365 | $— | $— | $518286 | $208946 | $21689 | $1271286 |
| &nbsp;&nbsp;&nbsp;Felipe Duran | 2025 | $371319 | $— | $— | $293447 | $89116 | $16199 | $770081 |
| &nbsp;&nbsp;&nbsp;*Chief Financial Officer* | 2024 | $360500 | $— | $— | $248646 | $144200 | $8524 | $761870 |
| &nbsp;&nbsp;&nbsp;Marc Banjak <sup>(4)</sup> | 2025 | $366932 | $— | $— | $245983 | $88130 | $11858 | $712903 |
| &nbsp;&nbsp;&nbsp;*Chief Legal Officer* |  |  |  |  |  |  |  |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Reflects the aggregate grant date fair value computed in accordance with ASC 718. The value assumption used in determining such amounts are described in Note 18 to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended June 30, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) The amounts reported represent actual bonuses earned for performance during the applicable year by our named executive officers based upon the achievement of our corporate objectives for such year, as described under "Annual Cash Incentive Bonuses."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) All Other Compensation for fiscal year 2025 included the Company's contributions to a Company sponsored qualified retirement plan of $9,858, $16,199 and $11,858 for Dr. Brenner and Messrs. Duran and Banjak, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4) Mr. Banjak was appointed Chief Legal Officer in August 2024.

**34** iBio, Inc.

[**Table of Contents**](#TOC)

Executive Compensation

**Outstanding Equity Awards at Fiscal Year-End (June 30, 2025)**

The following table provides information about the number of outstanding equity awards (post reverse split effected in November 2023) held by each of our named executive officers as of June 30, 2025:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Number of** | **Number of** |  |  |  |  |  |
|  | **securities** | **securities** |  |  |  | **Number of** | **Market value** |
|  | **underlying** | **underlying** |  |  |  | **shares or** | **of shares or** |
|  | **unexercised** | **unexercised** |  | **Option** | **Option** | **units of stock** | **units of stock** |
|  | **options** | **options** | **Grant** | **Exercise** | **Expiration** | **that have** | **that have** |
| &nbsp;&nbsp;&nbsp;**Name** | **exercisable** | **unexercisable** | **Date** | **Price** | **Date** | **not vested** | **not vested**<sup>(5)</sup> |
| &nbsp;&nbsp;Dr. Martin B. Brenner <sup>(1)</sup> | 1000 |  | 1/18/21 | $735.00 | 1/18/31 |  | $— |
| &nbsp;&nbsp;Dr. Martin B. Brenner <sup>(1)</sup> | 1312 | 88 | 8/23/21 | $630.00 | 8/23/31 |  | $— |
| &nbsp;&nbsp;Dr. Martin B. Brenner <sup>(1)</sup> | 962 | 438 | 8/29/22 | $140.00 | 8/29/32 |  | $— |
| &nbsp;&nbsp;Dr. Martin B. Brenner <sup>(1)</sup> | 2624 | 3375 | 8/23/23 | $7.00 | 8/23/33 |  | $— |
| &nbsp;&nbsp;Dr. Martin B. Brenner <sup>(1)</sup> | 36825 | 110475 | 5/9/24 | $1.88 | 5/9/34 |  | $— |
| &nbsp;&nbsp;Dr. Martin B. Brenner <sup>(2)</sup> | 36667 | 73333 | 5/9/24 | $1.88 | 5/9/34 |  | $— |
| &nbsp;&nbsp;Dr. Martin B. Brenner <sup>(1)</sup> |  | 230700 | 2/21/25 | $3.48 | 2/21/35 |  | $— |
| &nbsp;&nbsp;Felipe Duran <sup>(1)</sup> | 140 |  | 5/4/21 | $645.00 | 5/4/31 |  | $— |
| &nbsp;&nbsp;Felipe Duran <sup>(1)</sup> | 46 | 4 | 8/23/21 | $630.00 | 8/23/31 |  | $— |
| &nbsp;&nbsp;Felipe Duran <sup>(1)</sup> | 412 | 188 | 8/29/22 | $140.00 | 8/29/32 |  | $— |
| &nbsp;&nbsp;Felipe Duran <sup>(1)</sup> | 1312 | 1688 | 8/23/23 | $7.00 | 8/23/33 |  | $— |
| &nbsp;&nbsp;Felipe Duran <sup>(1)</sup> | 8950 | 26850 | 4/25/24 | $1.72 | 4/25/34 |  | $— |
| &nbsp;&nbsp;Felipe Duran <sup>(2)</sup> | 30000 | 60000 | 5/9/24 | $1.88 | 5/9/34 |  | $— |
| &nbsp;&nbsp;Felipe Duran <sup>(1)</sup> |  | 84700 | 2/21/25 | $3.48 | 2/21/35 |  | $— |
| &nbsp;&nbsp;Marc Banjak <sup>(1)</sup> | 650 | 150 | 2/21/22 | $170.00 | 2/21/32 |  | $— |
| &nbsp;&nbsp;Marc Banjak <sup>(1)</sup> | 412 | 188 | 8/29/22 | $140 | 8/29/32 |  | $— |
| &nbsp;&nbsp;Marc Banjak <sup>(1)</sup> | 1312 | 1688 | 8/23/23 | $7 | 8/23/33 |  | $— |
| &nbsp;&nbsp;Marc Banjak <sup>(1)</sup> | 7250 | 21750 | 4/25/24 | $2 | 4/25/34 |  | $— |
| &nbsp;&nbsp;Marc Banjak <sup>(2)</sup> | 18334 | 36666 | 5/9/24 | $1.88 | 5/9/34 |  | $— |
| &nbsp;&nbsp;Marc Banjak <sup>(1)</sup> |  | 71000 | 2/21/25 | $3.48 | 2/21/35 |  | $— |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) The options vest twenty-five percent on the first anniversary of the grant dates and then pro-rata on a quarterly basis thereafter.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) The options vest quarterly over three years.

**Employment Agreements in Effect During Fiscal Year 2025**

We have entered into employment agreements with our executive officers, the material terms of which are set forth below.

#### Dr. Martin B. Brenner
On December 23, 2020, the Company entered into an employment agreement (the "Brenner Employment Agreement") with Dr. Martin Brenner to serve as the Company's CSO, effective as of January 18, 2021. In addition to a base salary of $405,000 for serving as the Company's CSO (which was increased as described below) and a discretionary incentive bonus with a target of 40% of his annual base salary while serving as Interim CEO. Dr. Brenner received a monthly cash stipend of $7,500 as part of Dr. Brenner serving as Interim CEO. Dr. Brenner was also granted RSUs to acquire 6,500 (post reverse split effected in November 2023) shares of the Company's Common Stock, which RSUs would vest pro rata over a twelve-month period, with such vesting to terminate when Dr. Brenner was no longer serving as the Company's Interim CEO. The grant-date fair value of the RSUs totaled approximately $91,000. On November 11, 2022, Dr. Brenner was granted RSUs to acquire 4,767 (post reverse split effected in November 2023) shares of Common Stock in exchange for Dr. Brenner's agreement to continue employment with the Company through July 1, 2023, whereby such RSUs would vest on the earlier of (i) July 1, 2023, or (ii) the successful achievement of the Company's 2023 objectives, as defined by the Board of Directors. Such RSUs vested on June 30, 2023.

The Brenner Employment Agreement also provided for an initial grant of options to purchase 1,000 (post reverse splits effected in October 2022 and November 2023) shares of our Common Stock (the "Brenner Option") to Dr. Brenner pursuant to the 2020 Plan, with an exercise price at the fair market value on the date of grant, as determined by our Board of Directors. The Brenner Option vests ratably as follows: (1) 25% of the options granted vests after one year of

Proxy Statement **35**

[**Table of Contents**](#TOC)

Executive Compensation

employment with the Company; and (2) after one year of employment with the Company, 6.25% of the options granted vests for each additional three (3) months of employment, subject to the conditions of the 2020 Plan and the stock option grant agreement. The Brenner Employment Agreement also provides that Dr. Brenner is eligible for additional grants of equity compensation from time to time, in a similar manner to other similarly situated executives, subject to the Company's grant policy and applicable approvals of grants. The Company also provides Dr. Brenner with directors' and officers' liability insurance.

On March 31, 2023, Dr. Brenner was also granted RSUs to acquire 2,500 shares of the Company's Common Stock, which RSUs vested quarterly over one year. The grant-date fair value of the RSUs totaled approximately $104,000.

On June 26, 2023, the Board approved including the monthly cash stipend of $7,500 Dr. Brenner received while serving as Interim CEO as part of his annual base salary for serving as permanent CEO, for an annual base salary of $507,150. In addition, upon appointment as the Company's permanent CEO, 3,791 RSUs terminated because Dr. Brenner was no longer serving as Interim CEO. On June 26, 2023, Dr. Brenner was granted RSUs to acquire 3,791 shares of the Company's Common Stock, which RSUs vested pro rata over a seven-month period. The grant-date fair value of the RSUs totaled approximately $52,000.

On July 23, 2024, we entered into an amended and restated employment agreement (the "Restated Brenner Employment Agreement"), effective as of July 1, 2024 with Dr. Brenner. Pursuant to the Restated Brenner Employment Agreement, Dr. Brenner's base salary was set at $522,365 (the "Base Salary") and his bonus target was increased, effective for fiscal year 2025, to 50% of the Base Salary. The Restated Brenner Employment Agreement provides that Dr. Brenner's Base Salary will be reviewed from time to time by the Compensation Committee and may be increased based upon the evaluation of Dr. Brenner's performance and the compensation policies of the Company in effect at the time of each such review.

The Restated Brenner Employment Agreement provides that Dr. Brenner is eligible to participate in all benefit and fringe benefit plans generally made available to the Company's other executive officers.

Dr. Brenner's employment is on an "at will" basis and may be terminated at any time by him or the Company. If Dr. Brenner is terminated for any reason or no reason, he is entitled to receive the following standard termination benefits: his accrued and unpaid base salary, any unreimbursed expenses accrued through the termination date, any earned but unpaid annual bonus from a prior year and any amounts payable under any benefit plans in which he was a participant.

In the event of a termination by Dr. Brenner for Good Reason (as defined in the Restated Brenner Employment Agreement) or by the Company without "Cause" (as defined in the Restated Brenner Employment Agreement), in addition to the standard termination benefits Dr. Brenner will receive: (i) an amount equal to his then current base salary for twelve months, to be paid out in equal installments in accordance with the Company's regular payroll dates; (ii) a pro rata share of any bonus earned by him during the fiscal year in which the separation occurs based on the actual attainment of metrics upon which the bonus is calculated (as determined by the Board of Directors) to be paid in a lump sum at the time the Company pays bonuses to similarly-situated employees; and (iii) if Dr. Brenner elects continuation coverage for health insurance under COBRA, the Company will pay the full cost of this benefit for a period of twelve (12) months following the termination.

The Restated Brenner Employment Agreement further provides that in the event of a termination by Dr. Brenner for good reason within twelve months after a "Sale Event" (as defined in the 2023 Plan) or by the Company without cause one month prior or twelve months after a Sale Event, in addition to the standard termination benefits Dr. Brenner will receive: (i) an amount equal to his then current base salary for eighteen months, paid out in equal installments in accordance with the Company's regular payroll dates; (ii) an amount equal to the target bonus for which Dr. Brenner would have been eligible during the Company fiscal year in which he terminates employment, to be paid within thirty (30) days of his execution of a separation agreement; (iii) vesting of any unvested time-vested equity awards held by him and (iv) if he elects continuation coverage for health insurance under COBRA, the Company will pay the full cost of this benefit for a period of eighteen (18) months following the termination.

Severance payments begin upon expiration of the revocation period under a general release of claims.

Dr. Brenner has agreed to assign to the Company all of his rights in any Inventions, including all Intellectual Property Rights (as such terms are defined in the employment agreements) that are made, conceived or reduced to practice, in whole or in part, alone or with others, by him during his employment with the Company and has agreed to certain non-solicitation terms.

**36** iBio, Inc.

[**Table of Contents**](#TOC)

Executive Compensation

#### Felipe Duran
On January 23, 2023, Mr. Duran accepted an offer letter from the Company to serve as the Interim CFO (the "Duran Offer Letter"), effective as of February 13, 2023. Upon his appointment to the position of Interim CFO, Mr. Duran's base salary was increased from $300,000 to a base salary of $350,000, and he was eligible for a discretionary incentive bonus with a target of 40% of his annual base salary and was granted a $140,000 special incentive bonus (40% of his fiscal year 2023 annualized salary) in exchange for his agreement to continue employment with the Company through the earlier of: (a) July 1, 2023, or (b) the successful achievement of the Company's 2023 objectives, as defined by the Board of Directors minus any retention bonus he was paid during the fiscal year 2023. Before his appointment as the Company's Interim CFO, Mr. Duran became eligible to receive a retention bonus of $70,000 in exchange for Mr. Duran's agreement to continue employment with the Company through March 31, 2023. Mr. Duran was appointed our permanent CFO in June 2023. We also provide Mr. Duran with directors' and officers' liability insurance.

Mr. Duran's employment is on an "at will" basis and may be terminated at any time by Mr. Duran or the Company. If Mr. Duran separates from employment for any reason or no reason, he is entitled to receive his accrued and unpaid base salary, any unreimbursed expenses and benefits accrued through the termination date. If the Company terminates Mr. Duran's employment for reasons other than for "Cause" (as defined in the Duran Offer Letter), the Company is required to pay the accrued and unpaid base salary, any unreimbursed expenses and benefits accrued through the termination/separation date and provided, that Mr. Duran executes and does not revoke a separation agreement in form acceptable to the Company, Mr. Duran will receive (1) an amount equal to his base salary for nine months, (2) a pro rata share of any bonus earned by him during the Company's fiscal year in which he was terminated, within thirty (30) days of his execution of a separation agreement, and (3) payment of the full amount of all premiums for continued health benefits (including COBRA) under the Company's health plans for a period of nine (9) months following the termination.

If Mr. Duran's employment is terminated without Cause within twelve (12) months after a Change of Control (as defined in the Company's equity incentive plan), provided Mr. Duran executes and does not revoke a separation agreement in a form acceptable to the Company, Mr. Duran will be entitled to receive: (1) an amount equal to his base salary for twelve months, (2) an amount equal to the target bonus for which he would have been eligible during the Company's fiscal year in which he was terminated, within thirty (30) days of his execution of a separation agreement, (3) immediate vesting of 100% of any unvested time-vested equity awards held by him at such time, and (4) payment of the full amount of all premiums for continued health benefits (including COBRA) under the Company's health plans for a period of twelve (12) months following the termination.

Mr. Duran has agreed to assign to the Company all of his rights in any Inventions, including all Intellectual Property Rights (as such terms are defined in his agreement) that are made, conceived or reduced to practice, in whole or in part, alone or with others, by him during his employment with the Company and agreed to certain non-compete and non-solicitation terms.

Mr. Duran and the Company entered into an amended and restated employment agreement on September 3, 2025. See "Changes to Executive Compensation Subsequent to Fiscal Year 2025."

**Marc Banjak**

On January 22, 2022, the Company entered into an employment agreement with Marc Banjak (the "Banjak Employment Agreement"), pursuant to which he earned a base salary of $325,000 per year for serving as the Company's General Counsel, effective as of February 21, 2022 (until his appointment as the Company's Chief Legal Officer in August 2024) and was eligible for a target bonus of 40% of his annual base salary. In connection with his employment, Mr. Banjak received a grant of nonqualified stock options to purchase 20,000 shares of Common Stock (post reverse split effected in November 2023) pursuant to the 2020 Plan, which options vested 25% on the first anniversary of the date of grant and thereafter 6.25% every three months of employment. The Banjak Employment Agreement also provided that Mr. Banjak was eligible for additional grants of equity compensation from time to time, in a similar manner to other similarly situated executives, subject to the Company's grant policy and applicable approvals of grants. The Company also provides Mr. Banjak with directors' and officers' liability insurance.

Mr. Banjak's employment is on an "at will" basis and may be terminated at any time by Mr. Banjak or the Company. If Mr. Banjak separates from employment for any reason or no reason, he is entitled to receive his accrued and unpaid base salary, earned but unpaid annual bonus from a prior fiscal year, any unreimbursed expenses and benefits accrued through the termination date. If the Company terminates Mr. Banjak's employment for reasons other than for "Cause" (as defined in the Banjak Employment Agreement), the Company is required to pay the accrued and unpaid base salary, any unreimbursed expenses and benefits accrued through the termination/separation date and

Proxy Statement **37**

[**Table of Contents**](#TOC)

Executive Compensation

provided, that Mr. Banjak executes and does not revoke a separation agreement in form acceptable to the Company, Mr. Banjak will receive (1) an amount equal to his base salary for nine months, (2) a pro rata share of any bonus earned by him during the Company's fiscal year in which he was terminated, and (3) payment of the full amount of all premiums for continued health benefits (including COBRA) under the Company's health plans for a period of nine (9) months following the termination.

If Mr. Banjak's employment is terminated without Cause within twelve (12) months after a Change of Control (as defined in the Company's equity incentive plan), provided Mr. Banjak executes and does not revoke a separation agreement in a form acceptable to the Company, Mr. Banjak will be entitled to receive: (1) an amount equal to his base salary for twelve months, (2) an amount equal to the target bonus for which he would have been eligible during the Company's fiscal year in which he was terminated, within thirty (30) days of his execution of a separation agreement, (3) immediate vesting of 100% of any unvested time-vested equity awards held by him at such time, and (4) payment of the full amount of all premiums for continued health benefits (including COBRA) under the Company's health plans for a period of twelve (12) months following the termination.

Mr. Banjak has agreed to assign to the Company all of his rights in any Inventions, including all Intellectual Property Rights (as such terms are defined in his agreement) that are made, conceived or reduced to practice, in whole or in part, alone or with others, by him during his employment with the Company and agreed to certain non-compete, non-solicitation and non-disparagement terms.

Mr. Banjak and the Company entered into an amended and restated employment agreement on September 3, 2025. See "Changes to Executive Compensation Subsequent to Fiscal Year 2025."

**38** iBio, Inc.

[**Table of Contents**](#TOC)

Executive Compensation

**Officer Severance Benefit Plan** 

On May 9, 2024, our Board adopted our Officer Severance Benefit Plan (the "Severance Benefit Plan") which provides severance benefits in connection with a "Qualifying Termination" for officers designated as eligible participants thereunder, which currently includes Dr. Brenner, Mr. Duran and Mr. Banjak. The benefits provided by the Severance Benefit Plan coincide with the severance benefits provided to our executive officers pursuant to their respective employment agreements. However, severance benefits provided under the Severance Benefit Plan will be reduced, in whole or in part, by other similar benefits payable to such eligible officer by the Company that become payable in connection with the eligible officer's termination of employment pursuant to any change in control, severance, separation pay or similar plan or any written employment or severance agreement between the eligible officer and the Company. A Qualifying Termination is defined as a resignation for Good Reason or an Involuntary Termination Without Cause (as such terms are defined in the Severance Benefit Plan). Pursuant to the Severance Benefit Plan, if the Company's Chief Executive Officer is a participant in the Severance Benefit Plan and is terminated in a Qualifying Termination then, upon execution of a general waiver and release, he or she will be entitled to (i) a cash payment paid in equal installments in the amount of 18 months of the then-effective base salary of such Chief Executive Officer if such Qualifying Termination is a Sale Event Related Termination (as such term is defined in the Severance Benefit Plan) or 12 months of the then-effective base salary if such Qualifying Termination is a Non-Sale Event Related Termination (as such term is defined in the Severance Benefit Plan); (ii) plus a lump sum equal to 150% of such person's target bonus percentage if such Qualifying Termination is a Sale Event Related Termination or 100% of such person's target bonus percentage pro- rated during the fiscal year of the Qualifying Termination if such Qualifying Termination is a Non-Sale Event Related Termination; (iii) the full amount of his or her COBRA premiums for the period which the participant is paid severance; and (iv) if the Qualifying Termination is a Sale Event Related Termination, the vesting and exercisability of all outstanding Time-Based Vesting Equity Awards and Performance-Based Vesting Equity Awards (as such terms are defined in the Severance Benefit Plan) that are held by such person on such date shall be accelerated in full as of the date of such Sale Event Related Termination and the vesting of any other equity awards granted to the participant by the Company, and any issuance of shares triggered by the vesting of such equity awards, shall be accelerated in full as of the date of such Sale Event Related Termination. For purposes of determining the number of shares that will vest with respect to any Performance-Based Vesting Equity Awards for which the performance period has not ended and that has multiple vesting levels depending upon the level of performance, vesting acceleration with respect to any ongoing performance period(s) shall occur with respect to the number of shares subject to the award as if the applicable performance criteria had been attained at a 100% level or, if greater, based on actual performance as of the Sale Event Related Termination. Pursuant to the Severance Benefit Plan, if an Executive Officer other than the Chief Executive Officer is a participant in the Severance Benefit Plan and is terminated in a Qualifying Termination then, upon execution of a general waiver and release, he or she will be entitled to (i) a cash payment paid in equal installments in the amount of 12 months of the then-effective base salary of such executive officer if such Qualifying Termination is a Sale Event Related Termination or 9 months of the then-effective base salary if such Qualifying Termination is a Non-Sale Event Related Termination; (ii) plus a lump sum equal to 100% of such person's target bonus percentage if such Qualifying Termination is a Sale Event Related Termination or 100% of such person's target bonus percentage pro- rated during the fiscal year of the Qualifying Termination if such Qualifying Termination is a Non-Sale Event Related Termination; (iii) the full amount of his COBRA premiums for the period which the participant is paid severance; and (iv) if the Qualifying Termination is a Sale Event Related Termination, the vesting and exercisability of all outstanding Time-Based Vesting Equity Awards and Performance-Based Vesting Equity Awards (as such terms are defined in the Severance Benefit Plan) that are held by such person on such date shall be accelerated in full as of the date of such Sale Event Related Termination and the vesting of any other equity awards granted to the participant by the Company, and any issuance of shares triggered by the vesting of such equity awards, shall be accelerated in full as of the date of such Sale Event Related Termination. For purposes of determining the number of shares that will vest with respect to any Performance-Based Vesting Equity Awards for which the performance period has not ended and that has multiple vesting levels depending upon the level of performance, vesting acceleration with respect to any ongoing performance period(s) shall occur with respect to the number of shares subject to the award as if the applicable performance criteria had been attained at a 100% level or, if greater, based on actual performance as of the Sale Event Related Termination.

**Changes to Executive Compensation Subsequent to Fiscal Year 2025** 

Subsequent to the end of fiscal year 2025, the Compensation Committee and the Board considered the market competitiveness of the Company's current executive officer base salaries compared to the Peer Group based on the analysis prepared by Aon, while also giving consideration to individual performance, expected future contribution and internal pay equity contributions to corporate performance. This resulted in all of the named executive officers receiving the increases in base salary for fiscal year 2026 as set forth below:

Proxy Statement **39**

[**Table of Contents**](#TOC)

Executive Compensation

---

| | |
|:---|:---|
|  | **FY2026 Base** |
|  | **Salary** |
|  | **($)** |
| &nbsp;&nbsp;Dr. Martin B. Brenner | $580000 |
| &nbsp;&nbsp;Felipe Duran | $415500 |
| &nbsp;&nbsp;Marc Banjak | $400000 |

---

In addition, on September 3, 2025, we entered into amended and restated employment agreements (each an "A&R Employment Agreement") with each of Mr. Duran and Mr. Banjak (for purposes of this discussion, each an "Executive"). Mr. Duran's A&R Employment Agreement provides that Mr. Duran will continue to serve as our Chief Financial Officer, effective as of July 1, 2025, and will receive a base salary of $415,500 per year and is eligible to receive a discretionary incentive bonus with a target of 40% of his annual base salary. Mr. Banjak's A&R Employment Agreement provides that Mr. Banjak will continue to serve as our Chief Legal Officer, effective as of July 1, 2025, and will receive a base salary of $400,000 per year and is eligible to receive a discretionary incentive bonus with a target of 40% of his annual base salary. Each A&R Employment Agreement provides that such Executive's base salary will be reviewed from time to time by the Compensation Committee and may be increased based upon the evaluation of such Executive's performance and the compensation policies of the Company in effect at the time of each such review.

Each A&R Employment Agreement also provides that Executive is eligible for additional grants of equity compensation from time to time, subject to approval of the Board, pursuant to our 2023 Plan, or any successor plan. We also provide each Executive with directors' and officers' liability insurance. Each A&R Employment Agreement provides that Executive is eligible to participate in all benefit plans generally made available to our other executive officers.

Each Executive's employment is on an "at will" basis and may be terminated at any time by him or the Company. If Executive is terminated for any reason or no reason, he is entitled to receive the following standard termination benefits: his accrued and unpaid base salary, any unreimbursed expenses accrued through the termination date, any earned but unpaid annual bonus from a prior year and any amounts payable under any benefit plans in which Executive was a participant (the "Standard Termination Benefits").

In the event of a termination by us without Cause or by Executive for Good Reason (as such terms are defined in each A&R Employment Agreement), in addition to the Standard Termination Benefits, the Executive will receive: (i) an amount equal to his then current base salary for nine months, to be paid out in equal installments in accordance with our regular payroll dates; (ii) a pro rata share of any bonus earned by him during the fiscal year in which the separation occurs based on the actual attainment of metrics upon which the bonus is calculated (as recommended by the Compensation Committee and determined by the Board of Directors) to be paid in a lump sum at the time we pay bonuses to similarly-situated employees; and (iii) if the Executive elects continuation coverage for health insurance under COBRA, we will pay the full cost of this benefit for a period of nine months following the termination.

Each A&R Employment Agreement further provides that in the event of a termination by Executive for Good Reason within twelve months after a "Sale Event" (as defined in the 2023 Plan) or by us without Cause during the period commencing one month prior and ending twelve months after a Sale Event, in addition to the Standard Termination Benefits, Executive will receive: (i) an amount equal to his then current base salary for twelve months, paid out in equal installments in accordance with our regular payroll dates; (ii) an amount equal to the target bonus for which Executive would have been eligible during the fiscal year in which he terminates employment, to be paid within thirty (30) days of his execution of a separation agreement; (iii) vesting of any unvested time-vested equity awards held by him and (iv) if he elects continuation coverage for health insurance under COBRA, we will pay the full cost of this benefit for a period of twelve months following the termination. Severance payments begin upon expiration of the revocation period under a general release of claims.

Each Executive has agreed to assign to the Company all of his rights in any Inventions, including all Intellectual Property Rights (as such terms are defined in each A&R Employment Agreement) that are made, conceived or reduced to practice, in whole or in part, alone or with others, by him during his employment with the Company and has agreed to comply with certain non-solicitation, non-interference and non-disparagement provisions.

**40** iBio, Inc.

[**Table of Contents**](#TOC)

Pay Versus Performance

### Pay Versus Performance
The table below shows compensation actually paid (as defined by the SEC in Item 402(v) of Regulation S-K) for our executives and our financial performance for the years shown in the table. For purposes of this discussion, our CEO is also referred to as our principal executive officer or "PEO" and our other Named Executive Officers are referred to as our "Non-PEO NEOs." We are permitted to report as a "smaller reporting company" as defined under the U.S. federal securities laws. Accordingly, we have not included a tabular list of financial performance measures, and the table below does not include a column for a "Company-Selected Measure" as defined in Item 402(v) of Regulation S-K. For further information regarding our compensation philosophy and how we seek to align executive compensation with the Company's performance, refer to "Executive Compensation."

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  |  |  |  |  |  |  | **Value of** |  |
|  |  |  |  |  |  |  | **Initial Fixed** |  |
|  |  |  |  |  | **Average** |  | **$100**  |  |
|  |  |  |  |  | **Summary** | **Average** | **Investment** |  |
|  |  |  |  |  | **Compensation** | **Compensation** | **Based on** |  |
|  | **Summary Compensation Table** | **Summary Compensation Table** | **Compensation Actually Paid to** | **Compensation Actually Paid to** | **Table Total for** | **Actually Paid** | **Total** |  |
|  | **Total for PEO ($)**<sup>1,2</sup> | **Total for PEO ($)**<sup>1,2</sup> | **PEO ($)**<sup>1,3</sup> | **PEO ($)**<sup>1,3</sup> | **Non-PEO** | **to Non-PEO** | **Shareholder** | **Net Income** |
| &nbsp;&nbsp;&nbsp;**Fiscal Year** | **PEO - Isett** | **PEO - Brenner** | **PEO - Isett** | **PEO - Brenner** | **NEOs**<sup>1,2</sup> | **NEOs**<sup>1,3</sup> | **Return**<sup>4</sup> | **($ Millions)**<sup>5</sup> |
| 2025 | $— | $1509907 | $— | $621717 | $741492 | $432769 | $0.58 | $(18.38) |
| 2024 | $— | $1271286 | $— | $1179292 | $761870 | $742380 | $1.60 | $(24.91) |
| 2023 | $1670498 | $1069174 | $189265 | $629453 | $630739 | $336310 | $9.24 | $(65.01) |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) PEOs/NEOs included in these columns reflect the following individuals:

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**Fiscal Year** | **PEO** | **Non-PEO NEOs** |
| 2025 | Dr. Martin B. Brenner | Felipe Duran, Marc Banjak<sup>(e)</sup> |
| 2024 | Dr. Martin B. Brenner | Felipe Duran |
| 2023 | Thomas F. Isett<sup>(a)</sup>, Dr. Martin B. Brenner<sup>(b)</sup> | Felipe Duran<sup>(c)</sup>, Robert Lutz<sup>(d)</sup> |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Mr. Isett resigned as the Company's Chief Executive Officer on December 1, 2022.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Dr. Brenner has served as the Company's Chief Scientific Officer since January 2021, was appointed as the Company's Interim CEO on January 20, 2023 and as the Company's Chief Executive Officer on June 22, 2023. Dr. Brenner was a Non-PEO NEO in fiscal year 2022.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Mr. Duran was appointed as the Company's Interim CFO effective as of February 13, 2023 and as the Company's Chief Financial Officer on June 22, 2023.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) On January 11, 2023, Mr. Lutz resigned as the Company's Chief Financial Officer effective as of February 10, 2023.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) On August 8, 2024, Mr. Banjak was appointed as the Company's Chief Legal Officer.

&nbsp;&nbsp;&nbsp;&nbsp;(2) Amounts reflect the total compensation for our PEO, and on an average basis, our Non-PEO NEOs as set forth in the summary compensation tables (" SCT ") in the Company's proxy statements for fiscal years 2025, 2024 and 2023.

Proxy Statement **41**

[**Table of Contents**](#TOC)

Pay Versus Performance

&nbsp;&nbsp;&nbsp;&nbsp;(3) The following tables illustrate the adjustments to the SCT total compensation for our PEOs, as well as the average for our other NEOs, to determine "compensation actually paid", as computed in accordance with Item 402(v). Amounts do not reflect actual compensation earned by or paid to our NEOs during the applicable year.

---

| | |
|:---|:---|
|  | **PEO (Brenner)** |
| &nbsp;&nbsp;**Reconciliation of Summary Compensation Table Total to** | **Fiscal Year** |
| &nbsp;&nbsp;**Compensation Actually Paid for PEO**  | **June 30, 2025 ($)** |
| &nbsp;&nbsp;**Summary Compensation Table Total** | $**1509907** |
| &nbsp;&nbsp;**Minus:** Grant Date Fair Value of Option and Stock Awards Granted in Fiscal Year | $799272 |
| &nbsp;&nbsp;**Plus:** Fair Value at Fiscal Year-End of Outstanding and Unvested Option and Stock Awards Granted in Fiscal Year | $— |
| &nbsp;&nbsp;**Plus:** Change in Fair Value of Outstanding and Unvested Option and Stock Awards Granted in Prior Fiscal Years | $(211979) |
| &nbsp;&nbsp;**Plus:** Fair Value at Vesting of Option and Stock Awards Granted in Fiscal Year That Vested During Fiscal Year | $163797 |
| &nbsp;&nbsp;**Plus:** Change in Fair Value as of Vesting Date of Option and Stock Awards Granted in Prior Fiscal Years For Which Applicable Vesting Conditions Were Satisfied During Fiscal Year | $(40736) |
| &nbsp;&nbsp;**Minus:** Fair Value as of Prior Fiscal Year-End of Option and Stock Awards Granted in Prior Fiscal Years That Failed to Meet Applicable Vesting Conditions During Fiscal Year | $— |
| &nbsp;&nbsp;**Plus:** Value of Dividends or Other Earnings Paid on Option and Stock Awards Not Otherwise Reflected in Total Compensation | $— |
| &nbsp;&nbsp;**Compensation Actually Paid** | $**621717** |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;**Reconciliation of Average Summary Compensation Table Total to Average Compensation Actually Paid for Non-PEO NEOs** | **Fiscal YearJune 30, 2025 ($)** |
| &nbsp;&nbsp;**Summary Compensation Table Total** | $**741492** |
| &nbsp;&nbsp;**Minus:** Grant Date Fair Value of Option and Stock Awards Granted in Fiscal Year | $269715 |
| &nbsp;&nbsp;**Plus:** Fair Value at Fiscal Year-End of Outstanding and Unvested Option and Stock Awards Granted in Fiscal Year | $55274 |
| &nbsp;&nbsp;**Plus:** Change in Fair Value of Outstanding and Unvested Option and Stock Awards Granted in Prior Fiscal Years | $(85195) |
| &nbsp;&nbsp;**Plus:** Fair Value at Vesting of Option and Stock Awards Granted in Fiscal Year That Vested During Fiscal Year | $— |
| &nbsp;&nbsp;**Plus:** Change in Fair Value as of Vesting Date of Option and Stock Awards Granted in Prior Fiscal Years For Which Applicable Vesting Conditions Were Satisfied During Fiscal Year | $(9087) |
| &nbsp;&nbsp;**Minus:** Fair Value as of Prior Fiscal Year-End of Option and Stock Awards Granted in Prior Fiscal Years That Failed to Meet Applicable Vesting Conditions During Fiscal Year | $— |
| &nbsp;&nbsp;**Plus:** Value of Dividends or Other Earnings Paid on Option and Stock Awards Not Otherwise Reflected in Total Compensation | $— |
| &nbsp;&nbsp;**Compensation Actually Paid** | $**432769** |

---

For purposes of the above adjustments, the fair value of equity awards on the applicable date were determined in accordance with ASC Topic 718, using valuation methodologies that are generally consistent with those used to determine the grant-date fair value for accounting purposes. For more information, please see the notes to our

**42** iBio, Inc.

[**Table of Contents**](#TOC)

Pay Versus Performance

financial statements in our Annual Report on Form 10-K and the footnotes to the Summary Compensation Table of this proxy statement.

&nbsp;&nbsp;&nbsp;&nbsp;(4) Total Shareholder Return (TSR) represents the cumulative return on a fixed investment of $100 in the Common Stock of iBio, Inc. , at the beginning of the measurement period.

&nbsp;&nbsp;&nbsp;&nbsp;(5) The dollar amounts reported represent the net income reflected in the Company's audited financial statements for the applicable year.

#### Relationship between CAP vs. Cumulative TSR of Company
The following chart illustrates the relationship between compensation actually paid (CAP) for our PEO and the average CAP for our Non-PEO NEOs against our TSR:

![Graphic](ibio-20251120xdef14a_a044.jpg)

Proxy Statement **43**

[**Table of Contents**](#TOC)

Pay Versus Performance

#### Relationship between CAP vs. Net Income
The following chart illustrates the CAP for our PEO and the average CAP for our Non-PEO NEOs against our net income:

![Graphic](ibio-20251120xdef14a_a045.jpg)

All information provided above under the heading "Pay Versus Performance" will not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing, except to the extent the Company specifically incorporates such information by reference.

**44** iBio, Inc.

[**Table of Contents**](#TOC)

Security Ownership of Certain Beneficial Owners and Management

### Security Ownership of

## Certain Beneficial Owners and Management
The following table sets forth the beneficial ownership of our common stock as of October 3, 2025, the Record Date, by:

● each person, or group of affiliated persons, who is known by us to beneficially own more than 5% of our Common Stock;

● each of the named executive officers listed in the Summary Compensation Table;

● each of our directors and director nominees; and

● all of our current executive officers and directors as a group.

As of October 3, 2025, we had 20,254,599 shares of Common Stock outstanding.

Except as otherwise indicated, to our knowledge, the beneficial owners of our Common Stock listed below have sole investment and voting power with respect to such shares. Unless otherwise indicated, the address of each beneficial owner listed in the table below is c/o iBio, Inc. 11750 Sorrento Valley Road, Suite 200, San Diego, California 92121.

---

| | | |
|:---|:---|:---|
|  |  | **Percentage of** |
|  | **Number of shares** | **shares** |
|  | **beneficially** | **beneficially** |
| &nbsp;&nbsp;**Name and address of beneficial owner** | **owned**<sup>(1)</sup> | **owned**<sup>(1)</sup> |
| &nbsp;&nbsp;**Named Executive Officers and Directors:** |  |  |
| &nbsp;&nbsp;David Arkowitz <sup>(2)</sup> | 22582 | \*% |
| &nbsp;&nbsp;Marc Banjak <sup>(3)</sup> | 52365 | \*% |
| &nbsp;&nbsp;Dr. Martin B. Brenner <sup>(4)</sup> | 135466 | \*% |
| &nbsp;&nbsp;William D. Clark <sup>(5)</sup> | 21156 | \*% |
| &nbsp;&nbsp;Felipe Duran <sup>(6)</sup> | 71928 | \*% |
| &nbsp;&nbsp;Dr. Alexandra Kropotova <sup>(7)</sup> | 19318 | \*% |
| &nbsp;&nbsp;António Parada <sup>(8)</sup> | 188023 | \*% |
| &nbsp;&nbsp;Evert Schimmelpennink <sup>(7)</sup> | 19318 | \*% |
| &nbsp;&nbsp;Gary Sender <sup>(9)</sup> | 28509 | \*% |
| &nbsp;&nbsp;All current executive officers and directors as a group (9 persons) | 558665 | 2.75% |
| &nbsp;&nbsp;**5% Stockholders other than executive officers and directors** |  |  |
| &nbsp;&nbsp;ADAR1 Partners, LP <sup>(10)</sup> | 2241926 | 9.99% |
| &nbsp;&nbsp;Lynx1 Master Fund LP <sup>(11)</sup> | 2064230 | 9.99% |
| &nbsp;&nbsp;Point72 Associates, LLC <sup>(12)</sup> | 2247997 | 9.99% |
| &nbsp;&nbsp;Ikarian Healthcare Master Fund LP, Boothbay Absolute Return Strategies, LP and Boothbay Diversified Alpha Master Fund LP <sup>(13)</sup> | 1754298 | 8.19% |
| &nbsp;&nbsp;Affinity Healthcare Fund, LP <sup>(14)</sup> | 2248010 | 9.99% |
| &nbsp;&nbsp;Cormorant Global Healthcare Master Fund, LP <sup>(15)</sup> | 2248010 | 9.99% |
| &nbsp;&nbsp;Adage Capital Partners, L.P. <sup>(16)</sup> | 2248010 | 9.99% |
| &nbsp;&nbsp;Vestal Point Master Fund, LP and affiliates <sup>(17)</sup> | 2248010 | 9.99% |
| &nbsp;&nbsp;SilverArc Capital Alpha Fund I, LP and affiliates <sup>(18)</sup> | 2248010 | 9.99% |

---

\* Represents less than one percent (1%) of the outstanding Common Stock.

&nbsp;&nbsp;&nbsp;&nbsp;(1) Beneficial ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to shares of our Common Stock. On October 3, 2025, there were 20,254,599 shares of our Common Stock outstanding.

Proxy Statement **45**

[**Table of Contents**](#TOC)

Security Ownership of Certain Beneficial Owners and Management

Shares of Common Stock issuable under stock options that are exercisable within 60 days after October 3, 2025 are deemed outstanding and are included for purposes of computing the number of shares owned and percentage ownership of the person holding the option but are not deemed outstanding for computing the percentage ownership of any other person.

&nbsp;&nbsp;&nbsp;&nbsp;(2) Includes 18,382 shares of Common Stock and an aggregate of 4,200 shares of Common Stock underlying options that are vested or will vest within 60 days of October 3, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;(3) Includes 11,066 shares of Common Stock and an aggregate of 41,299 shares of Common Stock underlying options that are vested or will vest within 60 days of October 3, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;(4) Includes 18,316 shares of Common Stock and an aggregate of 117,150 shares of Common Stock underlying options that are vested or will vest within 60 days of October 3, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;(5) Includes 1,838 shares of Common Stock and an aggregate of 19,318 shares of Common Stock underlying options that are vested or will vest within 60 days of October 3, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;(6) Includes 11,139 shares of Common Stock and an aggregate of 60,789 shares of Common Stock underlying options that are vested or will vest within 60 days of October 3, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;(7) Includes an aggregate of 19,318 shares of Common Stock underlying options that are vested or will vest within 60 days of October 3, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;(8) Includes 183,823 shares of Common Stock and an aggregate of 4,200 shares of Common Stock underlying options that are vested or will vest within 60 days of October 3, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;(9) Includes 9,191 shares of Common Stock and an aggregate of 19,318 shares of Common Stock underlying options that are vested or will vest within 60 days of October 3, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;(10) Based upon Company records as of the Record Date and, in part, information provided by the investor as of June 30, 2025 in a Schedule 13G filed with the SEC on August 14, 2025, consists of: (i) 54,819 shares of Common Stock held by ADAR1 Partners, LP and (ii) 2,187,107 shares of Common Stock underlying milestone warrants held by ADAR1 Partners, LP as of June 30, 2025, all of which are exercisable. Does not include an aggregate of 269,033 shares of Common Stock issuable upon the exercise of milestone warrants because ADAR1 Capital Management LLC and its affiliates are prohibited from exercising such warrants, if, as a result of such exercise, they would beneficially own more than 9.99% of the total number of shares of Common Stock then issued and outstanding immediately after giving effect to the exercise. ADAR1 Capital Management, LLC acts as an investment adviser to, and manages investment and trading accounts of, ADAR1 Fund Partners, LP (" ADAR1 Fund "). ADAR1 Capital Management GP, LLC (" ADAR1 General Partner ") acts as the general partner of ADAR1 Fund. ADAR1 Capital Management and ADAR1 General Partner may be deemed to indirectly beneficially own securities held by ADAR1 Fund. Mr. Daniel Schneeberger is the Manager of ADAR1 Capital Management, LLC and ADAR1 General Partner. Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Fund. The address of ADAR1 Capital Management, LLC is 3503 Wild Cherry Drive, Building 9, Austin, Texas 78738.

&nbsp;&nbsp;&nbsp;&nbsp;(11) Based upon Company records as of the Record Date, consists of: (i) 1,655,860 shares of Common Stock and (ii) 408,370 shares of Common Stock issuable upon the exercise of warrants, all of which are exercisable. Does not include an aggregate of 3,659,216 shares of Common Stock issuable upon the exercise of warrants because Lynx1 Capital Management LP is prohibited from exercising such warrants, if, as a result of such exercise, it and its affiliates would beneficially own more than 9.99% of the total number of shares of Common Stock then issued and outstanding immediately after giving effect to the exercise. Lynx1 Capital Management LP is the investment manager of Lynx1 Master Fund LP (" Lynx1 Fund "). Mr. Weston Nichols, the sole member of Lynx1 Capital Management GP LLC, the general partner of Lynx1 Capital Management LP, has sole voting and investment control over the shares held by Lynx1 Capital Management LP. The address for the above referenced entity is 151 Calle de San Francisco, Suite 200, PMB 1237, San Juan, Puerto Rico 00901-1607.

&nbsp;&nbsp;&nbsp;&nbsp;(12) Based upon Company records as of the Record Date and, in part, upon information provided by the investor as of August 22, 2025 in a Schedule 13G filed with the SEC on August 25, 2025, consists of (i) 118 shares of Common Stock held by Point72 Associates, LLC; and (ii) 2,247,997 shares of Common Stock issuable upon exercise of pre-funded warrants and Series G warrants held by Point72 Associates, LLC, all of which are immediately exercisable. Does not include an aggregate of 8,462,121 shares of Common Stock issuable upon the exercise of pre-funded warrants and Series G warrants because Point72 Associates, LLC and its affiliates are prohibited from exercising such warrants, if, as a result of such exercise, they would beneficially own more than 9.99% of the total number of shares of Common Stock then issued and outstanding immediately after giving effect to the exercise. Also does not include 3,570,000 shares of Common Stock issuable upon exercise of a Series H warrant that is issuable upon exercise of the Series G warrant. Point72 Associates, LLC is an investment fund managed by Point72 Capital Advisors, Inc. Steven A. Cohen may be deemed to indirectly beneficially own securities held by Point72 Associates, LLC. The address of the principal business office of Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902.

&nbsp;&nbsp;&nbsp;&nbsp;(13) Based upon Company records as of the Record Date, consists of an aggregate of 599,913 shares of Common Stock and an aggregate of 1,154,385 shares of Common Stock issuable upon exercise of pre-funded warrants held by Ikarian Healthcare Master Fund LP, Boothbay Absolute Return Strategies, LP, and Boothbay Diversified Alpha Master Fund LP. Does not include an aggregate of 1,784,385 shares of Common Stock issuable upon exercise of warrants held by Ikarian Healthcare Master Fund LP, Boothbay Absolute Return Strategies, LP and Boothbay Diversified Alpha Master Fund LP; because Ikarian Healthcare

**46** iBio, Inc.

[**Table of Contents**](#TOC)

Security Ownership of Certain Beneficial Owners and Management

Master Fund, LP and its affiliated entities are prohibited from exercising such warrants, if, as a result of such exercise, they would beneficially own more than 4.99% of the total number of shares of Common Stock then issued and outstanding immediately after giving effect to the exercise. Ikarian Healthcare Master Fund, LP is managed by Ikarian Capital LLC. Boothbay Absolute Return Strategies, LP and Boothbay Diversified Alpha Master Fund LP are managed by Boothbay Fund Management LLC. Neil Shahrestani has voting or investment control over the shares held by Ikarian Healthcare Master Fund, LP, Boothbay Absolute Return Strategies, LP and Boothbay Diversified Alpha Master Fund LP. The address of the foregoing entities is c/o Ikarian Capital LLC, 100 Crescent Court, Suite 1620, Dallas, Texas 75201.

&nbsp;&nbsp;&nbsp;&nbsp;(14) Based upon Company records as of the Record Date and, in part, upon information provided by the investor as of August 19, 2025 in a Schedule 13G filed with the SEC on August 26, 2025, consists of 2,248,010 shares of Common Stock issuable upon exercise of pre-funded warrants and Series G warrants held by Affinity Healthcare Fund, LP, all of which are currently exercisable. Does not include an aggregate of 961,990 shares of Common Stock issuable upon the exercise of pre-funded warrants and Series G warrants because Affinity Healthcare Fund, LP and its affiliates are prohibited from exercising such warrants, if, as a result of such exercise, they would beneficially own more than 9.99% of the total number of shares of Common Stock then issued and outstanding immediately after giving effect to the exercise. Also does not include 1,070,000 shares of Common Stock issuable upon exercise of a Series H warrant that is issuable upon exercise of the Series G warrant. Affinity Asset Advisors, LLC (the " Advisor ") is the investment manager of Affinity Healthcare Fund, LP (the " Fund ") and exercises investment discretion with regard to the securities reported herein. The Advisor may be deemed to be the beneficial owner of the securities reported herein owned by the Fund by virtue of its position as investment manager of the Fund. The Fund and the Advisor have the shared power to vote or to direct the vote and to dispose or direct the disposition of the securities reported herein. Andrew Weinstein, Chief Financial Officer and Chief Compliance Officer of the Advisor and the Fund, may be deemed to indirectly beneficially own securities held by the Fund. The address of the Fund, the Advisor and Mr. Weinstein is 450 Park Avenue Suite 1403, New York, NY 10022.

&nbsp;&nbsp;&nbsp;&nbsp;(15) Based upon Company records as of the Record Date, consists of 2,248,010 shares of Common Stock issuable upon exercise of pre-funded warrants and/or Series G warrants held by Cormorant Global Healthcare Master Fund, LP, all of which are currently exercisable and does not include 8,461,990 shares of Common Stock issuable upon exercise of such warrants because Cormorant Global Healthcare Master Fund, LP is prohibited from exercising such warrants, if, as a result of such exercise, it would beneficially own more than 9.99% of the total number of shares of Common Stock then issued and outstanding immediately after giving effect to the exercise. Also does not include 3,570,000 shares of Common Stock issuable upon exercise of a Series H warrant that is issuable upon exercise of the Series G warrant. Bihua Chen has voting and dispositive power over the shares held by the fund. The address of Cormorant Global Healthcare Master Fund, LP is 200 Clarendon Street, 52nd Floor Boston, MA 02116.

&nbsp;&nbsp;&nbsp;&nbsp;(16) Based upon Company records as of the Record Date, consists of 2,248,010 shares of Common Stock issuable upon exercise of pre-funded warrants and/or Series G warrants held by Adage Capital Partners, L.P., all of which are currently exercisable and does not include 5,251,990 shares of Common Stock issuable upon exercise of such warrants because Adage Capital Partners, L.P. is prohibited from exercising such warrants, if, as a result of such exercise, it would beneficially own more than 9.99% of the total number of shares of Common Stock then issued and outstanding immediately after giving effect to the exercise. Also does not include 2,500,000 shares of Common Stock issuable upon exercise of a Series H warrant that is issuable upon exercise of the Series G warrant. The address of Adage Capital Partners, L.P. is 200 Clarendon Street, 52nd Floor, Boston, Massachusetts 02116.

&nbsp;&nbsp;&nbsp;&nbsp;(17) Based upon Company records as of the Record Date, consists of 2,248,010 shares of Common Stock issuable upon exercise of pre-funded warrants and/or Series G warrants held by Vestal Point Master Fund, LP and an account separately managed by Vestal Point Capital, LP, all of which are currently exercisable and does not include 2,026,990 shares of Common Stock issuable upon exercise of such warrants because Vestal Point Master Fund, LP and the account separately managed by Vestal Point Capital, LP are prohibited from exercising such warrants, if, as a result of such exercise, they would beneficially own more than 9.99% of the total number of shares of Common Stock then issued and outstanding immediately after giving effect to the exercise. Also does not include 1,425,000 shares of Common Stock issuable upon exercise of a Series H warrant that is issuable upon exercise of the Series G warrant. The sole general partner of Vestal Point Master Fund, LP is Vestal Point Partners GP, LLC. The managing member of Vestal Point Partners GP, LLC is Ryan Wilder. The sole general partner of Vestal Point Capital, LP is Vestal Point Capital, LLC. The managing member of Vestal Point Capital, LLC is Mr. Wilder. As a result, Mr. Wilder may be deemed to have voting and investment power over the securities held by Vestal Point Master Fund, LP and the account separately managed by Vestal Point Capital, LP. Mr. Wilder disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. The address of these entities and Mr. Wilder is c/o Vestal Point Capital, LP, 632 Broadway, Suite 602, New York, NY 10012.

&nbsp;&nbsp;&nbsp;&nbsp;(18) Based upon Company records as of the Record Date, consists of 2,248,010 shares of Common Stock issuable upon exercise of pre-funded warrants and/or Series G warrants held by SilverArc Capital Alpha Fund I, LP, SilverArc Capital Alpha Fund II, LP and Squarepoint Diversified Partners Fund Limited (collectively, " SilverArc "), all of which are currently exercisable and does not include 8,461,990 shares of Common Stock issuable upon exercise of such warrants because SilverArc and their affiliates are prohibited from exercising such warrants, if, as a result of such exercise, they would beneficially own more than 9.99% of the total number of shares of Common Stock then issued and outstanding immediately after giving effect to the exercise. Also does not include 3,570,000 shares of Common Stock issuable upon exercise of a Series H warrant that is issuable upon exercise of the Series G warrant. The address of SilverArc is 20 Park Plaza, Boston MA 02116.

Proxy Statement **47**

[**Table of Contents**](#TOC)

Transactions with Related Persons, Promoters and Certain Control Persons

### TRANSACTIONS

## With Related Persons, Promoters and Certain Control Persons
Each of the related party transactions described below was negotiated on an arm's length basis. We believe that the terms of such agreements are as favorable as those we could have obtained from parties not related to us. The following are summaries of certain provisions of our related party agreements and are qualified in their entirety by reference to all of the provisions of such agreements. Because these descriptions are only summaries of the applicable agreements, they do not necessarily contain all of the information that you may find useful. We therefore urge you to review the agreements in their entirety. Copies of the forms of the agreements have been filed as exhibits to our Annual Report on Form 10-K for the year ended June 30, 2025 and are available electronically on the website of the SEC at www.sec.gov.

Pursuant to its charter, our Audit Committee shall review on an on-going basis for potential conflicts of interest, and approve if appropriate, all our "related party transactions." For purposes of the Audit Committee Charter, "Related Party Transactions" shall mean those transactions required to be disclosed pursuant to Regulation S-K, Item 404.

The following is a summary of transactions since July 1, 2023 to which we have been a party in which the amount involved exceeded $120,000 and in which any of our executive officers, directors, director nominees or beneficial holders of more than five percent of our capital stock had or will have a direct or indirect material interest, other than compensation arrangements which are described under the sections of this Proxy Statement "Director Compensation for 2025 Fiscal Year" and "Executive Compensation."

**Side Letter with Lynx1 Capital Management LP**

In connection with the private placement transaction consummated in March 2025, we entered into a letter agreement with Lynx1 (the "Letter Agreement"). Subject to the terms of the Letter Agreement, Lynx1 was entitled to nominate one individual to serve as a director on our Board of Directors for one three-year term commencing with our 2024 Annual Meeting. Accordingly, Lynx1 nominated Antonio Parada for election as Class I director at the 2024 Annual Meeting.

**Private Placement** 

On January 10, 2025, we entered into a securities purchase agreement (the "Purchase Agreement") with certain of our officers and directors (the "Investors"), pursuant to which we agreed to issue and sell to the Investors, in a private placement priced at-the-market (the "Private Placement"), an aggregate of 240,807 shares (the "Shares") of Common Stock. The purchase price of each Share was $2.72, the last reported closing price of the Common Stock on the date of execution of the Purchase Agreement, which closing price was greater than the book value of the Common Stock on the date of the execution of the Purchase Agreement. MagicRoad SGPS, Unipessoal LDA ("MagicRoad") was the only Investor whose purchase in the Private Placement exceeded $120,000, as it purchased 183,823 shares for an aggregate purchase price of $500,000. Antonio Parada is the sole director and shareholder of MagicRoad.

The Private Placement closed on January 10, 2025. We received aggregate gross proceeds from the Private Placement of approximately $655,000, before deducting estimated offering expenses payable by us.

**Review, Approval and Ratification of Transactions with Related Persons**

The general policy of iBio and our Audit Committee is that all material transactions with a related-party and agreements with related parties, as well as all material transactions in which there is an actual, or in some cases, perceived, conflict of interest, will be subject to prior review and approval by our Audit Committee and its independent members, which will determine whether such transactions or proposals are fair and reasonable to our Company and our stockholders. In general, potential related-party transactions will be identified by our management and discussed with our Audit Committee at our Audit Committee's meetings. Detailed proposals, including, where applicable, financial and legal analyses, alternatives and management recommendations, will be provided to our Audit Committee with respect to each issue under consideration and decisions will be made by our Audit Committee with respect to the foregoing related-party transactions after opportunity for discussion and review of materials. When

**48** iBio, Inc.

[**Table of Contents**](#TOC)

Transactions with Related Persons, Promoters and Certain Control Persons

applicable, our Audit Committee will request further information and, from time to time, will request guidance or confirmation from internal or external counsel or auditors. Our policies and procedures regarding related-party transactions are set forth in our Audit Committee Charter and Code of Business Conduct and Ethics, both of which are publicly available on our website at www.ibioinc.com under the heading "Investors—Corporate Governance."

#### Policies and Procedures for Related Person Transactions
The policy we have implemented is that our Board of Directors is to review with management and our independent registered public accounting firm any related party transactions brought to the board's attention which could reasonably be expected to have a material impact on our financial statements. Our practice is for management to present to the Board of Directors each proposed related party transaction, including all relevant facts and circumstances relating thereto, and to update the Board of Directors as to any material changes to any approved related party transaction. In connection with this requirement, each of the transactions or relationships disclosed herein were disclosed to and approved by our Board of Directors. In addition, transactions involving our directors and their affiliated entities were disclosed and reviewed by our Board of Directors in its assessment of our directors' independence requirements.

Proxy Statement **49**

[**Table of Contents**](#TOC)

Additional Information About these Proxy Materials and Voting

### ADDITIONAL INFORMATION

## About these Proxy Materials and Voting
We are providing you with these proxy materials because the Board of Directors, is soliciting your proxy to vote at the 2025 Annual Meeting to be held on November 20, 2025, beginning at 1:00 p.m., Pacific Time including at any postponement or adjournment thereof. The purpose of the 2025 Annual Meeting and the matters to be acted on are stated in the accompanying Notice of Annual Meeting of Stockholders. The Board of Directors knows of no other business that will come before the 2025 Annual Meeting.

---

| | |
|:---|:---|
| **Q:** | &nbsp;&nbsp;**Why am I receiving these materials?** |
| **A:** | &nbsp;&nbsp;We have sent you these proxy materials because the Board of Directors of iBio is soliciting your proxy to vote at the 2025 Annual Meeting, including at any postponements or adjournments of the 2025 Annual Meeting. |

---

---

| | |
|:---|:---|
| **Q:** | &nbsp;&nbsp;**Who can vote at the 2025 Annual Meeting?** |
| **A:** | &nbsp;&nbsp;Only stockholders of record at the close of business on October 3, 2025, or the Record Date, will be entitled to vote at the 2025 Annual Meeting. On the Record Date, there were 20,254,599 shares of Common Stock outstanding and entitled to vote.<br>**Stockholder of Record: Shares Registered in Your Name**<br>If on October 3, 2025 your shares were registered directly in your name with the Company's transfer agent, Continental Stock Transfer & Trust Company, then you are a stockholder of record. As a stockholder of record, you may directly vote your shares or submit a proxy to have your shares voted. We urge you to fill out and return the enclosed proxy card or submit a proxy via the internet or by telephone as instructed herein to ensure your vote is counted.<br>**Beneficial Owner: Shares Registered in the Name of a Broker or Bank**<br>If on October 3, 2025 your shares were held, not in your name, but rather in an account at a brokerage firm, bank, dealer or other similar organization, then you are the beneficial owner of shares held in "street name" and these proxy materials are being forwarded to you by that organization. The organization holding your account is considered to be the stockholder of record for purposes of voting at the 2025 Annual Meeting. As a beneficial owner, you have the right to direct your broker, bank or other nominee regarding how to vote the shares in your account. You will receive voting instructions from your broker, bank or nominee describing the available processes for voting your stock.<br>Beneficial owners who wish to attend the 2025 Annual Meeting must obtain a legal proxy by contacting their account representative at the bank, broker, or other nominee that holds their shares and e-mail a copy (a legible photograph is sufficient) of their legal proxy to proxy@continentalstock.com. |

---

---

| | |
|:---|:---|
| **Q:** | &nbsp;&nbsp;**What information is contained in the Proxy Statement?** |
| **A:** | &nbsp;&nbsp;The information included in this proxy statement relates to the proposals to be considered and voted on at the 2025 Annual Meeting, the voting process, the compensation of our directors and executive officers, and other required information. |

---

**50** iBio, Inc.

[**Table of Contents**](#TOC)

Additional Information About these Proxy Materials and Voting

---

| | |
|:---|:---|
| **Q:** | &nbsp;&nbsp;**Who can help answer my questions?** |
| **A:** | &nbsp;&nbsp;If you have any questions about the 2025 Annual Meeting or how to vote, submit a proxy or revoke your proxy, or you need additional copies of this Proxy Statement or voting materials, you can contact our Corporate Secretary, iBio, Inc., 11750 Sorrento Valley Road, Suite 200, San Diego, California 92121, or by phone (979) 446-0027. |

---

---

| | |
|:---|:---|
| **Q:** | &nbsp;&nbsp;**How do I get electronic access to the proxy materials?** |
| **A:** | &nbsp;&nbsp;This Proxy Statement and the 2025 Annual Report are available at https://ir.ibioinc.com. |

---

---

| | |
|:---|:---|
| **Q:** | &nbsp;&nbsp;**What items of business will be considered and voted on at the 2025 Annual Meeting?** |
| **A:** | &nbsp;&nbsp;The business scheduled to be considered and voted on at the 2025 Annual Meeting are: (1) the election of our two (2) nominees named herein as Class II directors; (2) the ratification of Grassi & Co., CPAs, P.C. as our independent registered public accounting firm for the fiscal year ending on June 30, 2026; (3) the approval, on an advisory, non-binding basis, of the compensation of our named executive officers; and (4) the approval, on an advisory basis, of the frequency of future executive compensation advisory votes. |

---

---

| | |
|:---|:---|
| **Q:** | &nbsp;&nbsp;**How does the Board of Directors recommend that I vote?** |
| **A:** | &nbsp;&nbsp;For the reasons described under each Proposal, the Board of Directors recommends that you vote (1) **FOR** each of the two (2) Class II director nominees named herein for election to the Board of Directors; (2) **FOR** the Auditor Ratification Proposal; (3) **FOR** the Say-on-Pay Proposal; and (4) **EVERY ONE YEAR** for the Say-on-Frequency Proposal. |

---

---

| | |
|:---|:---|
| **Q:** | &nbsp;&nbsp;**What is a quorum and why is it necessary?** |
| **A:** | &nbsp;&nbsp;Conducting business at the 2025 Annual Meeting requires a quorum. <br>A quorum will be present if stockholders holding at least one third of the issued and outstanding shares entitled to vote at the close of business on October 3, 2025 are present at the 2025 Annual Meeting in person, present by means of remote communication in a manner, if any, authorized by the Board of Directors in its sole discretion, or represented by proxy. Abstentions are treated as present for purposes of determining whether a quorum exists. Your shares will be counted towards the quorum only if you submit a valid proxy (or one is submitted on your behalf by your broker, bank or other nominee) or if you vote at the 2025 Annual Meeting. If you are a beneficial owner whose shares are held by a broker, bank or other nominee, you must instruct the broker, bank or nominee how to vote your shares. If you do not provide voting instructions, your broker may register your shares as being present at the 2025 Annual Meeting for purposes of determining the presence of a quorum, but the shares will not be voted on proposals on which brokers do not have discretionary authority. This is called a "broker non-vote." Broker non-votes are counted as present and entitled to vote for purposes of determining a quorum. If there is no quorum, the stockholders present or represented at the 2025 Annual Meeting and entitled to vote may adjourn the meeting to another date or if no stockholder is present any officer entitled to preside at or act as secretary of the meeting may adjourn the meeting to another date. |

---

Proxy Statement **51**

[**Table of Contents**](#TOC)

Additional Information About these Proxy Materials and Voting

---

| | |
|:---|:---|
| **Q:** | &nbsp;&nbsp;**What is the voting requirement to approve each of the proposals?** |
| **A:** | &nbsp;&nbsp;If a quorum is present or represented by proxy at the 2025 Annual Meeting, the vote required to approve each of the proposals is as follows: |

---

---

| | | | |
|:---|:---|:---|:---|
| **PROPOSAL** | **VOTE REQUIREDFOR APPROVAL** | **EFFECT OF ABSTENTIONS (or the withholding of authority)** | **Impact of Broker Non-Votes** |
| **Proposal 1:**<br>Election of two (2) Class II directors | Plurality - the two (2) director nominees who receive the most "FOR" votes will be elected to serve as a Class II director | No effect | No effect |
| **Proposal 2:** Ratification of the appointment of independent auditor<br>| The affirmative vote of the holders of shares of stock having a majority of the votes cast by the holders of all shares of stock present or represented and voting on that proposal | No effect | Not applicable-There are not expected to be any. |
| <br>**Proposal 3:**<br>Advisory approval of the compensation of iBio's named executive officers | <br>The affirmative vote of the holders of shares of stock having a majority of the votes cast by the holders of all shares of stock present or represented and voting on that proposal  | <br>No effect | <br>No effect |
| <br>**Proposal 4:**<br>Advisory approval of the frequency of the proposal to approve the compensation of iBio's named executive officers | <br>The option of every "one-year," "two-years" or "three-years" that receives the highest number of votes cast | <br>No effect | <br>No effect |

---

&nbsp;&nbsp;If your shares are held in "street name" and you do not indicate how you wish to vote, your broker is permitted to exercise its discretion to vote your shares on certain "routine" matters. The only routine matter to be submitted to our stockholders at the 2025 Annual Meeting is the Auditor Ratification Proposal. If you do not direct your broker how to vote on the Auditor Ratification Proposal, your broker may exercise discretion and may vote your shares on such proposal in its discretion. None of our other proposals are routine matters. Accordingly, if you do not direct your broker how to vote for a director in the Election of Directors Proposal, on the Say-on-Pay Proposal or on the Say-on-Frequency Proposal, your broker may not exercise discretion and may not vote your shares on such proposals.<br>We encourage you to vote **FOR** each of the two (2) nominees for Class II director nominees named in the Election of Directors Proposal, **FOR** the Auditor Ratification Proposal, **FOR** the Say-on-Pay Proposal and **EVERY ONE YEAR** for the Say-on-Frequency Proposal.<br>

---

| | |
|:---|:---|
| **Q:** | &nbsp;&nbsp;**What shares can I vote?** |

---

**52** iBio, Inc.

[**Table of Contents**](#TOC)

Additional Information About these Proxy Materials and Voting

---

| | |
|:---|:---|
| **A:** | &nbsp;&nbsp;You may vote or cause to be voted all shares owned by you as of the close of business on October 3, 2025, the Record Date. These shares include: (1) shares held directly in your name as a stockholder of record; and (2) shares held for you, as the beneficial owner, through a broker or other nominee, such as a bank. |

---

---

| | |
|:---|:---|
| **Q:** | &nbsp;&nbsp;**How may I vote?** |
| **A:** | &nbsp;&nbsp;You may either vote FOR each of the two (2) nominees to the Board of Directors or you may WITHHOLD your vote for any nominee you specify. You may not cumulate your votes in the Election of Directors Proposal. With respect to each of the other proposals, you may vote FOR, AGAINST, or ABSTAIN.<br>The procedures for voting are fairly simple:<br>**STOCKHOLDER OF RECORD: SHARES REGISTERED IN YOUR NAME**<br>If you are a stockholder of record, you may have your shares voted by proxy. We urge you to have your shares voted by proxy to ensure your vote is counted.<br>&nbsp;&nbsp;&nbsp;&nbsp;●&nbsp;&nbsp;&nbsp;&nbsp; To have your shares voted using the proxy card, simply complete, sign and date the enclosed proxy card and return it promptly in the envelope provided. If you return your signed proxy card to us before the 2025 Annual Meeting, the proxyholder will vote your shares as you direct.<br>&nbsp;&nbsp;&nbsp;&nbsp;●&nbsp;&nbsp;&nbsp;&nbsp; To have your shares voted through the internet follow the instructions on the enclosed proxy card *(https://www.cstproxyvote.com)* to complete an electronic proxy card. You will be asked to provide the Company number and control number from the enclosed proxy card. Your internet vote must be received by 11:59 p.m. Eastern Time on November 19, 2025 to be counted.<br>&nbsp;&nbsp;&nbsp;&nbsp;●&nbsp;&nbsp;&nbsp;&nbsp; To have your shares voted through the telephone dial the toll-free number on the enclosed proxy card (866-894-0536) using a touch-tone phone and follow the recorded instructions. You will be asked to provide the Company number and control number from the enclosed proxy card. Your telephone vote must be received by 11:59 p.m. Eastern Time on November 19, 2025 to be counted. <br>&nbsp;&nbsp;&nbsp;&nbsp;●&nbsp;&nbsp;&nbsp;&nbsp; You or your proxyholder will be able to attend and vote at the 2025 Annual Meeting.<br>**Beneficial Owner: Shares Registered in the Name of Broker or Bank**<br>If you are a beneficial owner of shares registered in the name of your broker, bank, or other nominee, you should have received a voting instruction form with these proxy materials from that organization rather than from iBio. Follow the instructions from your broker, bank or other nominee included with these proxy materials, or contact your broker, bank or other nominee to request a proxy form. Internet voting may be available to beneficial owners. Please refer to the voting instruction form provided by your broker, bank or other nominee. |

---

---

| | |
|:---|:---|
| **Q:** | &nbsp;&nbsp;**How many votes do I have?** |
| **A:** | &nbsp;&nbsp;On each matter to be voted upon, you have one vote for each share of Common Stock you own as of the close of business on October 3, 2025, the Record Date. |

---

Proxy Statement **53**

[**Table of Contents**](#TOC)

Additional Information About these Proxy Materials and Voting

---

| | |
|:---|:---|
| **Q:** | &nbsp;&nbsp;**What happens if I do not vote?** |
| **A:** | &nbsp;&nbsp;**Stockholder of Record: Shares Registered in Your Name**<br>If you are a stockholder of record and do not vote at the 2025 Annual Meeting or by completing your proxy card or submitting your proxy via the internet or by telephone, your shares will not be voted.<br>**BENEFICIAL OWNER: SHARES REGISTERED IN THE NAME OF BROKER OR BANK**<br>If you are a beneficial owner and do not instruct your broker, bank, or other nominee how to vote your shares, the question of whether your broker will still be able to vote your shares depends on whether the New York Stock Exchange ("NYSE") deems the particular proposal to be a "routine" matter. Brokers can use their discretion to vote "uninstructed" shares with respect to matters that are considered to be "routine," but not with respect to "non-routine" matters. Under the rules and interpretations of NYSE, "non-routine" matters are matters that may substantially affect the rights or privileges of stockholder, such as mergers, stockholder proposals, elections of directors (even if not contested), executive compensation (including any advisory stockholder votes on executive compensation (say-on-pay) and on the frequency of stockholder votes on executive compensation), and certain corporate governance proposals, even if management-supported. We believe that Proposals 1, 3 and 4 will be treated by NYSE as non-routine matters and Proposal 2 will be treated by NYSE as a routine matter. Accordingly, your broker may register your shares as being present at the 2025 Annual Meeting for purposes of determining the presence of a quorum, but not vote your shares on Proposals 1, 3 and 4 without your instructions (referred to as broker non-votes), but may vote your shares on Proposal 2 even in the absence of your instruction. This belief is based on preliminary guidance from NYSE and may be incorrect or change before the 2025 Annual Meeting. |

---

---

| | |
|:---|:---|
| **Q:** | &nbsp;&nbsp;**What if I return a proxy card or otherwise submit a proxy but do not make specific choices?** |
| **A:** | &nbsp;&nbsp;If you are a record holder and return a signed and dated proxy card or otherwise submit a proxy without marking voting selections, your shares will be voted, as applicable, (1) **FOR** each of the two (2) nominees for Class II director named herein; (2) **FOR** the Auditor Ratification Proposal; (3) **FOR** the Say-on-Pay Proposal; and (4) **EVERY ONE YEAR** for the Say-on-Frequency Proposal. |

---

---

| | |
|:---|:---|
| **Q:** | &nbsp;&nbsp;**Can I change my vote or revoke my proxy?** |
| **A:** | &nbsp;&nbsp;You may change your vote or revoke your proxy at any time before the final vote at the 2025 Annual Meeting. To change how your shares are voted or to revoke your proxy if you are the record holder, you may (1) notify our Corporate Secretary in writing at iBio, Inc., 11750 Sorrento Valley Road, Suite 200, San Diego, California 92121; (2) submit a later-dated proxy by mail, via internet or by telephone, subject to the voting deadlines that are described on the proxy card; or (3) deliver to our Corporate Secretary another duly executed proxy bearing a later date. You may also revoke your proxy by attending the 2025 Annual Meeting and voting at the meeting. Attendance at the 2025 Annual Meeting alone will not revoke your proxy.<br>For shares you hold beneficially, you may change your vote by following the instructions provided by your broker, bank or nominee. |

---

---

| | |
|:---|:---|
| **Q:** | &nbsp;&nbsp;**What does it mean if I receive more than one proxy statement?** |
| **A:** | &nbsp;&nbsp;It means that your shares are held in more than one account at the transfer agent and/or with banks or brokers. Please vote all of your shares. To ensure that all of your shares are voted, please submit your proxy for each set of proxy materials via the internet, telephone or by signing, dating, and returning the enclosed proxy card and/or voting instruction card in the enclosed envelope. |

---

---

| | |
|:---|:---|
| **Q:** | &nbsp;&nbsp;**Where can I find the voting results of the 2025 Annual Meeting?** |

---

**54** iBio, Inc.

[**Table of Contents**](#TOC)

Additional Information About these Proxy Materials and Voting

---

| | |
|:---|:---|
| **A:** | &nbsp;&nbsp;We intend to announce preliminary voting results at the 2025 Annual Meeting and publish final results in a Current Report on Form 8-K, which will be filed within four (4) business days of the 2025 Annual Meeting. If final voting results are not available to us in time to file a Current Report on Form 8-K within four (4) business days after the 2025 Annual Meeting, we intend to file a Current Report on Form 8-K to publish preliminary results and, within four (4) business days after the final results are known to us, file an additional Current Report on Form 8-K to publish the final results. |

---

---

| | |
|:---|:---|
| **Q:** | &nbsp;&nbsp;**What happens if additional matters are presented at the 2025 Annual Meeting?** |
| **A:** | &nbsp;&nbsp;Other than the four (4) items of business described in this proxy statement, we are not aware of any other business to be acted upon at the 2025 Annual Meeting. If you grant a proxy, the persons named as proxy holders, Martin Brenner, our Chief Executive Officer and Felipe Duran our Chief Financial Officer, or either of them, will have the discretion to vote your shares on any additional matters properly presented for a vote at the 2025 Annual Meeting. If for any unforeseen reason any of our nominees are not available as a candidate for director, the persons named as proxy holders will vote your proxy for any one or more other candidates nominated by the Board of Directors. |

---

---

| | |
|:---|:---|
| **Q:** | &nbsp;&nbsp;**Who will count the votes?** |
| **A:** | &nbsp;&nbsp;One or more inspectors of election will tabulate the votes. |

---

---

| | |
|:---|:---|
| **Q:** | &nbsp;&nbsp;**Is my vote confidential?** |
| **A:** | &nbsp;&nbsp;Proxy instructions, ballots, and voting tabulations that identify individual stockholders are handled in a manner that protects your voting privacy. Your vote will not be disclosed, either within iBio or to anyone else, except: (1) as necessary to meet applicable legal requirements; (2) to allow for the tabulation of votes and certification of the vote; or (3) to facilitate a successful proxy solicitation. |

---

---

| | |
|:---|:---|
| **Q:** | &nbsp;&nbsp;**Who will bear the cost of soliciting votes for the 2025 Annual Meeting?** |
| **A:** | &nbsp;&nbsp;The Board of Directors is making this solicitation on behalf of iBio, which will pay the entire cost of preparing, assembling, printing, mailing, and distributing these proxy materials. Certain of our directors, officers, and employees, without any additional compensation, may also solicit your vote by telephone, or by electronic communication. On request, we will reimburse brokerage houses and other custodians, nominees, and fiduciaries for their reasonable out-of-pocket expenses for forwarding proxy and solicitation materials to stockholders. In addition to the use of the mail, proxies may be solicited by personal interview, telephone, telegram, facsimile and advertisement in periodicals and postings, in each case by our directors, officers and employees without additional compensation. Brokerage houses, nominees, fiduciaries and other custodians will be requested to forward solicitation materials to beneficial owners and will be reimbursed for their reasonable expenses incurred in so doing. Please contact our Corporate Secretary in writing at iBio, Inc., 11750 Sorrento Valley Road, Suite 200, San Diego, California 92121 with any questions you may have regarding our proposals. |

---

Proxy Statement **55**

[**Table of Contents**](#TOC)

Annual Report on Form 10-K

### ANNUAL REPORT ON

## Form 10-K
iBio's 2025 Annual Report is being made available to stockholders concurrently with this proxy statement at https://www.cstproxyvote.com. Copies of the 2025 Annual Report and any amendments thereto, as filed with the SEC, may be obtained without charge by writing to iBio, Inc., 11750 Sorrento Valley Road, Suite 200, San Diego, California 92121, Attention: Corporate Secretary. A complimentary copy may also be obtained at the internet website maintained by the SEC at www.sec.gov, and by visiting our internet website at *www.ibioinc.com*.

**56** iBio, Inc.

[**Table of Contents**](#TOC)

Notice regarding Delivery of Stockholder Documents ("Householding Information")

### NOTICE REGARDING DELIVERY OF

## Stockholder Documents ("Householding" Information)
The SEC has adopted rules that permit companies and intermediaries (e.g., brokers) to satisfy the delivery requirements for proxy statements and annual reports by delivering a single copy of these materials to an address shared by two or more iBio stockholders. This process, which is commonly referred to as "householding," potentially means extra convenience for stockholders and cost savings for companies and intermediaries. A number of brokers and other intermediaries with account holders who are our stockholders may be householding our stockholder materials, including this proxy statement. In that event, a single proxy statement, as the case may be, will be delivered to multiple stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Once you have received notice from your broker or other intermediary that it will be householding communications to your address, householding will continue until you are notified otherwise or until you revoke your consent, which is deemed to be given unless you inform the broker or other intermediary otherwise when you receive or received the original notice of householding. If, at any time, you no longer wish to participate in householding and would prefer to receive a separate proxy statement, please notify your broker or other intermediary to discontinue householding and direct your written request to receive a separate proxy statement to us at: iBio, Inc., Attention: Corporate Secretary, 11750 Sorrento Valley Road, Suite 200, San Diego, California 92121 or call us at (979) 446-0027. Stockholders who currently receive multiple copies of the proxy statement at their address and would like to request householding of their communications should contact their broker or other intermediary.

Proxy Statement **57**

[**Table of Contents**](#TOC)

Stockholder Proposals for the 2026 Annual Meeting

### STOCKHOLDER PROPOSALS

## For the 2026 Annual Meeting
Stockholder proposals intended to be included in the Company's proxy statement relating to the 2026 Annual Meeting of Stockholders (the "2026 Annual Meeting") must comply with SEC Rule 14a-8 which requires that the notice be received at the Company's principal executive office not less than 120 calendar days before the one-year anniversary date of the Company's proxy statement released to stockholders in connection with the previous year's annual meeting, and accordingly must be received in writing by the Company at its principal executive office at the address set forth above no later than June 8, 2026.

Stockholders who wish to nominate candidates for election to the Board of Directors at the next annual meeting or to bring any other proposals before the next annual meeting (that is not to be included in next year's proxy materials) may do so by delivering the notice required by our second amended and restated bylaws to the Secretary at 11750 Sorrento Valley Road, Suite 200, San Diego, California 92121, not later than 90th day nor earlier than 120th days before the first anniversary of the preceding year's annual meeting; however, if the annual meeting is advanced by more than 20 days, or delayed by more than 60 days, from the first anniversary of the preceding year's annual meeting, we must receive the notice not earlier than the close of business on the 120th day prior to such annual meeting and not later than the close of business on the later of the 90th day prior to such annual meeting or the 10th day following the day on which public announcement of the date of the annual meeting is first made. In addition, the stockholder must comply with the requirements set forth in our second amended and restated bylaws and the stockholder's notice must set forth the information required by our second amended and restated bylaws with respect to each stockholder making the proposal or nomination and each proposal or nomination that such stockholder intends to present at the 2026 Annual Meeting. The anniversary for this year's annual meeting will be November 20, 2026. Thus, a stockholder notice must be received by the Company no later than August 22, 2026, and no earlier than July 23, 2026. If the date of the 2026 Annual Meeting is advanced by more than 20 days, or delayed by more than 60 days from November 20, 2026, these dates may change.

In addition, to satisfying the foregoing requirements, to comply with the universal proxy rules, stockholders who intend to solicit proxies in support of director nominees other than the Company's nominees at the 2026 Annual Meeting must provide notice that sets forth the information required by Rule 14a-19 under the Exchange Act no later than September 21, 2026.

**58** iBio, Inc.

[**Table of Contents**](#TOC)

Other Matters

### OTHER

## Matters
As of the date of this Proxy Statement, the Board of Directors of iBio knows of no other matters to be presented for stockholder action at the 2025 Annual Meeting. However, if any other matter is properly brought before the 2025 Annual Meeting for action by the stockholders, proxies in the enclosed form returned to iBio will be voted in accordance with the discretion of the proxyholders.

---

| | |
|:---|:---|
|  | By order of the Board of Directors,<br>/s/ William D. Clark |
|  | William D. Clark |
|  | *Chairman of the Board* |
| San Diego, California |  |
| October 6, 2025 |  |

---

Proxy Statement **59**

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](ibio-20251120xdef14a_bg001.jpg) | &nbsp;&nbsp;iBio, Inc. PLEASE DO NOT RETURN THE PROXY CARD IF YOU ARE VOTING VIA THE INTERNET OR BY MOBILE VOTING.  FOLD HERE • DO NOT SEPARATE • INSERT IN ENVELOPE PROVIDED  1. Election of Directors Nominees: 01) Dr. Martin Brenner 02) Dr. Alexandra Kropotova The Board of Directors recommends you vote for ONE YEAR on proposal 4. The Board of Directors recommends you vote FOR proposals 2 and 3. Signature__________________________________Signature, if held jointly_________________________________ Date__________, 2025 Please sign exactly as your name(s) appear(s) hereon. When signing as attorney, executor, administrator, or other fiduciary, please give full title as such. Joint owners should each sign personally. All holders must sign. If a corporation or partnership, please sign in full corporate or partnership name, by authorized officer. Please mark your votes like this X FOR AGAINST ABSTAIN FOR AGAINST ABSTAIN ONE YEAR TWO YEARS THREE YEARS ABSTAIN INTERNET – www.cstproxyvote.com Use the Internet to vote your proxy. Have your proxy card available when you access the above website. Follow the prompts to vote your shares. MOBILE VOTING - 1 (866) 894-0536 Use a touch-tone telephone to vote your proxy. Have your proxy card available when you call. Follow the instructions to vote your shares. MAIL – Mark, sign and date your proxy card and return it in the postage-paid envelope provided. Your Mobile or Internet vote authorizes the named proxies to vote your shares in the same manner as if you marked, signed and returned your proxy card. Votes submitted electronically over the Internet or by mobile phone must be received by 11:59 p.m., Eastern Time, on November 19, 2025. YOUR VOTE IS IMPORTANT. PLEASE VOTE TODAY. IMMEDIATE - 24 Hours a Day, 7 Days a Week or by Mail Vote by Internet, Smartphone or Tablet - QUICK  EASY PROXY The Board of Directors recommends you vote FOR the election of each of the following: 201043 iBio, Inc. Proxy Card Rev3 Front CONTROL NUMBER FOR ALL WITHHOLD ALL FOR ALL EXCEPT To withhold authority to vote for any individual nominee(s), mark "For All Except" and write the number(s) of the nominees on the line below. ________________________________________________________ 4. To approve, on an advisory, non-binding basis, the frequency of future executive compensation advisory votes. 2. To ratify the appointment of Grassi & Co., CPAs, P.C. as our independent registered public accounting firm for our fiscal year ending on June 30, 2026. 3. To approve, on an advisory, non-binding basis, the compensation of our named ex-ecutive officers ("say-on-pay"). NOTE: IN THEIR DISCRETION, THE PROXIES ARE AUTHORIZED TO VOTE UPON SUCH OTHER BUSINESS AS MAY PROPERLY COME BEFORE THE MEETING OR ANY ADJOURNMENTS OR POSTPONEMENTS OF THE MEETING. THE UNDERSIGNED HEREBY ACKNOWLEDGES RECEIPT OF THE NOTICE OF ANNUAL MEETING OF STOCKHOLDERS, DATED OCTOBER 6, 2025. NOTE: ATTENDANCE OF THE UNDERSIGNED AT THE 2025 ANNUAL MEETING OR ANY ADJOURNMENT OR POSTPONEMENT THEREOF WILL NOT BE DEEMED TO REVOKE THIS PROXY UNLESS THE UNDERSIGNED SPECIFICALLY REVOKES THIS PROXY BEFORE IT IS EXERCISED. |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](ibio-20251120xdef14a_bg002.jpg) | &nbsp;&nbsp; FOLD HERE • DO NOT SEPARATE • INSERT IN ENVELOPE PROVIDED  Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting: The Notice and Proxy Statement and Form 10-K are available at https://ir.ibioinc.com. iBio, Inc. PROXY The undersigned stockholder hereby appoints Martin Brenner and Felipe Duran, or either of them, as proxies, each with the power to appoint his substitute, and hereby authorizes them to represent and to vote, as designated on the reverse side of this ballot, all of the shares of common stock of iBio, Inc. that the undersigned is entitled to vote at the 2025 Annual Meeting of Stockholders to be held at 1:00 p.m., pacific time, on November 20, 2025 at the Company's offices located at 11750 Sorrento Valley Road, Suite 200, San Diego, California 92121. The purpose of the 2025 Annual Meeting and the matters to be acted on are stated in the accompanying Notice of Annual Meeting of Stockholders. The Board of Directors knows of no other business that will come before the 2025 Annual Meeting. THIS PROXY, WHEN PROPERLY EXECUTED, WILL BE VOTED IN THE MANNER DIRECTED HEREIN. IF NO SUCH DIRECTION IS MADE, THIS PROXY WILL BE VOTED IN ACCORDANCE WITH THE BOARD OF DIRECTORS' RECOMMENDATIONS. Continued and to be signed on reverse side 201043 iBio, Inc. Proxy Card Rev3 Back 2025 ANNUAL MEETING OF STOCKHOLDERS NOVEMBER 20, 2025 1:00 P.M. PACIFIC TIME THIS PROXY IS SOLICITED BY THE BOARD OF DIRECTORS |

---